Autosomal recessive retinal dystrophies. Genotypes and phenotypes. by Ijzer, S.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/30177
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Autosomal recessive retinal dystrophies: 
genotypes & phenotypes
Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus, 
prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op maandag 2 juli 2007
om 15.30 uur precies
door
Suzanne IJzer
geboren op 7 Augustus 1974 te Groningen
Promotor  
Prof. Dr. F.P.M. Cremers
Copromotor  
Dr. L.I. van den Born (Het Oogziekenhuis Rotterdam) 
Dr. R.K. Koenekoop (McGill University Health Centre, Montreal) 
Manuscriptcommissie 
Prof. Dr. J.E. Keunen
Prof. Dr. A.A.B. Bergen (Netherlands Institute for Neuroscience, Amsterdam) 
Dr. M.J. van Schooneveld (Universitair Medisch Centrum Utrecht)

Contents
Autosomal recessive retinal dystrophies: genotypes and phenotypes
PhD thesis University Medical Centre Nijmegen
Suzanne Yzer, Radboud University Nijmegen Medical Centre
ISBN/EAN 978-90-9021934-9
© 2007 S. Yzer
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any 
means, electronic or mechanical, by print or otherwise, without permission in writing from the author.
Graphic design and lay-out
Esther de Bruijn, grafische vormgeving & dtp, Arnhem
Print
Gildeprint Drukkerijen BV, Enschede
0
contents  
Contents
Abbreviations	 8
1 General introduction 10
 1.1 Introduction 11
 1.2 Anatomy and physiology of the retina 12
 1.2.1 The	retinal	pigment	epithelium	 13
 1.2.2 The	neurosensory	retina	 14
 1.2.3 The	photoreceptor	cell	 14
 1.2.4 The	phototransduction	cascade	 16
 1.2. The	visual	(retinoid)	cycle		 17
 1.3 Phenotypical assessment 19
 1.3.1 Functional	testing	 19
 1.4 Clinical classification of selected retinal dystrophies 20
 1.4.1 Leber	congenital	amaurosis	 20
 1.4.2 Retinitis	pigmentosa	 21
 1.4.3 Cone-rod	dystrophy	 22
 1.4.4 Stargardt	disease	 23
 1. Molecular genetics 23
 1..1 Inheritance	patterns	 24
 1..2 Gentic	heterogeneity	 25
 1..3 Characteristics	of	a	selection	of	retinal	dystrophy-
	 	 associated	proteins	 26
 1..4 Strategies	for	gene	and	gene	mutation	detection	 28
 1.. Whole-genome	linkage	analysis	 29
 1..6 Mutation	detection	 29
 1.6 Therapeutical prospectives 33
 1.6.1 Gene	replacement	 33
 1.6.2 Mutation-independent	therapeutic	strategies	 33
 1.6.3 RPE	and	stem	cell	transplantations	 34
 1.7 Outline of this thesis 35
2 Genotype-phenotype analysis of ABCA4 42
 2.1 Microarray-based mutation analysis of the ABCA4 (ABCR) 
  gene in autosomal recessive cone-rod dystrophy and 
  retinitis pigmentosa 42
 2.2 Molecular and phenotypic analysis of a family with autosomal 
  recessive cone-rod dystrophy and Stargardt disease 60
63 Microarray-based mutation detection and 
 phenotypic characterization of patients 
 with Leber congenital amaurosis 72
4 A p.Y368H RPE65 founder mutation is 
 associated with variable expression and 
 progression of early-onset retinal dystrophy 
 in 10 families of a genetically isolated population 94
 CRB1 heterozygotes with regional retinal 
 dysfunction: Implications for genetic testing 
 of Leber congenital amaurosis 108
6 Discussion 126
7 Summary / Samenvatting 136
Dankwoord / Acknowledgements 144
Curriculum Vitae 147
List of publications 148
Color figures 150
contents  7
8Abbreviations
A2E    N-retinylidene-N-retinylethanolamine
aa    amino acid
AAV    adeno-associated virus
ABCA4    ATP-binding cassette transporter, subfamily A, member 4 (retina specific)        
ABCR    ATP-binding cassette transporter (retina-specific)
adRP    autosomal dominant retinitis pigmentosa
AGRA    Affymetrix’s GeneChip CustomSeq Resequencing Array
AIPL1    arylhydrocarbon-interacting receptor protein-like 1
AMD    age-related macular degeneration
APEX    allele-specific primer extension
ar    autosomal recessive
arCRD    autosomal recessive cone-rod dystrophy
arRP    autosomal recessive retinitis pigmentosa
ATP    adenosine triphosphate
BE    both eyes
bp    base pair
cd/m2    candela per square metre
cDNA    complementary deoxyribonucleic acid
CF    counting fingers
cGMP    cyclic guanosine-monophosphate
cM    centiMorgan 
CRB1    Crumbs homologue 1
CRD    cone-rod dystrophy
CRX    cone-rod otx-like photoreceptor homebox transcripiton factor
dHPLC    denaturating high-performance liquid chromatography   
DNA    deoxyribonucleic acid
ERG    electroretinogram
FAG    fluorescein angiogram
FR    fovea reflex
GUCY2D   retinal-specific guanylate cyclase 2D
HM    hand movements 
Hz    Hertz
IS    inner segment
ISCEV    International Society for Clinical Electrophysiology of Vision
kb    kilobases
LCA    Leber congenital amaurosis
LE    left eye
LP    light perception
LRAT    lecithin retinol acyltransferase  
Mb    megabases
MERTK   mer tyrosine kinase protooncogene   
mfERG    multi-focal electroretinogram 
mM    millimolar
MR    macula reflex
mRNA    messenger ribonucleic acid
mu    mutant
NLP    no light perception
NR    non recordable
nt    nucleotide
ONL    outer nuclear layer
OS    outer segment
PCR    polymerase chain reaction
Ph   photopic
PPRPE    preserved para-arteriolar retinal pigment epithelium
PR    photopic responses
RDH12    retinol dehydrogenase 12
RE    right eye
RFLP    restriction fragment length polymorphism
RP    retinitis pigmentosa
RPE    retinal pigment epithelium
RPE6    retinal pigment epithelium-specific protein, 65kD 
RPGRIP1   retinitis pigmentosa GTPase regulator-interacting protein
Sc    scotopic
SE    spherical equivalent
sec    second
SNP    single nucleotide polymorphism 
SR    scotopic responses
SSCP    single strand conformation polymorphism
STGD1   autosomal recessive Stargardt disease type 1
TULP1    tubby-like protein 1
VA    visual acuity
VF    visual field
wt    wild type
xlRP    X-linked retinitis pigmentosa
yr    year
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Introduction
Inherited retinal dystrophies afflict approximately one in every 2000 individuals1 and 
show wide clinical and genetic heterogeneity. Until recently, classification of these 
diseases was only based on their clinical presentation and inheritance pattern. After 
the identification of the first retinal disease genes in the early nineties2,3 a refined 
classification based upon the underlying genotype seemed rational, but this attempt 
is still in its infancy. Up to now more than 100 genes responsible for human retinal 
diseases have been discovered and many more await discovery. Paradoxically, this 
has raised as many questions as it has answered, for mutations in different genes 
may result in similar phenotypes, while on the other hand mutations in one gene can 
lead to different diseases, even with a different mode of inheritance. 
Detailed knowledge of the molecular genetic causes of inherited blindness is 
essential for understanding the underlying cellular and molecular mechanisms 
involved in these types of retinal dystrophies, giving more insight into both normal 
and pathologic RPE and photoreceptor function and development. Knowledge 
of final common pathways may lead to the discovery of new genes involved in 
hereditary retinal dystrophies, and eventually all this information will pave the way 
for the development of therapeutic interventions. Improved understanding will also 
provide an increasingly accurate basis for patient counseling. 
In this thesis patients with various types of retinal dystrophies have been studied 
clinically and at the molecular level, in order to improve genotype-phenotype 
correlations. 
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1.2 Anatomy and physiology of the retina
The complex process of vision has intrigued mankind for centuries and the first 
records date back to Aristotle (4th century BC). A first realistic understanding of the 
function of the eye began after the gross anatomy of the eye had been established. 
We have come to realize that vision is possible through very complex, finely tuned 
sets of molecular cascades and cellular machineries. 
 
In the macro-anatomy of the posterior part of the globe, three major cell-layers are 
recognizable. The outer layer, the sclera, is mainly formed by collagen fibrils providing 
the globes firmness. The middle layer, the choroid, is composed of arterioles and 
venules and a fenestrated capillary network that nourishes the outer part of the third 
and most inner layer, the retina (figure 1.1). The retina is the most vital layer for vision 
since it contains neurons that are sensitive to light and are capable of amplifying, 
integrating, and transmitting visual signals. The retina is a highly organized structure 
that comprises two distinct layers: an outer layer, the retinal pigment epithelium 
(RPE) and the adjacent inner layer, the neurosensory retina. 
Figure 1.1a   Anatomy of the eye 
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Figure 1.1b   Structure of the retina
http:// webvision.med.utah.edu
1.2.1  The retinal pigment epithelium
This outer pigmented layer is situated between the choroid and the photoreceptor 
cells of the neurosensory retina (figure 1.1b). The RPE is a highly polarized and 
specialized epithelium that serves as a multifunctional and indispensable component 
of the eye. This single cell layer is formed by versatile hexagonally shaped cuboidal 
cells and originates as an anterior neural plate derivative from the neuro-ectoderm4,5. 
This makes RPE cells the only pigmented cells of the body that are not derived from 
the neural crest6. RPE cells are characterized by the presence of lysosome-related 
organelles that are committed to the biosynthesis and storage of melanin pigments, 
the melanosomes5. Melanin is a crucial component in the absorption of stray light 
that enters the eye. 
The apical side of the RPE cell has multiple villous processes into which the outer 
segments of cones and rods are embedded. The narrow space between the RPE 
and the photoreceptor cells is filled with a hyaluronan-rich extracellular matrix formed 
by apical secretion of hyaluronan by RPE cells7. This interphotoreceptor matrix forms 
a structural link between the neural retina and the RPE8.  
The RPE monolayer is responsible for many functions such as: 1. The participation 
in the outer retinal blood-ocular barrier, 2. The uptake, processing, transport and 
release of vitamin A (retinol), 3. Maintaining the adhesion and water and ions flow 
between the neural retina and the choroid, 4. Protection against free radicals, 5. 
Maintenance of the subretinal space, and 6. Phagocytosis of the outer segment 
discs of the photoreceptors and ensuring their renewal. Based on these functions, 
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the RPE plays a key role in the maintenance of the overlying photoreceptor layer 
from the neurosensory retina9,10. 
1.2.2  The neurosensory retina
The complex neurosensory retina comprises six types of neurons: the amacrine 
cells, bipolar cells, ganglion cells, horizontal cells, Müller cells and the photoreceptor 
cells. These cells together form three distinct layers of neurons (nuclear layers) and 
two different layers of synapses (plexiform layers). The outer nuclear layer contains 
cell bodies of the photoreceptors, the inner nuclear layer contains cell bodies of the 
amacrine, bipolar, horizontal and Müller cells (the interneurons) and the ganglion 
cell layer is formed by cell bodies of the ganglion cells. These nerve cell layers are 
divided by the layers of synapses: the outer plexiform and the inner plexiform layer. 
 
The neurosensory layer is responsible for the detection and transmission of 
photoreceptor-generated signals to the central visual pathway. Light-evoked signals 
are transferred from the synaptic terminals of the photoreceptor cells to the bipolar 
and the horizontal cells. The horizontal cells provide lateral interactions in the outer 
plexiform layer. The bipolar cells transfer the light signals to the inner plexiform 
layer into the dendrites of amacrine and ganglion cells. Müller cells span the entire 
neurosensory retina. These are glial cells involved in several essential activities for 
normal retinal function. Ganglion cell dendrites collect the signals of the bipolar and 
the amacrine cells and their axons finally transmit a nerve impulse to the central 
visual pathway11.
1.2.3  The photoreceptor cell
Mammals have two main types of highly specialized neuro-epithelial photoreceptor 
cells, the rods and cones. Photoreceptor cells are responsible for transducing 
light (electromagnetic signal) into a molecular signal, and then into a neurological 
(electrical) signal. The human retina contains approximately 120 million rods and 6 
million cones. Whereas rods mediate dim-light vision and sense contrast, brightness 
and motion, cones function in bright light and subserve fine and spatial resolution, 
and realize the differentiation between spectral modulations (color vision). 
 
The density of rods is much greater than the density of cones throughout most 
of the retina, with the exception of the fovea. This is a highly specialized region of 
the central retina that measures about 1.2 millimeters in diameter with the highest 
receptor packing density, and exclusively contains cones. This partitioning is in 
concordance with the distinct function of rods and cones. In the fovea the high 
spatial resolution (high visual acuity) is ensured by a nearly one-to-one relationship 
between a cone photoreceptor cell, its bipolar and ganglion cell and its nerve fiber. 
The peripheral photoreceptors are not individually coupled to a bipolar cell or to a 
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single ganglion cell but are grouped and coupled. This so-called convergent wiring is 
necessary in order to maintain detection levels of small amounts of light. 
Both rods and cones contain an outer (OS) and an inner segment (IS), a nucleus and 
a synaptic terminal, but are histological distinguishable by the shape and position of 
the nucleus. Photoreceptors are characterized by the presence of discs in their outer 
segments, which arise as a series of invaginations of the cell’s plasma membrane. 
Each outer segment contains roughly 1000 discs. Approximately 10% of these are 
renewed on a daily basis. They are formed at the IS/OS junction and released to 
the RPE at the apical end which then binds, ingests and digests the shedded discs. 
This makes the RPE cell perhaps the most efficient phagocyte of the human body4.
 
Crucial molecules and proteins involved in the activation and quenching of the visual 
cascade (the phototransduction cascade), are embedded in these photoreceptor 
discs. One such indispensable component are visual pigment molecules which 
are necessary for capturing light and the convertion of light into an electrical signal 
(figure 1.2). Rods and cones harbor different types of pigment. The rods contain the 
rhodopsin protein whereas cones contain one of three different types of iodopsin 
(red, green and blue), which respond selectively to photons in different regions of the 
visible light spectrum, enabling color vision. 
The inner segments of the photoreceptors contain the metabolic machinery, like 
mitochondria, ribosomes and the Golgi complex. The cellular compartments of the 
light sensitive outer segments are linked to the biosynthetically active inner segments 
by a thin cylindrical cytoplasm bridge containing an immotile cilium. This connecting 
cilium serves as a barrier for membrane components and soluble proteins and 
thus regulates and facilitates the free diffusion of OS proteins synthesized in the IS. 
Furthermore, since this is the only intracellular bridge between the two segments, 
intracellular exchanges between the segments are forced to occur through the 
connecting cilium. 
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Figure 1.2   The phototransduction cascade
After the light activation of rhodopsin consecutive reactions occur. When cGMP is hydrolized the 
permeability of the plasma membrane cGMP channels decreases. This leads to hyperpolarization of the 
photorecptor cell membrane and decreased neurotransmitter release at synapses.  
1.2.4  The phototransduction cascade
The phototransduction system consists of a cascade of successive molecules 
involved in the processes of light activation and inactivation. Activation occurs 
when light is absorbed by visual pigments to which a highly photosensitive vitamin 
A analogue is covalently bound (11-cis-retinal). Vitamin A is converted to 11-
cis-retinal in the RPE and is recycled through the visual cycle. Light absorption 
results in the isomerization of 11-cis-retinal to all-trans-retinal, which subsequently 
forms a photoactive visual pigment (metarhodopsinII), which decays through 
several intermediates12. One of these intermediates activates transducin, a 
G-protein specific to photoreceptor cells which in its turn activates a cGMP 
phosphodiesterase resulting in the hydrolysis of the “second messenger” cGMP to 
5’-GMP13. For the biosynthesis of rod cGMP phosphodiesterase, the chaperone 
aryl hydrocarbon receptor-interacting protein-like 1 protein (AIPL1) is required14. The 
hydrolysis of cGMP after photon stimulation leads to a decrease of cGMP reducing 
the permeability of the photoreceptor plasma membrane cGMP-gated cation 
channels. This initiates a significant lowering of the intracellular calcium levels and 
as a consequence the photoreceptor cell plasma membrane is hyperpolarized. This 
then leads to a decreased release of the neurotransmitter glutamate at the synaptic 
terminal (figure 1.2).
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The inactivation of the light-induced response, the recovery phase, occurs via 
several mechanisms leading to the dissociation of all-trans-retinal from the 
visual pigments, the phosphorylation of rhodopsin by rhodopsin kinase and the 
subsequent binding of rhodopsin to arrestin and finally to the restoration of the 
cytoplasmic levels of cGMP by guanylyl cyclase in order to reset the light sensitivity 
of photoreceptor cells15,16 (figure 1.2). One of the key enzymes in this process is 
probably RDH1217,18.
1.2.5  The visual (retinoid) cycle
Vitamin A (all-trans-retinol) is a crucial component for the phototransduction 
cascade and is absorbed via dietary intake and converted to 11-cis-retinal in the 
RPE. The metabolism of vitamin A and the cycling of the retinoid analogues between 
the RPE and the photoreceptor cells is a complex process called the visual cycle. 
The visual cycle begins following a light response, which leads to the release of all-
trans-retinal from the activated visual pigment. In the lumen of the photoreceptor 
cell disc membranes, all-trans-retinal reacts with phosphatidylethanolamine and 
forms N-retinylidene-phosphatidylethanolamine (A2N)19. Through a flippase activity 
of the ABCR protein, A2N is translocated from the inner to the outer half of the lipid 
layer of the photoreceptor discs and all-trans-retinal is released to the cytoplasm20,21 
(figure 1.3). In the cytoplasmic space, all-trans-retinal is reduced to all-trans-retinol 
by an all-trans-retinol dehydrogenase (RDH) and is transported to the RPE22,23. 
Lecithin retinol acyltransferase (LRAT) is the first enzyme in the RPE portion of 
the retinoid cycle and esterifies a phosphatidylcholine to all-trans-retinol in order 
to form all-trans-retinyl esters24,25. These esters are then isomerohydrolysed to 
from 11-cis-retinol26. A crucial enzyme in the isomerohydrolyses of all-trans-retinyl 
esters is the retinal pigment-specific 65kDa protein (RPE65)27. Finally, 11-cis-retinol 
dehydrogenase (11-cis-RDH) converts 11-cis-retinol in 11-cis-retinal for which the 
presence of the cellular retinaldehyde-binding protein (CRALBP) is necessary28. 
11-cis-retinal eventually exits the RPE, traverses the subretinal space and then 
re-enters the photoreceptor outer segment where it is recombined with an opsin 
protein to yield a light-sensitive rhodopsin molecule (figure 1.4). 
Sustained vision in bright illumination requires continuous regeneration of the visual 
pigments in cones. It has been suggested that the maximum throughput of this 
visual cycle is too slow to keep up with the high demand and a novel visual cycle for 
sustained daylight vision was proposed after studying cone-dominant squirrel and 
chicken retina’s. This pathway is located outside of the RPE in cone outer segments 
and Müller cells, and involves three catalytic activities in cone membrane fractions, 
regenerating opsin photopigments at a 20-fold faster rate20. 
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Figure 1.3   The function of the ABCR protein 
After light activation all-trans-retinal is released from the activated visual pigment, which will subsequently
lead to formation of N-retinylidene-phosphatidylethanolamine (A2N). Through the activity of ABCR all-trans-
retinal is translocated from the intra disc lumen to the cytoplasm. In the cytoplasmic space, all-trans-retinal 
is reduced to all-trans-retinol and is transported to the RPE and finally returned to the photoreceptor outer 
segment where it is combined with an opsin molecule.
Figure 1.4   Schematic of the (re)cycling of vitamin A (all-trans-retinol)
A2E: N-retinylidene-phosphatidylehanolamine; A2-PE: phosphatidylethanolamine-bisretinoid; ABCR: ATP-
binding cassette transporter; LRAT: lecithinretinol acyltransferase; RPE65: RPE-specific 65kDa protein.
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1.3  Phenotypical assessment
Inherited retinal dystrophies display a wide clinical spectrum. Their diagnosis 
is usually based on the age of onset, the type and severity of symptoms, their 
progression, the family history and a thorough ophthalmologic exam, in particular 
the retinal appearance. In addition to the clinical aspects of the phenotyping effort, 
functional retinal assessments such as visual acuity, electroretinography, visual 
field measurements, and color vision testing, are of great importance to identify the 
nature of the disorder and for patient’s follow-up. Nevertheless, it is often difficult to 
establish a clear-cut clinical diagnosis as several retinal dystrophies have significant 
clinical overlap. 
Furthermore, although the primary defects may be very different at the genetic and 
molecular level, there is evidence that only a few final common cell death pathways 
exist so that there is convergence from the initial insult to the retinal cells to the final 
cell death pathways. These pathways are highly controlled and complex systems of 
effector cascades that converge to a common death execution program of single 
cells (apoptosis). The induction of apoptosis is very complicated and as yet poorly 
understood. It has been proposed to arise within the diseased cell or to be triggered 
by extracellular signals. Both of these conditions may be enhanced by exogenous 
factors such as light exposure, nutrition or toxic agents29,30.
1.3.1  Functional testing
Visual acuity (VA) is measured under standardized conditions and provides important 
information on the spatial resolving capacity of the central visual system. In general, 
VA is measured by asking the person to discriminate letters (or figures) of known 
visual angle at standard distances under standard illumination. Snellen charts are the 
universal standard, which uses a pragmatic sequence of letter sizes. The small steps 
represent the range of normal vision and the larger steps the range for poorer vision. 
Letter spacing varies and accordingly the number of letters per line. ETDRS (Early 
Treatment Diabetic Retinopathy Study) charts uses proportional spacing (geometric 
or logarithmic progression), meaning that step sizes are constant at all levels of 
vision, so that the relative crowding and contour interaction remains the same for 
all lines and only the magnification varies with a logarithmic step size. The outcome 
is presented in a quotient, d/D, in which d represents the distance of the patients 
eye to see the letter and D represents the distance (meter) from which a “normal” 
eye would see the specific letter. Preverbal children cannot perform this type of 
testing and many age-adapted tests are now available. One such test uses the Teller 
visual acuity cards, which measures preferential looking at lines of which the VA is 
determined by the frequency of the line spacing. Central, steady and maintained 
fixation on a target or a child’s fixing and following behaviour are used as indicators 
of vision in newborns. 
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Another test of great importance in the field of retinal dystrophies is the full-field 
electroretinogram (ERG), which measures a mass electrical response of an action 
potential produced by the whole retina when stimulated by illumination. The ERG 
can be elicited in both light-adapted (photopic) and dark-adapted (scotopic) states. 
Photopic recordings are the exclusive responses of the cones. Under scotopic 
conditions, isolated rod responses can be measured as well as mixed cone-rod 
responses. A normal ERG result is a biphasic waveform consisting of an a-wave 
and b-wave. The a-wave originates in the photoreceptors and represents a negative 
deflection from baseline and identifies the closing of the cGMP-gated channels, 
whereas the b-wave is a positive deflection from baseline and originates in the post-
receptor cell layer including the bipolar cells and Müller cells. ERGs made for the 
purpose of studies presented in this thesis were made under conditions dictated by 
the “International Society for Clinical Electrophysiology of Vision” (www.iscev.org).
Multifocal ERG (mfERG) allows simultaneous recordings of 64 local cone ERGs and 
in contrast to the conventional ERG, specific information on multiple small areas is 
gathered. 
 
Goldmann kinetic perimetry measures suprathreshold retinal sensitivity and gives a 
definition of the spatial retinal localization of the retinal disorder. 
Color vision tests discriminate between separate types of cone defects and indicate 
protan (red), deutan (green) and tritan (blue) cone photoreceptor abnormalities.
1.4  Clinical classification of selected retinal dystrophies
A straightforward classification of inherited retinal dystrophies is complicated since 
the different disorders comprise a spectrum and show overlapping characteristics. 
The general clinical features of Leber congenital amaurosis, retinitis pigmentosa, 
cone-rod dystrophy, and Stargardt disease will be discussed since they are the 
subject of this thesis. Some of these diseases may be a component of multisystem 
disorders (syndromic disease) but for the purpose of this thesis only the non-
syndromic forms will be discussed. 
1.4.1  Leber congenital amaurosis
Leber congenital amaurosis (LCA) was first described by Theodor Leber in 186931. He 
described patients who were congenitally blind and who did not have obvious fundus 
abnormalities on initial examination. Later in life many of these children developed 
retinitis pigmentosa-like fundus changes. LCA is the earliest and most severe form 
of all inherited retinal dystrophies leading to blindness or severe visual impairment 
from birth with an incidence of 3:100.00031. It is postulated that LCA accounts for 
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more than 5% of all inherited retinal dystrophies and affects approximately 20% of the 
children attending schools for the blind around the world32. 
 
LCA is characterized by poor fixation in the first 6 months of life, a sensory 
(wandering) nystagmus, amaurotic pupils and a variable fundus appearance. The 
fundus changes may vary from completely normal (even later in life), to mild pigment 
mottling with mild vascular attenuation, to a full blown RP type fundus. An absolute 
diagnostic prerequisite is a severely reduced or non-detectable ERG in the first year 
of life. LCA may be accompanied by other ocular features such as eye-poking (the 
oculodigital sign of Franceschetti), ptosis, strabismus, high hyperopia, high myopia, 
microphthalmos, cataracts early in life, keratoconus, macular coloboma, and disc 
edema33. 
Most clinical studies show that LCA patients have relatively stable visual function, 
with some patients deteriorating (especially those with macular colobomas, 
cataracts, keratoconus, etc), and some patients improving. The improvement usually 
does not last and the prognosis is poor.
Histological studies appear to corroborate the clinical studies and have shown 
LCA to be a heterogeneous group of disorders, which may be classified in three 
functional subtypes according to the underlying pathological processes; aplasia 
(or agenesis) due to an abnormal embryological formation of the photoreceptors; a 
degeneration caused by an early progressive photoreceptor cell death, and third, 
a dysfunction in which the retinal anatomy remains normal but a key biochemical 
messenger is missing. This is of significance in the development of future therapies.
1.4.2  Retinitis pigmentosa
The name retinitis pigmentosa (RP) was coined by the Dutch physiologist and 
ophthalmologist Donders in 185734, but is actually a misnomer since the retinal 
dystrophy is not caused by an inflammation. RP patients form the largest group of 
patients with inherited retinal disorders worldwide with a prevalence of 1:300035. RP 
comprises a surprisingly heterogeneous group of in general progressive disorders 
that primarily affect the function of the photoreceptors and the RPE, with a large 
variability in age of onset, progression, retinal appearances and eventual visual 
outcome. Patients usually present with nyctalopia (night blindness), followed by or 
concurrent with peripheral visual field (VF) loss. The long-term prognosis is generally 
poor for most RP patients since maculopathy will eventually affect the central visual 
acuity. Some patients lose light perception at the end stage of the disease.
The ophthalmoscopic features typically consist of bone spicule formation in the 
retina which represents pigment granules released from RPE cells that have 
migrated to perivascular sites in the inner retina secondary to photoreceptor 
death36. Hyperpigmentation of the areas of the retina may alternate with areas 
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of hypopigmentation or intraretinal white dots. The posterior pole may also be 
relatively spared. The attenuation of the retinal arterioles and veins is probably the 
result secondary to photoreceptor death. Finally, optic nerve alterations described 
as waxy pallor appearance or optic atrophy are often seen. The loss of pigment of 
the RPE and the loss of choriocapillaris enables visualization of the larger choroidal 
vessels, which may appear whitish (choroidal sclerosis). In addition to these classical 
symptoms, RP may be associated with early posterior subcapsular cataracts, 
early vitreous degeneration, hyaline bodies or drusen of the optic disc, and cystoid 
macular edema37. 
Crucial in the diagnosis of RP are results captured by the electroretinogram (ERG) 
showing abnormal rod responses. Later in the disease course both cone- and rod-
mediated responses are reduced and eventually may become undetectable. 
Visual field defects are variable and may be classified into several types. Grover 
and co-workers38 classified visual fields of 86 RP patients into three patterns. 
Pattern I shows a characteristic progressive concentric loss, pattern II shows an 
initial superior loss subsequently leading to an arcuate scotoma winding around 
the central area from either the nasal or temporal side. The main motif of pattern 
III progression is characterized by an incomplete or complete ring scotoma in the 
midperipheral areas. In their study the pattern of visual field loss is consistent within 
members of the same family. A specific pattern of photoreceptor cell death may be 
explained by the underlying molecular mechanism initiating cell apoptosis38. 
1.4.3  Cone-rod dystrophy
In contrast to the clinical presentation of RP, patients with cone-rod dystrophy 
(CRD) initially have a predominant loss of cone function. Their symptoms reflect 
cone dysfunction and consequently patients usually present with photoaversion and 
dyschromatopsia (in adolescence or early adult life), day blindness, and progressive 
loss of visual acuity. The degeneration of rod photoreceptors is by definition later in the 
disease course and accompanying symptoms like night blindness may then occur. 
The retinal findings of CRD patients may be surprisingly subtle, especially early in 
the disease process. Funduscopic examination may show either minimal or non-
specific pigmentary changes within the fovea, an atrophic-appearing macular lesion 
(which may have a bull’s-eye-like appearance), or even more diffuse pigmentary 
degenerative changes involving both the macula and more peripheral regions of 
the retina39. This may be accompanied by mild attenuation of the retinal vessels. 
Perimetry shows central scotomas and eventually large paracentral scotomas and 
mild peripheral constriction. 
ERG is crucial in the diagnosis of CRD, which demonstrates a predominant 
reduction of the cone rather than the rod mediated response. It may be difficult 
chapter 1  23
to clinically distinguish between advanced CRD and advanced RP since their 
funduscopic appearances may be similar and both rod and cone ERGs may be non-
recordable. The long-term prognosis of CRD is often poor.
1.4.4  Stargardt disease
Stargardt disease (STGD1) was first described by Karl Stargardt in 190940 and 
is the most common hereditary juvenile macular dystrophy with a prevalence of 
approximately 1:10.00041. The disease is usually characterized by a bilateral loss of 
visual acuity in early childhood or early adolescence. 
The initial fundoscopy may reveal no obvious abnormalities whereas in later stages 
of the disease the typical subretinal yellowish flecks, which are variable in size and 
shape (and have a transient character), may be present in the posterior pole and 
may extend as far as the equator. As the disease develops, RPE atrophy in the 
macular region may show up as a beaten bronze appearance or a bull’s eye pattern. 
Pigmentary changes in the midperiphery may also be present. 
Electrophysiologic dysfunction is not uncommon in STGD1 patients even in presence 
of normal visual acuity. Fluorescein angiography (FAG) may also be useful, since 
the typical yellow-white flecks either appear as hypofluorescent or demonstrate an 
irregular pattern of fluorescence. A more important and typical FAG feature in STGD1 
is the obstruction of the normal choroidal background fluorescence formed by the 
accumulation of lipofuscin that is present in 50-85% of the patients (choroidal silence).
1.5  Molecular genetics
In 1953 research conducted by J. Watson, F. Crick, M. Wilkin and R. Franklin led 
to the important discovery of the double helix structure of DNA42-44. DNA is a linear 
polymer with two complementary strands, each made up of a linear array of the 
purine bases guanine (G) and adenine (A) and of the pyrimidine bases cytosine (C) 
and thymine (T). The specific genetic information is captured in the unique sequence 
of these four bases. A gene consists of several hundreds to thousands of basepairs. 
DNA is transcribed into mRNA, which in turn encodes a protein. A change (mutation) 
in one or a few of the bases of a gene can result in a change of the structure or 
stability of the mRNA or in a change of the encoded protein, and this may cause 
disease. Mutations derived from the parental DNA can be passed on to the next 
generation and subsequently cause inherited diseases. 
DNA carries genetic information and, together with nuclear proteins, is packaged 
into chromosomes. In humans the cell nuclei contain 23 pairs of chromosomes, 22 
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pairs of autosomes and one pair of sex-chromosomes (XY in males, XX in females). 
The chromosomes are distinguishable because they carry nucleotide variations in 
~ 1 in 1000 base pairs. Each member of a pair is derived from the father or mother. 
The human genome actually comprises two types of genomes; the above-described 
nuclear genome carries approximately 30,000 genes (total size is 3,200,000 kb) 
and a much smaller mitochondrial genome with 37 genes (total size is 16.6 kb). 
Mitochondria reside in the cytoplasm and are only transmitted through females.
1.5.1  Inheritance patterns 
The different modes of monogenic (single-gene) disorder inheritance are described 
in this paragraph. In autosomal dominant (ad) inherited disease, a mutation in one 
of the two gene copies leads to disease. A carrier of the mutation, in most cases, 
will develop the disease and has a 50% probability of passing the mutation on to the 
next generation.
When both autosomal genes are required to harbor a disease-associated mutation 
the mode of inheritance is autosomal recessive (ar). A heterozygous carrier of a 
mutated and a normal gene will not develop the disease. A carrier couple has a 25% 
probability for any of their children to develop the disorder. A person suffering from 
the disease will pass one mutation on to the next generation, which automatically 
renders children carriers of the mutation. 
Men and women differ in their twenty-third pair of chromosomes. Women carry two 
fully homologous X chromosomes; men carry the X and Y chromosomes, which 
are fully homologous at the tips of the short arms of the X and Y chromosomes (~3 
Mbp; pseudo-autosomal region) and only partially homologous in other regions. In 
females most genes on one X chromosome are silenced as a result of X-inactivation. 
Apparently, the product of one of two gene copies is sufficient and necessary for 
normal function. The process of X-inactivation in female cells is initiated during early 
development and is controlled by the X-inactivation centre. The Y chromosome 
harbors the critical male-determining gene, sex-reversed Y (SRY). Since males are 
hemizygous for almost all genes on the X-chromosome, except for those located on 
the pseudo-autosomal region at Xpter, a mutation in a gene on the X chromosome 
in males, in most cases will lead to disease (X-linked). Female offspring of an 
affected male are obligate carriers but in most cases unaffected. Male offspring 
are unaffected since they inherit the Y-chromosome. The mitochondrial DNA is 
exclusively maternally inherited. 
All three types of Mendelian inheritance are possible in RP. The most frequently 
occuring mode of inheritance is autosomal dominant, followed by autosomal 
recessive and X-linked RP. The majority of patients however are so called isolated 
cases without any family history of RP. In these patients either of the above 
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mentioned modes of inheritance is possible. Only once a family with digenic 
inherited RP has been reported45. The affected family members had mutations in 
two unlinked photoreceptor-specific genes (ROM1 and peripherin/RDS), and were 
double heterozygous45. 
In progressive cone-rod dystrophy the mode of inheritance is similar to RP with 
again predominance for isolated cases followed by autosomal dominant, some 
autosomal recessive and some X-linked cases. LCA is mostly inherited in an 
autosomal recessive manner, although a few cases with autosomal dominant 
inheritance are described. STGD1 is an autosomal recessive inherited disease. 
Mitochondrial inheritance is not shown in the above-mentioned isolated diseases.
1.5.2  Genetic heterogeneity
Since the studies described in this thesis concentrate on autosomal recessively 
inherited retinal dystrophies, only the genetics of arRP, arCRD, LCA, and STGD1 
will be discussed. ArRP, arCRD, and LCA display wide genetic heterogeneity. The 
first arRP gene discovered was the rhodopsin gene46 and now, many years after this 
discovery, 19 arRP genes have been cloned, 5 are mapped and many more await 
discovery. 
The identification of the first LCA-causing gene in 199647 was followed by the 
identification of an additional seven genes. Together they account for approximately 
45%48 of the cases suffering from LCA, implicating that 55% of the LCA cases are 
caused by genes that are yet to be discovered. 
In arCRD the ABCA4 gene has been implicated in 40-50% of the cases, but many 
other genes are expected to be involved. STGD1 is the only disease studied here 
that is considered  to be caused solely by mutations in the ABCA4 gene49. The 
causative genes and loci of arRP, arCRD, LCA and STGD1 are listed in table 1.1.
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Table 1.1   The causative genes and loci for arRP, arCRD, LCA and STGD1
* Mutations are associated with juvenile RP
For an overview, see: www.ncbi.nlm.nih.gov/Omim/ and www.sph.uth.tmc.edu/Retnet/
ar retinitis pigmentosa Leber congenital amaurosis
genes ABCA4 1p21-p13 genes AIPL1 17p13.1
CERKL 2q31.2-q32.3 CRB1 1q31-q32.1
CNGA1 4p12-cen CRX 19q13.3
CNGB1 16q13 GUCY2D 17p13.1
CRB1 1q31-q32.1 IMPDH1 7q32.1
LRAT 4q31 RDH12 14q23.3
MERTK 2q14.1 RPE65 1p31
NR2E3 15q23 RPGRIP1 14q11
NRL 14q11.1-q11.2 loci LCA3 14q23.3
PDE6A 5q31.2-q34 LCA5 6q11-q16
PDE6B 4p16.3 LCA9 1p36
RGR 10q23 genes TULP1* 6p21.3
RHO 3q21-q24 LRAT* 4q31
RLBP1 15q26
RP1 8q11-q13
RPE65 1p31 ar cone-rod dystrophy
SAG 2q37.1 gene ABCA4 1p21-p13
TULP1 6p21.3 loci CORD8 1q12-q24
USH2A 1q41 CORD9 8p11
loci RP22 16p12.3-p12.1
RP25 6q14-q21
RP28 2p15-p11
RP29 4q32-q34 Stargardt disease 
RP32 1p34.3-p13.3 gene ABCA4 1p21-p13
1.5.3  Characteristics of a selection of retinal dystrophy-associated proteins
ABCA4  
The photoreceptor-specific ATP-binding cassette transporter (ABCA4) is a member 
of the ABC transporter family50. The ABCA4 glycoprotein is located at the rim of the 
outer segment disc membrane (figure 1.3) and functions as an outwardly directed 
flippase for N-retinylidene-phosphatidylethanolamine21, transporting all-trans-
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retinaldehyde from the outer segment disc to the photoreceptor cytoplasm from 
where it moves out of the cell to the RPE after conversion to all-trans-retinol.
AIPL1  
The arylhydrocarbon receptor interacting protein-like 1 (AIPL1) is a member of the 
fatty acid binding protein (FABP) family and possesses a peptidyl-prolyl isomerase 
(PPI) domain and three consecutive tetratricopeptide motifs (TPR)51. AIPL1 has a role 
in cone development but is surprisingly only detected in adult rod photoreceptors 
in which  AIPL1 functions as a chaperone required for rod cGMP phophodiesterase 
biosynthesis14. 
CRB1   
Crumbs homolog-1 (CRB1) is a transmembrane protein, synthesized in the 
developing and adult human retina and in human brain. CRB1 is localized 
specifically to the sub-apical region adjacent to the adherens junction complex at 
the outer limiting membrane in the retina. CRB1 consists of multiple domains of 
which the large extracellular domain possibly is involved in cell-cell interaction. A 
small intracellular domain functions as an anchor for several protein complexes in 
the cytoplasm and is essential for the maintenance of cell polarity and maintenance 
of the belt like structure called the outer limiting membrane. Furthermore, CRB1 
plays a crucial role in photoreceptor cell morphogenesis52,53.  
CRX  
The cone-rod homeobox protein (CRX) is a transcription factor synthesized in both 
photoreceptors and the pinealocytes of the pineal gland54. In the retina the CRX 
protein is required for the development and maintenance of photoreceptor function 
by regulating the transcription of many photoreceptor-specific genes39,54-57. Mutant 
mice with defective CRX do not elaborate an OS, and several key phototransduction 
proteins fail to be expressed58.
GUCY2D  
The guanylate cyclase 2D (GUCY2D, also referred to as RETGC1) transmembrane 
protein is predominantly present in the outer segments of photoreceptors (figure 
1.2). It consists of several functional domains, i.e. an extracellular domain, a 
transmembrane domain, a kinase homologous domain, a dimerisation domain, 
and a catalytic domain59. Mutations in GUCY2D prohibit the production of 
cGMP resulting in the continued closure of the cGMP-gated channels. Once 
the phototransduction cascade is initiated, mutations in this gene will lead to a 
state resembling continuous light exposure, since the recovery state cannot be 
accomplished because of the lack of guanylyl cyclase enzyme.  
RDH12  
Retinol dehydrogenase 12 (RDH12) belongs to the superfamily of short-chain 
alcohol dehydrogenases and reductases and is specifically synthesized in 
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photoreceptor cells. The exact role of RDH12 is not known yet, but it was suggested 
that RDH12 plays a pivotal role in the formation of 11-cis-retinal from 11-cis-retinol, 
during regeneration of cone visual pigments18. 
RPE65  
The retinal pigment-specific 65 kDa (RPE65) protein is crucial in the visual cycle 
in order to regenerate the chromophore 11-cis-retinol27,60. Mutations in RPE65 
prohibit the isomerohydrolysation of 11-cis-retinol resulting in accumulation of all-
trans-retinal and opsin apoprotein (unliganded opsin). Apoptosis may be initiated by 
the high levels of unliganded opsin, for they lead to spontaneous activation of the 
visual cascade and consequently lead to closure of cGMP-gated channels, again 
suggesting a state resembling continuous light exposure. The subsequent low levels 
of intracellular calcium may be a trigger for cell death61. 
RPGRIP1  
The retinitis pigmentosa GTPase regulator-interacting protein (RPGRIP1) interacts 
with the RPGR protein and both are localized at the connecting cilia of rods and 
cones62. Mutations in RPGR cause up to 72% of the X-linked RP cases63, whereas 
RPGRIP1 mutations are associated with the much more severe LCA. There are 
numerous isoforms of RPGRIP1, and they seem to have complementary functions in 
cytoskeletal-mediated processes in photoreceptors and amacrine neurons64.
1.5.4  Strategies for gene and gene mutation detection
Since the identification of the first retinal disease genes 15 years ago2,3  a host of 
retinal genes have been identified. The thus far identified genes harbor mutations in 
approximately 50% of the patients, which leaves 50% of the molecular causes as 
yet unknown. 
The identification of the underlying genes has had a tremendous impact. It improved 
our understanding of the function of the normal retina and the pathogenesis of 
several degenerative diseases. Furthermore, it forms the basis for studies aimed at 
therapeutic intervention. Unfortunately, molecular diagnostics has not yet made its 
way into the every day clinical practice, a fact that has much to do with the staggering 
amount of genetic heterogeneity and its resulting costs and manpower issues. 
Several newly developed therapies are currently being tested, some of which have 
already reached the human clinical trial phase. As a consequence, there is a need 
for the discovery of the additional 50% of retinal disease causing genes and a need 
for methods that provide a rapid and accurate screening ability in order to identify 
the causative genes and their mutations in individual patients. 
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1.5.5  Whole-genome linkage analysis
The discovery of new disease genes is expensive and time consuming. Through the 
effort of the human genome project, the human DNA sequence is now completely 
known, enabling the physical localization of microsatellite markers and single 
nucleotide polymorphisms (SNP). 
In the past 10 years microsatellite markers were traditionally used for linkage 
studies. They contain tandem repeats of a simple DNA sequence and are often very 
polymorphic, i.e. consist of many different alleles. In whole-genome scans these 
markers are spaced at intervals of approximately 10 cM across the genome. This is 
a labor-intensive method and relatively costly (approximately €12.000 for a genome 
scan of a family with 20 individuals). 
SNPs are only biallelic and therefore are generally less polymorphic than microsatellite 
markers. On the other hand, SNPs are present more frequently. Their analysis can 
be carried out using high-density microarrays, which makes it very fast and less 
expensive (approximately  €5.400 for a genome scan of a family with 20 individuals).
1.5.6  Mutation detection
The identification of retinal disease genes gave rise to a demand for rapid and 
reliable screening tools for genotyping. For several reasons it is important to 
establish the underlying molecular cause in a patient with a retinal dystrophy. 1. 
It provides an exact diagnosis, based on the molecular defect and thus is much 
more accurate than a diagnosis based on retinal appearance, disease onset and 
progression. This is important because different retinal dystrophies have overlapping 
symptoms and signs. 2. It provides a tool to give a prognosis for the future visual 
course, 3. It enables well-founded genetic counseling, 4. It may enable prenatal 
screening, 5. It aids in determining eligibility for certain therapies, 6. It allows the 
identification of novel cellular and molecular processes, through the identification of 
new retinal dystrophy genes. 
Sequence analysis of the involved gene is considered the “golden standard” when 
there is a small number of candidate genes and when the numbers of exons are 
limited. Exons are part of the nucleotide sequence in DNA that carries the code for 
the mature mRNA molecule and thus encodes the protein’s amino acid sequence. 
Alternatively only the exons containing hotspots (a region in a gene in which there is 
a high occurrence of mutations) for mutations can be sequenced. 
When a large number of highly complex genes need to be analyzed, alternative 
methods are needed. One such a screening tool that serves this demand is the 
Affymetrix’s GeneChip CustomSeq Resequencing Array (AGRA). This technique 
uses a four-probe interrogation strategy. For the reference sequence of the coding 
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region of the genes of interest and small stretches of their flanking intron sequences, 
four probes (17-mer oligonucleotides) are designed to interrogate a single position. 
One probe is designed to be perfectly complementary to a stretch of the reference 
sequence; the other three are identical to the first, except at one position where 
one of the other three bases are substituted. Sample DNA is amplified, fragmented, 
fluorescently labeled, purified and hybridized to the designed probes. The probe 
that forms the most stable duplex will provide the highest fluorescent signal among 
the four probes assigned to interrogate the central base. The next nucleotide in the 
target sequence is identically interrogated, using another set of four oligonucleotide 
probes (figure 1.5). This analysis is carried out for both DNA strands of the double 
helix. This strategy is repeated in a manner that covers a single continuous 
sequence of interest. For example, one hundred sets of eight probes are used to 
interrogate one hundred bases of sequence. Specially designed software (Affymetrix 
GeneChip DNA Analysis Software) is used to analyze the results. In general this 
technique detects homozygous and heterozygous base substitutions robustly. 
Currently, these arrays also test for the presence of one-nucleotide deletions, but not 
for the presence of other heterozygous abnormalities such as insertions and other 
deletions (www.affymetrix.com). This is an effective though expensive approach in 
small families or isolated cases for detecting both known as well as new mutations. 
For arRP such an array is now available. It contains 17-mers from most of the open 
reading frame from sequences of 11 out of the currently known 19 arRP genes65. 
A different approach is the arrayed primed extension (APEX) technology (mini-
sequencing), in which oligonucleotides, custom-designed to identify previously 
detected gene mutations, are arrayed on a glass slide. A mini-sequencing reaction 
is performed using four unique dye-labeled terminator nucleotides and DNA 
polymerase, followed by stringent washing of the slides. The slides are imaged 
with the Genorama™ QuattroImager and the sequence variants are identified by 
Genorama™ genotyping software. The slides can only be used once, and can of 
course only detect previously identified mutations (figure 1.6). The ABCR500, LCA 
and Usher syndrome microarrays are currently available, and arRP, adRP and xlRP 
microarrays are under development (www.asperbio.org). A comparison between the 
AGRA, APEX and sequence analysis techniques is outlined in table 1.2.
Table 1.2    Comparison of different genotyping techniques for one patient analyzed for defects in
10 genes (with an average of 10 exons)
AGRA APEX Sequence analysis
Advantage • identifies all small
   nucleotide substitutions
• rapid
• affordable (€100/
   sample)
• identifies all small 
   nucleotide changes
Disadvantage
• misses heterozygous 
   insertions and deletions
• expensive (€1.500/
   sample)
• does not detect 
   new mutations
• time consuming
• expensive in larger
   genes (€1.200/sample)
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Figure 1.5  Schematic representation of the AGRA technique
The same 17-mer probe hybridisation is depicted for wildtype and mutant template (PCRed genomic) 
DNA. A. ‘Wild-type’ 17-mer linked to glass slide. B. Hybridization of wild-type template (perfect match) and 
mutant template (mismatch) to the 17-mer. C. Upon stringent wash, only the wild-type template remains 
annealed and a signal is detected.
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Figure 1.6  Outline of the allele-specific primer extension (APEX) technique
Step 1: 25-mers specific for a nucleotide sequence just next to a variant nucleotide are linked to a 
            glass slide. 
Step 2: hybridization of fractionated wild-type or mutant genomic sequences amplified by PCR. 
Step 3: primer-extension using fluorescently labeled dideoxynucleotides distinguishes between different  
 variants. 
Step 4: separation of template DNA and detection of specific fluorescent dye.
1.6  Therapeutic prospectives
With the exception of LCA patients, who are generally born blind or severely visually 
impaired, patients suffering from most other inherited retinal dystrophies most 
commonly slowly lose their remaining visual function. As yet there is no definitive 
treatment available. This devastating knowledge has led desperate patients to seek 
controversial “treatments”, sometimes with serious adverse events66. Currently, three 
experimental treatments are being tested in human clinical trials after many years of 
successful animal model studies. 
1.6.1  Gene replacement
Gene replacement therapy represents the most logical approach for long-term 
therapeutic effects in inherited retinal degenerations. In principle, mutations that 
lead to loss-of-function (as in autosomal recessive and X-linked diseases, but also 
in autosomal dominant diseases caused by haplo-insufficiency), the genetic defect 
in principle can be corrected through the introduction of a wild-type version of the 
gene into the cells in which normal functioning of this gene is required (in most 
cases photoreceptor cells or the RPE). Replacement is actually not correct since the 
mutant gene is not removed.
There are many animal models of autosomal recessive retinal diseases, and some 
studies with these animals have proven great potential. Rpe65-/- canines lack 
the RPE65 protein involved in the retinoid metabolism. By a single injection of a 
recombinant adeno-associated virus (AAV) carrying the missing wild-type RPE65 
cDNA into the subretinal space, Acland and co-workers obtained definitive recovery 
of the visual function as was proven objectively by functional tests (ERG, reaching 
20% of the normal cone response) and subjectively by behavioral studies and the 
apparent loss of nystagmus67,68. At the time of writing this thesis the first human trials 
for gene-replacement therapy for retinal disease are about to start. It will take time 
though, before this technology comes into clinical practice. Moreover, this therapy 
will not be applicable to all LCA and RP patients, for mutations in RPE65 have been 
identified in only a minority (6-16%) of the LCA and juvenile RP patients48. 
1.6.2  Mutation-independent therapeutic strategies
Mutation-independent therapies may play an important role in future treatments 
of RP, but will theoretically only slow down or stop photoreceptor apoptosis. They 
will be applicable to most patients regardless of the genetic defect and will limit 
their handicap. The therapeutic effects of these therapies are based on transferring 
anti-apoptotic genes to the photoreceptors or, more readily, deliver neuroprotective 
factors. These modulate the microenvironment of the photoreceptors and by that 
stabilize the disease before loss of cone photoreceptor cells occurs.
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Several trophic factors are used in studies with animal models and all show 
promising results on delaying photoreceptor degeneration. Unfortunately the serious 
negative side effects have thus far made these factors unacceptable for human 
therapy69-71. Currently, the most promising trophic factors for treatment of RP are 
glial cell line-derived neurotrophic factor (GDNF)72 and brain-derived neurotrophic 
factor (BDNF)73. So far, the precise pathway of action of the neuroprotective factors 
remains unknown and more fundamental research is necessary. 
In 1993 Berson and colleagues demonstrated in a large randomized, controlled, 
double-masked blind treatment trial with vitamin A palmitate, a small but 
significant slowing of the retinal disease progression by a daily intake of 15.000 
IU73-75. In a more recent study Berson demonstrated that docosahexaenoic 
acid taken in addition to vitamin A had a positive effect on further slowing down 
disease course73,76,77. Caution should be taken since the patient cohort was very 
heterogeneous. In some cases, depending on the type of molecular defect, 
accumulation of vitamin A may occur, which as a consequence may result in toxic 
levels of vitamin A. Furthermore, high doses of vitamin A are teratogenic and should 
therefore not be subscribed before or during pregnancy. 
The sensation of a visual stimulus does not require viable eye tissue since this can 
also be reached by direct stimulation of the appropriate area of the visual cortex. 
For this purpose epiretinal devices have been developed that deliver a signal that 
bypasses the sophisticated coding of the visual system. In RP the photoreceptors 
are damaged, dead or absent but the inner retina remains relatively healthy. In five 
patients with bare or no light perception, intraocular placed electrodes coupled with 
an optically isolated, constant current generator, were used to deliver these pulses 
and proved to elicit a visual perception of a correct retinotopical spot. In one of 
the five patients this resulted in a visual acuity of 1/6073,78. Ultimately, these artificial 
retinal chip implants may serve patients with severe generalized retinal degeneration 
who have little or no perception of light. 
 
1.6.3.  RPE and stem cell transplantations
Replacement studies of the RPE, in order to obtain beneficial effects for the adjacent 
photoreceptors, and of retinal neuronal transplantation, in order to replace the 
degenerate tissue altogether, were moderately successful in animal models. The 
ultimate goal of these transplantations is to replace lost tissue with viable and 
healthy cells that have the capacity to re-establish the cellular connections73,79. 
Currently, it is even possible to transplant embryonic retinal cells to degenerating 
retinas in animal models. The cells are viable, proliferate, differentiate and are 
protected by the immune privilege of the eye. Unfortunately, only a small fraction of 
the transplanted cells survive and the normal retinal structure is never regained80. 
Of course in humans the transplant of embryonic cells faces ethical questions and 
alternatives are under investigation. The transplantation of healthy RPE cells in the 
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subretinal space in an animal model proved to delay photoreceptor and retinal 
function loss81-84. Unfortunately this will be of little relevance to most human forms of 
retinal dystrophy. Radtke and co-workers used a graft of fetal neural retina with its 
RPE and transplanted this, unilaterally, into the subretinal space under the fovea of 
an RP patient. After one year there were still no clinical signs of graft rejection and 
there was an improvement of the visual acuity from 20/800 to 20/16085.
Recently Tomita86 and Kicic and co-workers87 demonstrated the ability of bone 
marrow-derived stem cells to integrate into the host retinas, to differentiate into cells 
expressing photoreceptor-specific markers and to establish neuronal connections 
after transplantation of these cells in vivo. Previous studies that demonstrated stem 
cell transplantation as a therapy in neurodegenerative diseases were under heavy 
discussion and faced ethical and legislative opposition for they used allogenic adult 
brain-derived neural progenitor cells or embryonic retinal precursors. Furthermore, 
these techniques were of potential risk for infection transmission and potential graft 
rejection. The new techniques use autologous bone marrow-derived stem cells and 
so bypasses these oppositions. 
In conclusion, worldwide efforts for generating treatments for inherited retinal 
diseases are promising but are still facing a long way before becoming accessible 
for humans suffering from inherited retinal dystrophies. A better understanding of the 
cellular and molecular interactions of photoreceptors and their environment before 
and during degeneration will not only provide novel information on normal retinal 
development and function but will also help in understanding disease pathogenesis 
forming a true basis for identifying treatment possibilities.
1.7  Outline of this thesis
Accurate genotype-phenotype correlation studies of the heterogeneous group of 
retinal dystrophies will contribute to delineate different and overlapping types of 
disease and improve the present classifications. A more detailed clinical and genetic 
classification will help ophthalmologists to give a more accurate diagnosis and 
enhance the knowledge on disease course. In addition will the clinical appearance 
help to suggest the underlying molecular defect. Accordingly, accuracy of individual 
counseling will increase. Structural molecular analysis will also allow prenatal 
diagnostics in selected cases and in the future, it will help in differentiating patients 
for different kinds of therapy. Patients in which no molecular defects can be found 
will also be of interest as they form a patient cohort in which new retinal dystrophy 
genes can be identified with novel strategies.
There is a growing need for the integration of the clinical characteristics of inherited 
retinal dystrophies with the molecular diagnosis. The main objective of this 
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thesis was to contribute to the clarification of genotype-phenotype correlations 
in autosomal recessive inherited retinal dystrophies. In chapters 2.1 and 2.2 the 
molecular analysis of mutations in the ABCA4 gene using two new techniques, 
and their phenotypical correlation, are discussed. This provided new information 
on the use and usefulness of rapid molecular screening tools and the phenotypical 
descriptions of arRP and arCRD patients with mutations in ABCA4.
In chapter 3 the different genotypes and phenotypes in Leber congenital amaurosis 
are discussed showing that mutations in different LCA genes lead to different clinical 
subtypes of LCA, both clinical and functional. 
Two of the LCA genes discussed in chapter 3 are discussed in more detail 
in chapters 4 and 5. In chapter 4 a large Dutch consanguineous family with 
homozygous mutations in the RPE65 gene is described, suggesting that patients 
with the same mutations do not necessarily display an identical phenotype. In 
chapter 5, data are presented that show that most heterozygous carriers of CRB1 
mutations display a focal functional abnormality upon multifocal ERG testing 
predominantly affecting the infero-nasal retina. 
Finally, the results of this thesis on autosomal recessive retinal dystrophies is 
discussed and summarized in chapters 6 and 7 respectively.
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Abstract
Mutations in the ABCA4 gene have been associated with autosomal recessive 
Stargardt disease (STGD1), cone-rod dystrophy (CRD), and retinitis pigmentosa 
(RP). We employed a recently developed genotyping microarray, the ABCR400 
chip, to search for known ABCA4 mutations in patients with isolated or 
autosomal recessive CRD (54 cases) or RP (90 cases). We performed detailed 
ophthalmologic examinations and identified at least one ABCA4 mutation in 
18 patients (33%) with CRD and in 5 patients (5.6%) with RP. Single strand 
conformation polymorphism (SSCP) analysis and subsequent DNA sequencing 
revealed four novel missense mutations (R24C, E161K, P597S, G618E) and 
a novel 1-bp deletion (5888delG) on the second allele of the patients in this 
cohort. Ophthalmoscopic abnormalities in CRD patients ranged from minor 
granular pigmentary changes in the posterior pole to widespread atrophy. In 12 
patients with recordable electroretinogram (ERG) tracings, a cone-rod pattern 
was detected. Three patients demonstrated progression from a retinal dystrophy 
resembling STGD1 to a more widespread degeneration, and subsequently 
received the diagnosis of CRD. In addition to a variable degree of atrophy, 
all RP patients displayed ophthalmologic characteristics of classic RP. When 
detectable, ERG recordings in these patients demonstrated rod-cone patterns 
of photoreceptor degeneration. In conclusion, in this study we show that the 
ABCA4 mutation chip is an efficient first screening tool for autosomal recessive 
CRD. 
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Introduction
The ABCA4 (ABCR) gene was identified as the gene underlying autosomal 
recessive Stargardt disease (STGD1)1. Since the cloning of the ABCA4 gene, other 
studies have implicated this gene also in autosomal recessive CRD (arCRD) and in 
autosomal recessive RP (arRP)2-17. In addition, heterozygous ABCA4 mutations were 
found in 16% of cases with age-related macular degeneration18. The high prevalence 
of heterozygous ABCA4 mutations in the general population and the inability of 
relatively small-sized studies to replicate this result, shed doubt on the significance 
of the molecular findings in patients with AMD19-24. In a larger independent study, two 
ABCA4 mutations were significantly associated with AMD25.
The ABCA4 gene encodes the ABCR protein, previously identified as the rim 
protein (RmP), a retina-specific (adenosine triphosphate) ATP-binding cassette 
transporter. This protein is thought to act as a flippase for N-retinylidene 
phosphatidylethanolamine (N-retinylidene-PE), thereby facilitating the transport of 
all-trans-retinal from the disk lumen to the photoreceptor cytoplasm26,27. In Abcr-/- 
mice, N-retinylidene-PE is converted, through various intermediates, into A2E, 
a major component of lipofuscin. A2E accumulates in toxic levels in the retinal 
pigment epithelium (RPE), eventually resulting in the degeneration of the RPE and 
the overlying neuroretina. Interestingly, Abcr-/- mice raised in complete darkness do 
not accumulate A2E, suggesting that avoiding excessive light might be beneficial 
for humans with ABCA4-associated retinal dystrophy28. Recently, Radu and 
colleagues were able to rescue retinal dystrophy in Abcr-/- mice by treating them 
with isotretinoin, a drug commonly used in dermatology for the treatment of severe 
acne29. Both studies show that therapeutic approaches for humans with ABCA4-
associated retinal dystrophies are feasible, which underlines the importance to 
identify patients with CRD and RP caused by mutations in ABCA4.
Numerous mutation analysis studies in patients with STGD1 have yielded more 
than 400 different ABCA4 mutations1,6,8,9,22,30-35. Unlike STGD1, arCRD and arRP 
are not genetically homogeneous disorders (www.sph.uth.tmc.edu/RetNet)2,36-38. 
Studies investigating the role of ABCA4 mutations in arCRD estimate involvement 
of this gene in 24-75% of all cases5-9,11,16. ABCA4 mutation analysis in arRP patients 
thus far was restricted to families in which STGD1 and RP segregated4,10,14,15,17.  
Therefore, it has not been possible to accurately predict the contribution of ABCA4 
mutations in arRP pathology. Recently, a genotyping microarray (ABCR400 chip) 
was developed containing all currently known ABCA4 mutations which reliably 
identifies all known ABCA4 mutations in patients with STGD139. 
In this study, we utilized the ABCR400 array to systematically screen for mutations 
in patients with isolated or autosomal recessive RP (90 patients) and CRD (54 
patients). We re-evaluated the clinical features in patients with ABCA4 mutations 
and provide, for the first time, an assessment of the contribution of ABCA4 gene 
mutations as a cause for arRP in a Caucasian population.
Materials and Methods
Patients and controls
The charts of 90 patients with isolated (56) or autosomal recessive (34) RP and 54 
patients with isolated (35) or autosomal recessive (19) CRD were collected from the 
centres collaborating in this study. RP patients were ascertained in Nijmegen (74), 
Rotterdam (10), and Heidelberg (6). CRD patients were ascertained in Heidelberg 
(36), Nijmegen (14), and Rotterdam (4). Some of these cases might be due to X-
linked or autosomal dominant mutations. In the remainder of this chapter the patient 
groups will be designated as CRD and RP. 
This study was approved by the institutional review board (CCMO). After informed 
consent was obtained, blood samples were taken. Samples from 93 healthy Dutch 
blood donors were used as controls. The clinical data of all patients were examined 
and, when data were incomplete or obtained with obsolete methods, patients 
were clinically re-evaluated. Kinetic perimetry was performed with the Goldmann 
perimeter. A recent electroretinogram (ERG), recorded in accordance with the ISCEV 
protocol40, was available for all patients, except for patient 9444. The employed 
ERG methods for this patient, as well as the earlier ERGs of three other patients, 
were performed as described by Thijssen et al41 (patients 12608 and 15680) and 
Alexandridis et al (patient 15730)42. When possible, color vision was tested with the 
Ishihara and Panel D15 tests. The diagnosis of CRD was based on initial complaints 
of decreased or blurred central vision, without a history of night blindness. 
Maculopathy, characterized by a bull’s eye pattern or granular alterations of the 
macular RPE, with or without relatively mild peripheral retinopathy was considered 
typical. Visual field testing usually shows a central scotoma, while the peripheral 
fields are either normal or show a mild to moderate constriction. In addition, ERG 
recordings in CRD either show reduction or absence of cone responses in the 
presence of quantitatively less reduction in rod responses, or an equal impairment 
of both photoreceptor systems43-46. The initial symptom in RP patients is night 
blindness. Visual field defects typically originate in the midperiphery, with gradual 
enlargement to both the periphery and the centre of the retina. Typically, the ERG 
recordings demonstrate photoreceptor degeneration in a rod-cone pattern47. In 
many cases, especially in the later stages of both CRD and RP, rod and cone ERGs 
may be equally impaired or may become non-recordable, which makes it difficult 
to provide an accurate diagnosis. In such cases the nature of the initial complaints, 
the aspect of the fundus and - if available - ERG recordings of an earlier stage of the 
retinal dystrophy are used to discriminate between RP and CRD.
Mutation screening 
The microarray mutation analysis of the ABCA4 gene with the ABCR400 chip 
was performed as described earlier39.  In patients with one ABCA4 mutation, we 
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searched for the second mutation using single strand conformation polymorphism 
(SSCP) analysis and DNA sequence analysis of aberrantly migrating fragments 
as described elsewhere5 (ref 5 and references therein). The ABI PRISM Big Dye 
Terminator Cycle Sequencing V2.0 Kit was used for sequencing and the reactions 
were analyzed with the ABI PRISM 3700 DNA analyzer (Applied Biosystems). 
Four novel missense mutations were tested in 93 control DNA samples. The 
presence of p.R24C (c.70C>T) was analyzed using HinfI restriction fragment analysis 
of PCR-amplified exon 2. The normal PCR product (191 nts) was cut into fragments 
of 167 and 24 nts; the mutant PCR product with the 70C>T alteration was not 
digested. p.E161K (c.481G>A) was tested using MboII which cuts the normal PCR 
product of exon 5 (240 nts) in three fragments (170, 40, 30 nts) and the mutant PCR 
product in two fragments (200 and 40 nts). The p.P597S (c.1789C>T) mutation was 
analyzed using AlwI, which cuts the normal PCR product of exon 13 (280 nts) into 
fragments of 100, 90, 60 and 30 nts and the mutant PCR product into fragments 
of 160, 90 and 30 nts. An amplification-refractory mutation specific (ARMS) assay48 
was performed to test p.G618E (c.1853G>A). For specific amplification of the 
mutant sequence, the SSCP reverse primer was used and a mutation-specific 
forward primer (5’ GCAGGACATGGTTGAACAGCA 3’). ARMS cycling parameters 
consisted of 94oC for 5 min, followed by 35 cycles of 94oC for 30 sec, 58oC for 30 
sec, 72oC for 1 min, and a final extension of 5 min at 72oC using 2.0 mM MgCl2. 
Results
Mutation analysis
Genotyping was performed on DNA isolated from blood samples of 54 CRD patients 
and 90 RP patients with the ABCR400 chip. Employing the ABCR400 microarray 
chip we identified ABCA4 mutations in 18 (33%) patients with CRD (table 2.1.1) 
and in five (5.6%) patients with RP (table 2.1.2). Eleven of 54 CRD patients were 
compound heterozygous (9) or homozygous (2) for ABCA4 variants; seven were 
heterozygous. Four out of 90 RP patients were heterozygous; one patient was 
compound heterozygous for ABCA4 variants. Although the segregation of the 
p.L541P and p.A1038V mutations could not be tested in the respective families, we 
have grouped them as complex alleles, based on previous observations that these 
alterations invariably occur in cis configuration in German patients with CRD (table 
2.1.1)5,34. Indeed, all four patients carrying these variants (14488, 14752, 16242 
and 16582) were from Germany. Likewise, the ΔG863 variants are presumed to be 
located in the same allele since the p.G863A allele in previous studies was always 
found together with p.R943Q (see discussion)33,51. 
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Next, we employed SSCP analysis and DNA sequencing in patients with one 
ABCA4 mutation and identified five novel ABCA4 mutations that were not present 
on the microarray, that is, p.R24C, p.E161K, p.P597S, p.G618E, and c.5888delG. 
None of the four new missense mutations could be identified in a panel of 93 healthy 
control individuals. The c.5888delG mutation is predicted to result in the truncation 
of the second nucleotide binding domain of the ABCR protein and can thus be 
considered a null mutation. The four novel missense mutations significantly alter the 
charge or hydrophobicity of the respective amino acid residues, which invariably are 
conserved in mouse Abcr and, with the exception of p.R24C, also in human ABCA1 
(data not shown). p.R24C is located in the N-terminal cytoplasmic domain, one 
residue next to the first transmembrane domain of ABCR. p.E161K is located in the 
first lumenal loop; p.P597S and p.G618E are both located in first cytoplasmic loop.
In three cases with isolated CRD (12608, 16697, and 16887) we were able to 
perform segregation analysis of the mutations. The mutations in patients 12608 and 
16887 were shown to be located on different chromosomes. In family members 
of patient 16697, the p.G863A; p.R943Q variants segregated from the p.G618E; 
p.V1433I mutations. For the other patients with two or more ABCA4 variants, no 
parents or unaffected siblings were available for genetic analysis. The three variants 
identified in patient 16243 were arbitrarily indicated in the table since we were 
unable to test their segregation.
Ophthalmologic analysis of CRD patients
An overview of the clinical findings in the patients with ABCA4-associated CRD is 
given in table 2.1.3. All patients experienced a loss of central visual acuity as the 
initial symptom; in most patients a central scotoma was present, varying from ten to 
40 degrees in size. The visual acuity in most of these patients is 20/125 or lower. An 
exception is patient 15429 with a visual acuity of 20/32 at 53 years, which cannot 
be attributed to the early stage of the disease progression. Color vision tests could 
be performed in 11 patients, who all demonstrated a red-green defect. In ten of the 
18 patients, the photopic (cone) responses on the ERG are more severely decreased 
compared to the scotopic (rod) responses. In patients with nonrecordable or equally 
reduced cone and rod responses, the diagnosis CRD was based on earlier ERG 
recordings, the initial symptoms, and the overall aspect of the fundus. 
Three patients (14752, 16697, and 16887) presented with yellow flecks, located 
at the posterior pole and midperiphery (figure 2.1.1b, patient 16887). Two of these 
individuals were initially diagnosed with STGD1 and demonstrated characteristic 
blocking of choroidal background fluorescence. However, in the later stage of their 
disease, these patients developed full-field ERG abnormalities in a cone-rod pattern. 
These patients should therefore be classified either as STGD1 with peripheral 
involvement or as CRD.
48
Table 2.1.1   ABCA4 sequence variants in CRD patients
Novel variants in bold lettering. *Mutation which is presumed to be in linkage disequilibrium with unknown 
pathologic ABCA4 mutation. $polymorphic variants 4203A, 5603T, and 5682C also present. ?, segregation 
analysis not possible or not determined; NA, not applicable.
CRD
patient
number
Inheri-
tance
Allele 1 Allele 2
Mutations 
segregateNucleotide
change
Effect
Nucleotide 
change
Effect
12608 Isolated IVS38-10T>C Unknown* IVS38-10T>C Unknown* yes
14488 Isolated
1622T>C; 
3113C>T
L541P; 
A1038V
Not identified
NA
14750 Isolated 4918C>T R1640W Not identified NA
14752 Isolated
1622T>C; 
3113C>T
L541P; 
A1038V
IVS38-10T>C Unknown* ?
15105 Isolated IVS36+2T>C Splicing IVS40+5G>A Splicing ?
15428 Isolated
1622T>C;
3113C>T
L541P; 
A1038V
2300T>A V767D ?
15429 Isolated 52C>T R18W 70C>T R24C ?
15680 Isolated 5882G>A G1961E Not identified NA
15730 Isolated
2588G>C; 
2828G>A
ΔG863/G863A; 
R943Q
2588G>C; 
2828G>A
ΔG863/
G863A; 
R943Q
?
16242 Isolated
1622T>C; 
3113C>T
L541P;  
A1038V
Not identified NA
16243 Isolated 5381C>A A1794D 1789C>T P597S ?
481G>A E161K
16569 Aut. rec. 3259G>A E1087K Not identified NA
16582 Isolated
1622T>C; 
3113C>T
L541P; 
A1038V
IVS38-10T>C Unknown* ?
16583 Isolated 194G>A G65E 768G>T Splice site ?
16697 Isolated
2588G>C; 
2828G>A$
ΔG863/G863A; 
R943Q
1853G>A; 
4297G>A
G618E;
V1433I
yes
16755 Isolated
2588G>C; 
2828G>A
ΔG863/G863A; 
R943Q
Not identified NA
16887 Isolated 768G>T Splicing IVS38-10T>C Unknown* yes
17906 Aut. rec. 768G>T Splicing Not identified NA
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Table 2.1.2   ABCA4 sequence variants in RP patients
Novel variant in bold lettering. $Polymorphic variants 4203A, 5603T, and 5682C also present. 
RP
patient
number
Inheri-
tance
Allele 1 Allele 2
Nucleotide 
change
Effect
Nucleotide 
change
Effect
9304 Aut. Rec.
2588G>C; 
2828G>A$
ΔG863/G863A; 
R943Q
5888delG R1963fs
9444 Aut. Rec. 6529G>A D2177N Not identified
9545 Isolated 6529G>A D2177N Not identified
14753 Isolated
1622T>C; 
3113C>T
L541P; 
A1038V
Not identified
17597 Isolated 6148G>C V2050L Not identified
 
Figure 2.1.1   Fundus pictures of patients with CRD and RP
a.  CRD patient 15680 with bull’s eye maculopathy and temporal pallor of the optic disc (with myelinated  
nerve fibers). In the periphery (not visible) there are minor hyperpigmentations but the retinal vessels are 
of normal size. 
b.  Chorioretinal atrophy in the posterior pole of CRD patient 16887. Mild granular changes located at mid-
peripheral retina (not visible). This patient was initially diagnosed as STGD1, in view of the yellow flecks, 
which are still faintly visible.  
c.  CRD patient 16569, taken at age 12, with an obvious pallor of the temporal optic nerve head and atro-
phic changes in the macula. At that time, the photopic ERG is already nonrecordable and the scotopic 
ERG is severely decreased. 
d.  RP patient 17597 shows typical RP features such as bone spiculas in the periphery and attenuated 
retinal vessels. Large choroidal vessels can be seen in the midperiphery indicative of atrophic changes.
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Ophthalmologic analysis RP patients
The clinical data of the five RP patients with ABCA4 mutations are summarized 
in table 2.1.4. Typical RP features like peripheral bone spicules and progressive 
attenuation of the retinal vasculature were invariably present. Only patient 9304 
demonstrated extensive chorioretinal atrophy. Color vision tests could be performed 
in three patients: all had blue-yellow type defects. In patients 9304 and 14753, no 
scotopic and photopic ERG responses could be elicited, the other three patients 
demonstrated a rod-cone pattern of photoreceptor degeneration.
Discussion
In previous ABCA4 mutation analysis studies, RP patients were ascertained because 
of their familial relationship with STGD1 patients. In this study, we describe the 
first systematic search for ABCA4 mutations in patients with isolated or autosomal 
recessive RP. In addition, this is the first CRD mutation analysis study that is primarily 
based on a genotyping microarray. The ABCA4 gene has shown an extraordinary 
allelic heterogeneity and most of the sequence variants have been observed in only a 
few cases. Therefore, the interpretation of the pathologic nature of sequence variants, 
in particular missense mutations and apparently benign variants, is problematic. 
Pathogenicity of ABCA4 variants
In table 2.1.5, the functional consequences of ABCA4 missense mutations, that 
is ABCR protein expression, ATP binding, and ATPase activity, are summarized. 
Likewise, the known or predicted effects of the splice site mutations are indicated. 
For two conservative missense mutations (p.V1433I and p.V2050L), the pathologic 
nature can be questioned. The c.IVS38-10T>C variant is a splice acceptor variant 
that has no detrimental effect on splicing, but has been found in 27 of 518 STGD1 
patients compared to one of 316 ethnically matched control individuals34,35. 
Therefore, it is very well possible that the c.IVS38-10C variants observed in five 
CRD alleles in our patient cohort are in linkage disequilibrium with an unidentified 
pathologic ABCA4 mutation. In two RP patients, we identified the p.D2177N 
mutation heterozygously. The p.D2177N mutation has never been found in patients 
with STGD1 but was found to be associated with age-related macular degeneration 
at a statistically significant level25. As shown by Sun et al50, this mutation, contrary to 
other mutations, results in increased ATP hydrolysis when compared to the wild type 
protein52. These data do not allow us to draw a definitive conclusion regarding the 
pathologic nature of p.D2177N. 
An unexpected finding is the detection of the ΔG863 variant in four patients; 
homozygous in one CRD patient and heterozygous in three CRD/RP patients. Based 
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on a genotype-phenotype correlation model proposed by us and others, individuals 
carrying two ΔG863 alleles would not be expected to show retinal pathology since 
this variant was deemed a mild allele33,49. In three of the ΔG863 carrying haplotypes 
(in patients 15730 and 16755, table 2.1.1), the ΔG863 and 2828A variants are 
not accompanied by the polymorphic variants 4203A, 5603T and 5682C (data 
not shown), but might have been linked to a more severe mutation in the 3’ part 
of the gene. Also, the ΔG863 variant has been found in cis with an intragenic 
deletion spanning exon 14 of the ABCA4 gene in a French RP patient4. Secondly, 
other genetic factors might have a significant effect on the phenotypic outcome 
of ABCA4 mutations. This was recently demonstrated in one of two siblings with 
autosomal dominant STGD3-associated macular dystrophy in which a heterozygous 
ABCA4 mutation aggravated the retinal dystrophy52. Finally, in view of the high 
carrier frequency of the ΔG863 allele in the Dutch (1.4%)51 and German (1.0%)51 
populations, patients 15730 and 16755, who only carry the ΔG863 variant(s), might 
do so by chance.
Table 2.1.5   Functional assessment of missense (A) and splice site (B) mutations
A.
Missense
mutation
Nature of amino 
acid change
Effect on ABCR function (ref.)
R18W Non-conservative Unknown
R24C Non-conservative Unknown; adjacent to 1st transmembrane domain
G65E Non-conservative Unknown
E161K Non-conservative Unknown
L541P Conservative Decreased ATP-binding & ATPase activity (52)
P597S Non-conservative Unknown
G618E Non-conservative Unknown
V767D Non-conservative Decreased ABCR expression (10)
G863A Non-conservative Decreased ATPase activity (52, 53)
R943Q Non-conservative Decreased ATPase activity (53)
A1038V Conservative Decreased ATP-binding & ATPase activity (52)
E1087K Non-conservative Decreased ATP-binding (52)
V1433I Conservative Unknown
R1640W Non-conservative Unknown
A1794D Non-conservative Introduction charged aa in 10th transmembrane domain
G1961E Non-conservative Decreased ATP-binding & ATPase activity (52)
V2050L Conservative Unknown
D2177N Non-conservative Increased ATPase activity (52)
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B.
Splice site
mutation
Effect on mRNA (ref.) Predicted effect on ABCR protein
768G>T Nonsense mediated decay (33) No protein
IVS36+2T>C Unknown
Truncation of exon 36 
resulting in V1673fs?
IVS38-10T>C No effect (34)
Variant in linkage disequilibrium 
with unknown mutation
IVS40+5G>T 350-bp insertion in ~50% of mRNA (34) Insertion of aberrant amino acid stretch?
Phenotypic spectrum of CRD and RP patients with ABCA4 mutations
CRD patients present with a substantial clinical heterogeneity as observed in other 
studies7,13,16,17. This variability is expressed in the rate of visual loss, the extend of the 
visual field defects, and the ophthalmoscopic appearance. Three of the 18 ABCA4-
associated CRD patients in this study represent a subtype that initially resembles 
STGD1 but, contrary to the classic juvenile macular degeneration of Stargardt, 
progresses to a more widespread loss of cone and rod photoreceptors. Improved 
genotype-phenotypes correlations in the future would enable the early detection of 
STGD1 patients that are at risk for progression to this CRD phenotype. 
Thus far, patients with RP and ABCA4 mutations have demonstrated a remarkably 
homogeneous phenotype, characterized by severe loss of visual functions, extensive 
atrophy, and early loss of ERG responses2-4,10,12,15,17. In this study, only one of five RP 
patients with ABCA4 variants (9304) demonstrates this characteristic atrophy. The 
RP phenotype in the remaining patients is moderately severe, with variable atrophy; 
in addition, ERG responses can often still be elicited. Given this clinical presentation 
and the fact that homozygous null mutations were not found in these patients, it is 
possible that the ABCA4 mutations did not contribute to the RP phenotype in some 
or all of these four patients. If, on the other hand, alterations in the ABCA4 gene are 
responsible for these RP phenotypes, the phenotypic variability of ABCA4-related 
RP is higher than assumed. 
ABCA4 involvement in CRD and RP patients
Genotyping of 90 RP patients revealed sequence variations in the ABCA4 gene 
in five individuals. As discussed above, only one of these patients shows the 
ophthalmologic features seen in other RP patients with ABCA4 mutations. Taken 
into consideration the high heterozygosity frequency of ABCA4 mutations in the 
general population, these data strongly suggest that ABCA4 mutations are only 
a minor cause (2-5%) of arRP not exceeding the contribution of most other arRP 
genes (www.sph.uth.tmc.edu/Retnet). 
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We also identified 27 putative pathologic ABCA4 alleles in 18 (33%) of 54 patients with 
CRD. Four additional missense mutations in three of these patients were identified 
using SSCP and sequence analysis. Besides the ABCA4 gene, only one other gene 
(retinol dehydrogenase 5 - RDH5) and two loci (CORD8 on 1q12-q24 and CORD9 
on 8p11) have been implicated in arCRD or arCD36-38. If earlier data are combined 
with the results of this study, ABCA4 mutations are found in 40% of the arCRD cases 
(table 2.1.6). It can be estimated that, on average, the mutation detection efficiency 
for ABCA4 mutations is 60% (ref. 39 and references therein), suggesting that ABCA4 
mutations could be present in approximately 67% of arCRD cases.
Table 2.1.6   Incidence of ABCA4 mutations in different cohorts of CRD patients
Study
Number of CRD 
patients analysed
Number of Patients 
with ABCA4 mutations
Maugeri et al5 20 13
Papaioannou et al6 8 4
Birch et al7 30 11
Briggs et al8 8 6
Paloma et al9 2 2
Ducroq et al11 55 13
Fishman et al16 30 16
Current study 54 18
Total 207 83 (40%)
Microarray analysis as a tool for DNA diagnostics in CRD and RP
The analysis of the ABCA4 gene is of importance to establish the mode of inheritance 
in CRD families, which is associated with very different recurrence risks in the offspring 
of mutation carriers. In the future, genotyping may also be helpful to accurately 
predict the development of ABCA4-associated retinal dystrophies, especially for 
the subgroup of patients initially diagnosed as STGD1 with subsequent progression 
to CRD. In addition, identification of patients with causal ABCA4 mutations might 
become very important if novel insights regarding ABCA4-associated pathology and 
treatment of Abcr-/- mice develop into rational therapeutics for human patients. It 
is likely that mutation chip technology, which enables fast, reliable and cost-efficient 
mutation analysis, will play an important role in these future developments.
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Abstract
Purpose 
To identify the causative gene mutations in three siblings with severe progressive 
autosomal recessive cone-rod dystrophy (arCRD) and their fifth paternal cousin 
with Stargardt disease (STGD1) and to specify the phenotypes.
Methods
A family displaying arCRD and STGD1 was ascertained and screened for 
mutations using a new microarray (arRP-I) for autosomal recessive retinitis 
pigmentosa (arRP). All clinical data were evaluated.
Results
We found a new pathologic ABCA4 splice-site mutation, c.3523-2A>T and the 
previously reported c.5327C>T (p.P1776L) missense mutation in the arCRD 
patients. The three siblings shared these two ABCA4 mutations and showed 
similar phenotypes. An unusual aspect was nystagmus which was found in one 
of the arCRD patients. In the STGD1 patient we found the c.5327C>T (p.P1776L) 
missense mutation and a novel c.868C>T (p.R290W) missense mutation.
Conclusions
Two new ABCA4 mutations were identified in a family with arCRD and STGD1. 
A new finding was nystagmus associated with arCRD in one of the patients. 
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Introduction
Retinal dystrophies display a high degree of clinical and genetic heterogeneity. 
Frequently, a single disease may be caused by mutations in a multitude of different 
genes, and in some cases mutations in a single gene may lead to clinically distinct 
diseases. One such gene is the retina specific ATP-binding cassette transporter 
(ABCA4) gene. Mutations in the ABCA4 gene have been shown to cause most 
cases of autosomal recessive Stargardt disease (STGD1) (MIM248200), a significant 
fraction of cases of autosomal recessive cone-rod dystrophy (arCRD) (MIM604116), 
and in some cases, mutations in ABCA4 were found in patients suffering from 
autosomal recessive retinitis pigmentosa (RP)1-16. ABCA4 has also been suggested 
to be a susceptibility factor for age-related macular degeneration (AMD)17,18.
ABCA4 is a member of the ATP-binding cassette (ABC) transporter gene 
superfamily and encodes the ABCR protein. ABCR is located at the rim of the 
outer segment discs of rod and cone photoreceptors19,20 and is involved in the 
transport of all-trans-retinaldehyde across photoreceptor disc membranes from the 
lumen to the photoreceptor cytoplasm through a flippase activity21-23. Mutations in 
ABCA4 lead to an accumulation of all-trans-retinal inside the photoreceptor disc 
lumen. This free all-trans-retinal is unfavourable and therefore Schiff-bonded to 
phosphatidyl ethanolamine. This bondage leads to toxic levels of N-retinylidene-N-
retinylethanolamine (A2E) in the RPE, which results in RPE cell apoptosis, followed 
by irreversible photoreceptor cell death23-25.
The variability of severity in the different diseases associated with ABCA4 mutations 
has led to a genotype-phenotype model in which the residual activity of the mutated 
ABCR protein is inversely correlated with the severity of the retinal dystrophy2-12. This 
model predicts that two severe (null) mutations may lead to arRP, a combination of a 
severe with a moderately severe mutation may result in CRD, and two moderate or a 
severe and a mild mutation may lead to STGD14.
We present a pedigree displaying both arCRD and STGD1 in which some of the 
causative mutations in ABCA4 were identified with the Affymetrix Gene Chip 
CustomSeqTM Resequencing Array (arRP-I)26. This technique allowed us to identify 
two novel ABCA4 mutations. Further, we present the ABCA4-associated CRD and 
STGD1 phenotypes and present a new clinical feature, nystagmus.
Methods and patients 
This study was approved by the Institutional Review Board of the Montreal Children’s 
Hospital in Montreal and the used protocol adhered to the declaration of Helsinki. 
After years of follow-up of a family with three siblings suffering from arCRD, all family 
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members were asked to participate in this study. Informed consents were obtained 
and blood samples were taken.
Methods 
DNA was isolated using the Qiagen DNA isolation kit. DNA samples were then 
analysed using the arRP-I array. This newly developed custom designed array 
contain oligonucleotides designed from the exons and 5 bps of flanking intronic 
sequences from 11 of the 19 currently known arRP genes; ABCA4, CNGA1, 
CRB1, MERTK, PDE6A, PDE6B, RGR, RHO, RLBP1, RPE65, and TULP126. DNA 
of patient VI-1 was sequenced bidirectionally for all coding exons using gene-
specific PCR primers as described elsewhere (ref. 26 and references therein). The 
PCR products were purified using the Millipore purification system and thereafter 
analyzed on ABI3730 or ABI3100 DNA analyzers. Automatic analysis was done by 
ABI basecaller.
The c.868C>T (p.R290W) sequence change was tested in DNAs from 92 
anonymous healthy Dutch individuals and 95 healthy individuals from the Island of 
São Miguel (Azores, Portugal), by amplifying exon 8 of the ABCA4 gene, followed by 
restriction fragment length polymorphism (RFLP) analysis using EagI. The amplicon 
consists of 400 base pairs (bp), which in case of a wild-type allele will be cut by EagI 
into fragments of 80 and 320 bp fragments. EagI will not cut the mutated allele. 
Patients  
The pedigree consisted of 3 siblings affected with arCRD and a fifth paternal cousin 
affected with STGD1 (figure 2.2.1). Genealogic studies revealed that IV:1, IV:2, 
V:7, and V:8 originated from Sao Miguel, which is part of the Azore Archipelago. All 
clinical data were analysed retrospectively and additional information was collected 
through ophthalmic examination including best corrected visual acuity, slit-lamp 
examination, fundoscopy, electroretinography (ERG), and Goldmann perimetry.
Results
In patient V:6 several likely benign sequence variants in the ABCA4 gene were 
identified with the arRP-I chip: c.141A>G (p.P47P), c.1268A>G (p.H423R), 
c.5603A>T (p.N1868I), c.5682C>G (p.L1894L), c.6069T>C (p.I2023I) and 
c.4203C>A (p.P1401L). In addition, two likely pathologic variants were identified in 
ABCA4, c.3523-2A>T and c.5327C>T (p.P1776L). Additional sequence analysis 
was performed to confirm the presence of these two mutations and several 
intronic sequence changes were then identified (c.302+26A>G, c.859-32T>C, 
c.1239+18C>A, c.1239+28C>A, c.1356+11delG, c.4352+54A>G, c.5585-51Adel 
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and c.6817-49C>G). Indeed, sequence analysis confirmed the presence off the two 
likely pathologic variants. 
Sequence analysis of V:2 and V:5 revealed the same mutations. The three unaffected 
siblings and the mother of the patients only carried the c.3523-2A>T mutation. 
Further investigation of the family history revealed a fifth paternal cousin with STGD1.
Direct sequence analysis of the DNA of patient VI:1 identified the c.5327C>T 
(p.P1776L) missense mutation and revealed a novel ABCA4 sequence change, 
c.868C>T (p.R290W). The c.868C>T (p.R290W) sequence change was not 
detected in DNA of 92 healthy Dutch controls and in DNAs of 95 healthy individuals 
from the island of São Miguel. 
Figure 2.2.1   Pedigree and ABCA4 sequence variants
/ = deceased, = male  = female, black = affected with arCRD, open = unaffected, shaded circle = 
affected with STGD1.
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Clinical evaluation
Unfortunately, no early clinical data were available for our CRD patients, as the 
affected siblings with the CRD visited our ocular genetics clinic for the first time in 
their early forties. On history however, all sibs reported visual acuity difficulties since  
early childhood followed by peripheral field loss in the second decade. Problems at 
night occurred in the third decade. 
The visual acuity at their first visit to us ranged from light perception to counting 
fingers. Patient V:2 showed distinct pendular nystagmus. Anterior segments were 
normal in all three patients. Funduscopy revealed pale optic discs with severely 
attenuated retinal vessels in all three patients. Individuals V:2 and V:5 showed 
distinct atrophy of the RPE in the macular area  (figures 2.2.2 and 2.2.3). Bone 
spicule pigmentations were seen throughout the retina in V:2, and limited to the 
posterior pole and midperiphery in patient V:5. Patient V:6 showed heavy bone 
spicule pigmentation throughout the entire retina with extensive macular involvement. 
On ERG, no detectable signals were found in all three patients. Goldmann kinetic 
perimetry revealed small temporal islands with target V4-e in the arCRD patients.
Patient VI:1 was diagnosed with STGD1 at the age of 11 years at another institution. 
At 52 years, VA was counting fingers in the right and hand movements in the left 
eye. Funduscopy revealed normal optic discs, mild attenuation of the vessels and 
large atrophic lesions in both maculae. In the mid and periphery lobular atrophy of 
the RPE was seen (figure 2.2.4). 
Figure 2.2.2  Fundus photograph of the left eye of patient V:2 (age 46 years)
Note the attenuated vessels, the atrophic lesion in the macula, and bone-spicule pigmentations.  
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Figure 2.2.3   Fundus photograph of the right eye of patient V:5 (age 43 years)
Note the pale optic disc, moderate attenuation of the vessels and heavy bone-spicule pigmentation in the
midperiphery with a relatively spared periphery.
Figure 2.2.4   Fundus photograph of the left eye of patient VI:1 (age 52)
Note the  relatively normal optic disc, mild attenuation of the vessels and large atrophic lesion with scattered
pigmentations in the macula. The remaining RPE has a lobular atrophic appearance.
Discussion
A family with arCRD and STGD1 was investigated using a new arRP-I array 
designed to detect mutations in 11 autosomal recessive RP genes including ABCA4. 
In hindsight, the use of the arRP-I chip in this particular pedigree was not logical 
given the indication of ABCA4 involvement through the ascertainment of the fifth 
paternal cousin with STGD1. An alternative much cheaper technique, arrayed primer 
extension (APEX)-based analysis of the known ABCA4 variants (ABCR500) could 
have been used instead. The ABCR500 array would also have identified one of the 
alleles in both branches of the pedigree.
In three siblings with arCRD both mutations in the ABCA4 gene were found, i.e. the 
c.5327C>T (p.P1776L) mutation previously described in a STGD1 patient10 and a 
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new splice site mutation; c.3523-2A>T. Direct sequencing of DNA of a fifth paternal 
cousin with STGD1 from Bermuda (but of Sao Miguel Island origin) revealed the 
c.5327C>T (p.P1776L) mutation and a new variant, c.868C>T (p.R290W). 
 The arginine at position 290 resides in the first intradiscal loop of ABCR and is 
conserved in man, mouse, rat, dog and Xenopus. The change from a basic to 
neutral/hydrophobic residue is likely to have functional implications. The proline 
residue at position 1776 resides in the middle of a stretch of hydrophobic residues 
constituting the 9th transmembrane domain of ABCR. 
Biochemical analysis of recombinant ABCR bearing these mutations was not 
performed. Given the previously presented model in which the residual ABCR 
protein activity is inversely correlated to disease severity suggests that the previously 
identified p.P1776L10 mutation  is a mild or moderately severe mutation, since both 
the arCRD and STGD1 sibs shared this mutation. Difference in phenotype would 
have to be explained by the difference in severity of the c.3523-2A>T (splice site 
mutation) and the p.R290W (missense) mutations. Most likely, this splice acceptor 
site mutation preceding exon 24 of ABCA4 results in the skipping of exon 24, which 
leads to a frameshift and a translational stopmutation in the third triplet following the 
exon 23/exon 25 splice junction.
It was difficult to determine the exact clinical diagnosis (especially the issue of RP 
versus CRD) in our three patients as no early ERGs were available. The occurrence 
of nystagmus, which is a new finding in a CRD patient with ABCA4 mutations, 
supports the history of early loss of central vision. The loss of visual acuity, followed 
by night blindness and peripheral field loss are suggestive for the diagnosis CRD. In 
our three siblings the retinal degeneration led to complete loss of the central retina 
and almost complete loss of the peripheral retina with an RP-like appearance at 
the age of 40 years. This is consistent with the results from Lorenz and Preising, 
who suggested that RP caused by ABCA4 mutations is in fact a severe progressive 
cone-rod disease15.  
In our STGD1 patient there seemed to be some peripheral involvement as can 
be expected since ABCA4 is expressed in both cones and rods. There is no ERG 
available for this patient, but one might assume that an ERG would also show a 
cone-rod pattern as in a significant fraction of STGD patients27.
Several studies are ongoing to design new treatment strategies for retinal dystrophies, 
some of which are specific for retinal diseases caused by ABCA4 mutations. Studies 
with administration of isotretoin and N-(4-hydroxyphenyl)retinamide (HPR) to Abcr -/- 
mice showed reduction of accumulation of the toxic lipofuscin fluorophores28,29. 
Given these developments, it is important to identify patients with ABCA4 mutations, 
as they may be eligible for therapeutic interventions in the near future. Detailed 
clinical description of these types of retinal dystrophy patients is essential in order to 
facilitate the search for the causal gene.
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In conclusion, mutations in the ABCA4 gene should be considered in patients with 
arCRD and in older patients presenting with a severe RP-like phenotype with a 
history of early central visual acuity loss. 
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Abstract
Purpose
To test the efficiency of a microarray chip as a diagnostic tool in a cohort of 
northwestern European patients with Leber congenital amaurosis (LCA) and 
to perform a genotype-phenotype analysis in patients in whom pathologic 
mutations were identified.
Methods
DNAs from 58 patients with LCA were analyzed using a microarray chip 
containing previously identified disease-associated sequence variants in six 
LCA genes. Mutations identified by chip analysis were confirmed by sequence 
analysis. On identification of one mutation, all protein coding exons of the 
relevant genes were sequenced. In addition, sequence analysis of the RDH12 
gene was performed in 22 patients. Patients with mutations were phenotyped.
Results
Pathogenic mutations were identified in 19 of the 58 patients with LCA (32.8%). 
Four novel sequence variants were identified. Mutations were most frequently 
found in CRB1 (15.5%), followed by GUCY2D (10.3%). The p.R768W mutation 
was found in eigth of 10 GUCY2D alleles, suggesting that it is a founder mutation 
in the northwest of Europe. In early childhood, patients with AIPL1 or GUCY2D 
mutations show essentially normal fundi. In our series, those patients with 
AIPL1-associated LCA progress to an RP-like fundus before the age of eight, 
whereas patients with GUCY2D-associated LCA still have relatively normal fundi 
in their mid-20s. Patients with CRB1 mutations present with distinct fundus 
abnormalities at birth and consistently show characteristics of RP12. Pathogenic 
GUCY2D mutations result in the most severe form of LCA in our series.
Conclusions
Microarray-based mutation detection allowed the identification of 32% of LCA 
sequence variants and represents an efficient first-pass screening tool. Mutations 
in CRB1, and to a lesser extent, in GUCY2D, underlie most LCA cases in this 
cohort. The present study establishes a genotype-phenotype correlation for 
AIPL1, CRB1 and GUCY2D.
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Introduction
In 1869, Theodor Leber reported an “intrauterine” form of retinitis pigmentosa (RP)1. 
These children, mostly from consanguineous marriages, were congenitally blind 
without any retinal abnormalities. Later in life, many displayed a fundus picture 
typically found in other retinal dystrophies such as RP. This condition is now known 
as Leber congenital amaurosis (LCA), a clinically and genetically heterogeneous 
disorder characterized by severe bilateral congenital retinal blindness, with 
nystagmus and a nondetectable electroretinogram (ERG) before the age of 1 year2 .
Thus far, mutations in seven genes (AIPL1, CRB1, CRX, GUCY2D, RDH12, RPE65 
and RPGRIP1) have been shown to cause LCA, accounting for 35% to 47.5% of 
cases of LCA3-12. Mutations in all these genes, except RPGRIP1, have also been 
found to cause other, clinically less severe retinal diseases, such as cone-rod 
dystrophy (CRD) or RP, with autosomal dominant inheritance shown in several cases 
(ref. 13,14 and references therein.)
Mutations in the CRB1 gene can cause either LCA or an early-onset form of retinitis 
pigmentosa, the latter usually refered to as RP12. The clinical characteristics of 
these autosomal recessive diseases include early central and peripheral visual loss, 
hyperopia, maculopathy, nummular rather than spicular pigmentation, and limited 
attenuation of vessels and para-arteriolar preservation of the RPE (PPRPE). Patients 
occasionally have a Coats-like exudative vasculopathy3,4.
At present, no treatment is available for LCA or allied retinal dystrophies. However, 
several treatment strategies are under study, and some have reached the human 
clinical trial phase15-19. Although all other potential treatments would also benefit 
from more profound knowledge of the underlying genetic defects and disease 
mechanisms, this is especially true for gene replacement therapy. Although the 
identification of the causal mutations in known LCA genes is technically not difficult 
(e.g. using sequence analysis), the genetic heterogeneity and complexity of several 
LCA genes has hampered their routine molecular analysis. For this purpose, high-
throughput techniques are necessary. One such technique, allele-specific primer 
extension (APEX), has been used in conjunction with a genotyping microarray chip 
to detect mutations in the ABCA4 gene. Mutations in this gene are associated with 
Stargardt disease, autosomal recessive cone-rod dystrophy, autosomal recessive 
rod-cone dystrophy, and possibly age-related macular degeneration20-22. This chip 
has been a robust and cost-effective screening tool23,24. A similar microarray chip 
was recently developed for genotyping ~300 known mutations in six LCA genes5.
In this study, we ascertained 58 unrelated patients with LCA, who predominantly live 
in Belgium and the Netherlands, and we identified the molecular causes in one third 
of the cases by means of the microarray chip. Clinical data of patients with mutations 
in the known LCA genes were analyzed retrospectively and all but three were re-
examined for the purpose of this study to establish genotype-phenotype correlations.
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Patients and methods
Patients
DNA samples from 58 unrelated white patients with a clinical diagnosis of LCA 
were collected from Belgium (36 cases; Ghent University Hospital, Ghent; 
University Hospital Leuven, Leuven), The Netherlands (20 cases; Rotterdam Eye 
Hospital, Rotterdam; Sensis International, Grave; Radboud University Nijmegen 
Medical Centre, Nijmegen), and Germany (2 cases; University Hospital Heidelberg, 
Heidelberg; University School of Medicine Berlin, Berlin). All procedures were 
approved by the ethics boards of the collaborating institutes and adhered to the 
tenets of the Declaration of Helsinki. All samples were acquired after written informed 
consent was obtained from the patient or in case of children, their legal guardians. 
LCA was defined as bilateral visual loss noticed before the age of 6 months, 
accompanied by wandering nystagmus, and an undetectable or significantly 
reduced electroretinogram (ERG). Only patients who had not been genotyped 
previously were included in this study. Patients with a juvenile onset RP (onset after 1 
year of age) or a syndromic form of LCA, such as Joubert syndrome, were excluded.
Microarray mutation analysis
Standard protocols were used to extract DNA from peripheral blood leukocytes25. 
The LCA microarray chip contained sense and antisense oligonucleotides (25-mers) 
corresponding to 301 previously identified disease-associated sequence variants in 
six of seven currently known LCA genes: AIPL1 (25 sequence variants), CRB1 (68 
sequence variants), CRX (29 sequence variants), GUCY2D (66 sequence variants), 
RPE65 (81 sequence variants), and RPGRIP1 (32 sequence variants)26. In addition, 
the chip contained disease-associated sequence variants in two early-onset RP 
genes:  LRAT (two sequence variants) and MERTK (three sequence variants). 
In brief, 68 DNA fragments containing the 301 sequence variants were amplified, 
and PCR-products were visualized on agarose gels. The PCR products were 
pooled, denatured and hybridized to the microarray chips. The sequence variants 
were detected by a sequence-specific primer extension using dideoxynucleotides. 
For technical details regarding the allele-specific primer extension (APEX) method, 
see Jaakson et al (ref. 23 and references therein). The results obtained from the LCA 
microarray chip were confirmed through bidirectional sequencing of the relevant 
amplicons (ABI3730 and ABI3100 Genetic Analyzers; Applied Biosystems, Inc. [ABI] 
Foster City, CA). Automatic analysis was performed by a basecaller (ABI). 
At the time of mutation chip analysis, RDH12 had not yet been identified. We therefore 
sequenced the 7 protein coding exons of RDH12 in all Dutch and German patients27.
In those patients in whom one mutation was identified, the entire gene was 
sequenced. Primers and PCR conditions have been described3,9,10,28. Four novel 
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sequence changes were identified. One of them was a new GUCY2D (c.2837C>T; 
p.A946V) missense mutation that was subsequently tested in DNA from 93 
anonymous healthy Dutch control individuals by restriction fragment length 
polymorphism (RFLP) analysis. BstUI cuts the normal but not the mutant PCR 
product containing exon 15 (288 bp) in 154 bp and 134 bp fragments. When 
parents or unaffected siblings were available, segregation analysis was performed.
Phenotyping
In patients with presumed pathologic sequence variants, clinical data were 
retrospectively collected. In most cases, follow-up clinical information was available, 
and we used the data from the first and last examinations. At the first visit, parents 
and patients were questioned about the age of onset of symptoms such as night 
blindness, photophobia, and photoattraction. A family history was taken and 
questions concerning pregnancy, birth, birth defects, and consanguinity were asked. 
Pupillary reactions were observed, and nystagmus and photophobia were evaluated. 
Ophthalmic examination included best-corrected, age-appropriate visual acuity 
testing and measurement of objective refractive error after cycloplegia. The anterior 
segment was examined by slit lamp biomicroscopy followed by fundoscopy after 
pupillary dilation. Goldmann visual field results were obtained when possible. ERGs 
made according to pediatric protocols were obtained in all patients but three at the 
collaborating institutes. Color vision was tested in four patients with a low-vision 
edition of the Panel D-15 test (large surfaces) under bright daylight illumination (3500 
lux; color temperature of approximately 4500 K), higher than levels normally used in 
color vision testing (1600 -1900 lux; color temperature of 6500 K)29. Images of the 
fundus were acquired with a fundus photography system (Topcon, Tokyo, Japan). 
Interpretable autofluorescence images were obtained in two patients with the same 
system. Interpretable autofluorescence and red free images were acquired with 
the Heidelberg Retinal Angiograph (HRA2; Heidelberg Engineering, Heidelberg, 
Germany)  in one patient.
Results
Genotypes
The molecular genetic results are summarized in table 3.1. The microarray chip 
allowed the identification of homozygous or compound heterozygous sequence 
variants in 14 of 58 patients and single heterozygous sequence variants in an 
additional six of 58. All variants were confirmed by using sequence analysis of the 
relevant exons. In the six heterozygous patients, the protein-encoding exons of the 
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respective genes were sequenced in an attempt to identify the second mutant allele, 
and four out of the six were identified and were found to be novel sequence variants. 
Phenotypes
All available clinical data of the first visit as well as fundoscopic findings at the last 
examination are summarized in table 3.2. In the following sections, a summary of 
relevant clinical information is provided. All patients had an ERG performed before 
the age of 12 months, which was nonrecordable in all except patients 21394, 24105 
and 246V1, in whom the ERG was severely reduced.
AIPL1
Genotypes. All three patients with mutations in AIPL1 were homozygous for 
p.R278W.
Phenotypes. Over a 15-year period, the visual acuity of patient 14962 remained 
stable. When he was initially examined during his first year of life because of 
nystagmus, fundoscopy was normal. At the age of 15, a bull’s eye maculopathy as 
well as increased pigment spicules in the periphery were observed.
Patient 20143 was first examined after he failed to fix and follow at the age of three 
months. He was mentally handicapped, and regularly poked his eyes (oculodigital 
sign) and had weak and slow pupillary reactions. At the age of 7.5 years, visual 
acuity (VA) was 0.003 for both eyes (BE) and the lenses showed a nuclear opacity. 
Funduscopy revealed a pale optic disc and attenuation of the retinal vasculature, 
with neither obvious maculopathy nor peripheral intraretinal pigmentation.
When patient 2040V1 was first seen at the age of five months because of 
nystagmus, fundoscopy revealed diffuse alterations of the retinal pigment epithelium 
and mild attenuation of vessels. She was night blind and preferred a well-lit 
environment. At eight years of age, she displayed nystagmus with a predominant 
slow horizontal component. Best corrected visual acuity was 0.02 with a refraction 
of +7.5 BE. Axial length was 19.6 mm RE and 19.9 mm LE. On fundoscopy, a 
bull’s eye maculopathy was present with diffuse RPE alterations with only limited 
spicular intraretinal pigmentation (figure 3.1a). Hyperfluorescent spots were seen on 
autofluorescence imaging (figure 3.1b).
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Figure 3.1   Fundus photographs of patients with LCA
a.  Patient 2040V1 (AIPL1 p.W278X/p.W278W) at age nine: composite of fundus of the left eye (LE), 
 showing macular dystrophy in a bull’s eye pattern, diffuse RPE alterations with scarce intraretinal pig-
 ment migration with spicular aspect, sub- or deep intraretinal fine white deposits predominantly along 
vascular arcades.
b. Patient 2040V1 (AIPL1 p.W278X/p.W278X) at age nine: autofluorescence image of fundus of the right 
eye (RE), showing fine deposits predominantly along vascular arcades that hyperfluoresce.
c.  Patient 21405 (CRB1 p.C948Y/p.T745M) at age 14: composite of fundus of RE showing an edema-
tous optic disc with perivascular sheating, mild narrowing of the arterioles showing tortuositas with 
 subretinal white dots along arterioles with PPRPE, macular aplasia, atrophic RPE in the periphery with
 PPRPE, and nummular and a few spicular pigmentations. The posterior pole showed edema with a few 
intraretinal hemorrhages.
d. Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): posterior pole of RE at age seven showing an edema-
tous optic disc with preretinal fibrosis, perivascular sheathing, macular dysplasia, and fine, white, deep 
intra- or subretinal deposits.
e.  Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): composite of fundus of RE at age 12 showing an 
edematous optic disc with preretinal fibrosis and perivascular fibrotic sheathing without clear PPRPE apart 
from vessel inferonasal to RE; macular dysplasia remains stable, whereas there is fine nummular intrareti-
nal hyperpigmentation with fine, white, deep intra- or subretinal deposits in the mid- and far periphery.
f.  Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): red free image of the optic disc and inferotemporal  
peripapillary area of LE at age 12 showing a better visualisation of perivascular fibrotic sheathing.
g. Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus picture of LE at age 14; Note that the 
optic disc is fairly normal; the macula is dysplastic; limited vascular attenuation with relative PPRPE; 
nummular hyperpigmentation in the macula and the retinal periphery and multiple white subretinal 
deposits scattered throughout the fundus.
h.  Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus picture of LE at age 30 shows limited 
visibility due to subcapsular cataract, stable dysplasia of the macula but a dramatic increase in the 
number of nummular pigmentations in the posterior pole, vascular attenuation; mixed nummular and 
spicular hyperpigmentation in the retinal periphery and multiple white subretinal deposits scattered 
throughout the fundus.
i.  Patient 21067 (GUCY2D p.R768W/p.A946V): Composite of fundus of RE at age 22 showing arteriolar 
attenuation and mild RPE alterations in the fovea.
j.  Patient 23207 (RPE65 p.R124X/p.F530fs) at age six and a half years: a relatively hypopigmented 
fundus of LE with mild attenuation of arterioles and diffuse RPE alterations.
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CRB1 
Genotypes.  Eight out of nine patients carrying mutations in CRB1 were compound 
heterozygous. The p.C984Y and p.K801X alleles were found in five and four patients, 
respectively. Two patients with CRB1 mutations were compound heterozygous for 
mutations p.C948Y and c.2842+5G>A, and one of them (patient 21551) also carried 
the p.V96I AIPL1 sequence variant. The latter sequence change was not considered 
to be pathologic, because it was identified in heterozygous form in 11 of 186 healthy 
control subjects. Two new nonsense mutations were identified in CRB1: p.Q362X 
and p.Q1222X.
Phenotypes.  Patient 21394 first presented at the age of three months with torticollis 
presumably related to nystagmus. His fundus was then essentially normal. At the 
age of five years, his VA had decreased to 0.02 BE. On fundoscopy, he had several 
characteristics of RP12, including pink optic discs, relatively normal arterioles, 
and extensive RPE atrophy, both in the posterior pole and in the periphery, with 
nummular pigmentations. He lacked para-arteriolar preservation of the RPE (PPRPE). 
Patient 21405 was first examined in the first year of life because of night blindness. 
At 0.17 RE and 0.20 LE, her visual acuity was then better than any other patient 
in this entire study cohort. Funduscopy showed macular and peripheral mild RPE 
changes as the only abnormalities. At age 14, the typical RP12 phenotype was 
seen with macular and optic disc edema, a dysplastic macular region, perivascular 
sheathing, mild arteriolar attenuation, and PPRPE (figure 3.1c). Goldmann perimetry 
performed at the time showed an absolute ring scotoma with relatively well 
preserved central fields (50º diameter RE, 30º diameter LE). 
The first symptom noticed in patient 21551 was a failure to develop eye contact at 
age four months. When the patient was initially seen at that age, ERG responses 
were absent. Very limited clinical data were available, but at 13 years of age, he had 
very poor pupillary reactions with a residual visual acuity and stable hypermetropic 
refraction. Goldmann visual field testing showed preservation of the central 15º field, 
albeit with a considerable decrease in sensitivity. 
LCA was diagnosed in patient 21554 at three months of age after the oculodigital 
sign had been noticed and ERG responses were absent. When examined at age 
three, she preferred a well-lit environment and was reported unable to see in dim 
light. She had a predominantly horizontal slow nystagmus and esotropia of the right 
eye. The VA was virtually stable when she was examined at the age of 12. She 
had by then lost nearly all her ability to recognize basic colors. A small posterior 
lenticular opacity was present inferior to the visual axis. On fundoscopy she showed 
the RP12 phenotype and over a nine year period both the aspect and size of the 
dysplastic regions in both maculae remained virtually stable (figures 3.1d and 3.1e). 
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Perivascular sheathing of retinal vessels around the optic disc was better seen on 
red free imaging (figure 3.1f).
Patient 21669 was born with palatoschisis. LCA was diagnosed when he was six 
months of age, when strabismus was noticed and ERG responses were absent. 
When seen last at age ten years, he showed funduscopic characteristics of RP12 
with Coats-like vasculopathy in both eyes. PPRPE was not present.
Patient 246V1 had received a diagnosis at age four months after presenting with 
nystagmus. Over 30 years, his VA of 0.01 BE and hypermetropia with pronounced 
astigmatism of +5.0D (-5.5D) 30° RE and +4.5D (-5.25D) 140° LE has remained 
fairly stable. When last seen at age 30, he preferred bright light. His nystagmus 
was horizontal. A subcapsular cataract was present in both eyes (LE>RE). Despite 
the considerable astigmatism, there were no obvious signs of keratoconus. Over a 
period of 16 years, some of the funduscopically visible RP12 characteristics, such 
as nummular hyperpigmentation and subretinal deposits, increased (figures 3.1g  
and 3.1h). 
In patient 278V1 the oculodigital sign had been noted since childhood. At the age 
of 34 years, her VA had decreased slightly due to scarring after acute hydrops of 
her bilateral keratoconus. Her vision was better in bright light. She had pronounced 
enophthalmos, esotropia, and nystagmus, which also had a predominant horizontal 
component. On fundoscopy a steady increase in the white subretinal deposits and 
nummular pigmentation was noted over the years. The size of the macular aplastic 
lesions had not changed since birth.
A diagnose of LCA was made in patient 2148V1 at age four months because of a 
failure to fix and follow objects. ERG responses were absent. At the age of eight 
years, he preferred bright light and had a VA of only hand movements. He had 
enophthalmos due to frequent eye–poking, and he displayed horizontal nystagmus. 
Slit lamp examination findings stayed unremarkable over the years. The nummular 
intraretinal pigmentation and number of deposits increased. There was some 
perception of colors as measured with a modified Panel D-15 test.
Patient 3460V1 was a 55-year-old blind woman who was severely mentally retarded 
presumably due to meningitis in the first weeks of life. When LCA was diagnosed 
at age three months she was failing to fix and follow objects, and ERG responses 
were absent. She frequently poked her eyes. After several painful episodes of acute 
corneal hydrops consequent from keratoconus, her right eye was enucleated at age 
53. Because of the presence of a dense cataract, fundoscopy of the left eye was 
impossible, and, because of mental retardation, visual acuity was unmeasurable.
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CRX
In one patient (22654) a heterozygous sequence change (p.Y142C) in the CRX 
gene was identified. Sequencing of the entire gene confirmed the presence of this 
variant but did not reveal a second change. Segregation analysis of the unaffected 
consanguineous parents revealed the mother to be homozygous for this sequence 
change and the father to carry two wild-type alleles. To rule out the possibility that 
we failed to amplify a wild-type allele by PCR in the mother due to a polymorphic 
sequence change underneath one of the amplicon primers, we repeated the 
sequence analysis with different primers and confirmed the homozygosity of the 
p.Y142C variant in the DNA of the patients’ mother. The maternal grandparents had 
normal vision. The sequence change was therefore considered a benign variant. 
GUCY2D
Genotypes.  The p.R768W mutation represented eight out of 12 alleles in five of six 
patients with GUCY2D-related LCA. One of the compound heterozygotes carried a 
novel mutation, p.A946V, which was absent in 93 control individuals.
Phenotypes. LCA was diagnosed in patient 441 at the age of three months after 
she failed to fix and follow objects. When examined at the age of one year, she 
frequently poked her eyes. She was able to follow objects, provided she was in a 
well-lit environment, after having started staring at lights at the age of five months. 
Her fundus examination had been unremarkable since birth.
Patient 20955 received a diagnosis of LCA in the weeks after birth because of eye 
poking, which she continued until the age of eight years. ERG responses were 
absent. At the age of 23 she preferred a dim environment. Her fundus was fairly 
normal, apart from arteriolar attenuation.
After a diagnosis because of strabismus at 6 months of age, patient 21067 was 
photophobic as a child, which markedly decreased later in life, and at the age of 
22 she instead preferred bright light. She had esotropia of the left eye. Apart from 
arteriolar attenuation and mild RPE alterations in the fovea, the fundus examination 
was unremarkable (figure 3.1i).
LCA was diagnosed in patient 21557 at the age of four months, because he failed 
to fix and follow objects. His ERG responses were absent, and he was completely 
blind. At the age of 39, he had a divergent strabismus as well as bilateral dense 
cataracts that precluded fundoscopy.
A diagnosis was made in patient 22018 at the age of two months after he failed to 
fix and follow objects. He showed the oculodigital sign and episodic head turns. At 
the age of two and a half years, there was no perception of light, and his pupils were 
wide and responded only minimally to bright light. Funduscopy was normal.
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Patient 22597 belonged to a family with 10 siblings, three of which had LCA. 
Therefore, an early clinical diagnosis was made soon after birth. There was congenital 
nystagmus, and her vision had never been better than light perception. Recently, she 
had acute hydrops of a keratoconus in one eye. At the age of 25 years, attenuation 
of the retinal vasculature was the only abnormality noted on fundoscopy.
RPE65
Genotype.  In this cohort, one patient had LCA due to mutations in RPE65. The 
p.R124X mutation was identified by chip analysis, and a novel frameshift mutation 
(p.F530fs) was identified by sequence analysis.
Phenotype.  Patient 23207 was night blind at the age of six years. He had a very 
poor VA in the first year of life, with gradual improvement up to 0.16 OD and 0.12 
OS, with a refraction of –2.5 OD and –3.5 OS at the age of six years. Nystagmus 
was present. He had a visual field of 60º and perceived the main colors. His fundus 
was relatively hypopigmented, with mild attenuation of the arterioles and diffuse RPE 
alterations (figure 3.1j). 
Discussion
The mutation-screening protocol applied in this study consisted of an initial 
microarray-based mutation analysis, followed by sequence analysis of genes in 
those patients with LCA in whom single heterozygous mutations were identified. 
In addition, mutations in patients who were either homozygous or compound 
heterozygous were confirmed by sequence analysis.
This approach allowed the identification of 37 disease alleles in 19 (33%) of 58 
patients with LCA. These represent nine different previously identified and four 
novel sequence variants. We identified one heterozygous pathologic LCA variant in 
patient 3460V1 among 58 patients with LCA. Possibly, mutations outside the protein 
coding exons and their immediate vicinity were missed in this particular patient, as 
are all heterozygous deletions. Also, the heterozygous variant in 3460V1 could be 
unrelated to the LCA, since the aggregate heterozygosity frequency of mutations 
in the AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1 genes in the general 
population is 1.3% assuming an LCA incidence of one in 100,000 (Cremers FPM, 
unpublished data, 2005).
In 13 families, segregation analysis of the sequence variants was compatible with 
autosomal recessive inheritance. Of five other families in whom no segregation 
analysis could be performed, three patients apparently were homozygous for 
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a disease-causing sequence change. However, the presence of heterozygous 
deletions cannot be ruled out in these cases.
Mutations in this patient cohort were most frequently identified in CRB1 (nine cases, 
15.5%), followed by GUCY2D (six cases, 10.3%), AIPL1 (three cases, 5.2%), and 
RPE65 (one case, 1.7%). No pathologic mutations were found in CRX, RDH12 (in 22 
patients), and RPGRIP1. The infrequent involvement of CRX, RDH12, and RPGRIP1 
in LCA is in accordance with the results of previous studies6,8,27,30. In addition, it is 
noteworthy that RPE65 seems to account for only a minority of cases (1.7%) in 
comparison to reported frequencies in other studies of 3% to15%31-34. This variation 
may be due to the relatively small patient cohort, the variable mutation detection 
strategies and the variable inclusion criteria applied by different groups. In general, 
mutations in the RPE65 gene are more frequently observed in patients with early- 
onset RP rather than LCA35 (Yzer S, unpublished results 2005). 
All three patients carrying AIPL1 mutations were homozygous for the p.W278X 
allele. Previously, nine patients from different ethnic backgrounds were described 
to be homozygous for this change by Dharmaraj et al36. The phenotype of these 
patients consisted of severe night blindness, some degree of maculopathy, 
attenuated vessels, and spicular intraretinal pigment migration in the periphery after 
several years of evolution. Keratoconus was observed in six of 19 patients with 
distinct AIPL1 mutations. The patients described in this study showed an apparently 
normal fundus on initial examination, which progressively evolved into peripheral 
spicular intraretinal pigment migration in early childhood. High hyperopia and a very 
poor visual acuity appear to be consistent findings. Night blindness is a frequent, 
albeit variable, characteristic6,36. 
Eight of nine patients with CRB1 mutations showed either all or some funduscopic 
characteristics of the RP12 phenotype, including relatively normal optic discs and 
vessels, a distinct maculopathy and a nummular rather than a spicular type of pig-
mentation. Yellow-white retinal dots were present in eight patients and PPRPE in 
three. Findings less frequently observed in RP12 or patients with CRB1 mutations, 
such as Coats-like exudative vasculopathy, vascular sheathing, optic disc edema, 
maculae dysplasia, and keratoconus were also observed in our patients. Moderate 
to high hyperopia and nystagmus are also associated with CRB1-associated 
LCA4,6,8,37. This RP12 phenotype is easily distinguishable from other RP-like 
phenotypes.
The CRX p.Y142C variant has been identified in heterozygous form in a patient with 
autosomal dominant LCA (Kaplan J, personal communication, 2004). In our cohort 
one patient from a consanguineous marriage was a heterozygous carrier of this 
variant. Sequence analysis revealed the healthy mother to be homozygous for this 
sequence change, suggesting that the p.Y142C change is nonpathogenic. Because 
the maternal grandparents had normal vision, a metabolic interference model 
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in which homozygous mutations abolish each other’s pathologic effects, seems 
unlikely. Therefore, we conclude that 33 of 116 disease alleles were identified by 
chip analysis alone.
Mutations in the GUCY2D gene in LCA were first reported in Mediterranean families10. 
In the LCA cohort of this study, the p.R768W mutation was found in eight (67%) of 
12 alleles. Four of the five patients carrying this allele were of Belgian or Dutch origin, 
and the fifth was of Belgian/Moroccan descent. Segregation analysis showed that 
the p.R768W allele came from her Belgian mother. Hanein et al6 found the p.R768W 
allele in only 1 of 75 GUCY2D alleles in 38 patients, most of which were from 
Mediterranean countries. This difference in frequency of the p.R768W mutation may 
be suggestive of a founder effect in the northwestern region of Europe. The three 
patients with the homozygous p.R768W GUCY2D mutation are severely affected, 
did not show light perception at initial examination, and had no signs of improvement 
later in life. In most patients, the initial fundoscopy was normal which, later in life, 
showed attenuated vasculature and subtle pigmentations. In accordance with 
previous findings by Dharmaraj et al30, refraction in GUCY2D-related patients with 
LCA varies from mild to severe hyperopia with VA showing a spectrum from no light 
perception to 0,1. In contrast, Hanein et al6 generally found hypermetropia (> +7).
A novel frameshift mutation, p.F530fs, was identified in the RPE65 gene in a patient 
heterozygous for p.R124X. The phenotype of this patient is similar to previously 
published phenotypes with very poor visual acuity early in life that gradually 
improves, myopia, and some residual visual field function. Overall, the phenotype 
of patients with LCA with RPE65 mutations seems relatively mild in comparison to 
other forms of LCA6,34,35.
Our patient cohort was relatively small, but our clinical data suggest that patients 
with homozygous p.W278X AIPL1 mutations have a very poor visual acuity, with 
hyperopia and an initially normal fundus, which progresses to an RP-like fundus 
in early childhood. In general, GUCY2D-related LCA results in the most severe 
visual impairment with a relatively normal fundus in the mid-20s. Furthermore, this 
study supports the existence of a fairly typical and consistent phenotype of CRB1-
associated LCA, including a maculopathy ranging from macular RPE alterations 
to macular aplasia, fine white sub- or deep intraretinal drusen-like deposits, and 
nummular rather than spicular hyperpigmentation in both maculae and periphery. 
The phenotypical data also confirm that PPRPE is a rather inconsistent feature in 
patients with CRB1 mutations, probably due to its transient nature. 
In this study, CRB1 was the most frequently involved gene (9/19 patients) in a cohort 
of predominantly Belgian and Dutch patients. In a Spanish LCA cohort, mutations in 
CRB1 turned out to underlie two thirds of all cases with mutations in the known LCA 
genes38. In contrast, no CRB1 mutations were detected in a Canadian cohort of 24 
patients with LCA, suggestive of sizeable geographic differences in the occurrence 
of mutations39.
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Taken together, the clinical findings in our patients suggest that both photophobia 
and night blindness do not seem to be reliable clinical features that can be used to 
direct gene analysis, as was proposed by Hanein et al6. Indeed, within the AIPL1-, 
GUCY2D-, and CRB1-associated patient cohorts in our study, both photophobia 
and night blindness were noted.
A comprehensive mutation analysis study of all currently known LCA genes has 
previously been performed6. Excluding this study’s findings in the TULP1 gene, as 
the TULP1 gene was not analyzed in our study, mutations were identified in 44.4% 
of the disease alleles using a combination of linkage analysis of known genes, 
denaturing high-pressure liquid chromatography mutation scanning, and direct 
sequencing. Our approach (i.e., a first-pass mutation detection of known mutations 
with the LCA microarray chip followed by sequence analysis of patients with 
heterozygous mutations) allowed the detection of 31.9% (37/116) of disease alleles. 
Hence, about 72% (31.9/44.4) of the expected disease alleles were identified with a 
relatively small effort. We therefore believe that the LCA mutation chip offers a cheap 
and efficient first-pass screening test. This robust technique is generally applicable 
and allows more carefully directed efforts of subsequent standard sequence 
analysis. Furthermore it is independent of a detailed clinical history necessary for a 
decisional molecular diagnostic flowchart, as outlined by Hanein et al6. Finally, by 
regular addition of newly identified alleles, the efficiency of the microarray will continu 
to improve.
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Abstract
We investigated the ophthalmologic characteristics and molecular cause of a 
retinal dystrophy in 14 patients belonging to ten families from a multigenerational 
pedigree in a genetic isolate in the Netherlands. All affected individuals experienced 
night blindness from early childhood and most of the patients had nystagmus. 
Visual acuity loss in these patients at first examination varied considerably (ability to 
observe hand movements at 2 m to 20/50). Moreover, visual acuity either improved 
(four patients), deteriorated (four cases) or was stable over a mean nine year follow- 
up period. Rod electroretinogram (ERG) responses were unrecordable in all patients, 
whereas cone responses (ERG) were recordable in early childhood in five patients. 
Peripheral vision was relatively well preserved. Based on previously published 
phenotypes associated with RPE65 mutations we hypothesized the involvement of 
the RPE65 gene. We found homozygosity-by-descent of a D1S2803 marker allele 
located very near the RPE65 gene. In nine families patients were homozygous for 
a RPE65 p.Y368H mutation; in one family a patient was compound heterozygous 
for the RPE65 p.Y368H and c.IVS1+5G>A mutations. Based on the estimated total 
number of patients with congenital retinal dystrophy in the genetic isolate and the 
DNA analysis of healthy controls of this population we estimate a carrier frequency 
of ~1 in 20 individuals rendering a significant risk of blindness in offspring of patients, 
their heterozygous siblings and other heterozygous individuals of the genetic isolate.
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Introduction
Autosomal recessive retinal dystrophies cause visual impairment in approximately 1 
in 4000 individuals worldwide1. The non-syndromic forms are highly heterogeneous 
and can be classified into clinical subgroups, the most frequent ones being retinitis 
pigmentosa (RP), cone- and cone-rod dystrophies, and Leber congenital amaurosis 
(LCA). LCA represents the most severe phenotype with an onset of symptoms 
before the age of six months, visual acuity below 20/400, a searching nystagmus, 
sluggish pupillary reactions and a non-detectable ERG. Visual fields are usually 
not measurable1. Photophobia is only occasionally reported in LCA2. Patients with 
juvenile and early-onset RP present with night blindness in early childhood, usually 
before the age of two years. They do not show searching nystagmus3 and have a 
relatively well preserved macular function. Central vision is often lost in the second or 
third decade of life4. 
The cloning of more than 20 genes allows the molecular characterization of 
approximately 50% of the autosomal recessive inherited retinal dystrophy cases 
(www.sph.uth.tmc.edu/Retnet5,6). To establish a useful clinical prognosis for patients 
a well defined genotype-phenotype correlation is required. 
Although the general population in the Netherlands is relatively outbred, there are a 
few examples of autosomal recessive diseases caused by Dutch founder mutations. 
Batten disease was found to be due to identity-by-descent in a highly inbred family7. 
A frequent LDL receptor mutation originating from Dutch 17th century settlers causes 
familial hypercholesterolaemia in South Africa and Canada8. The RP12 locus was 
mapped through linkage analysis in a genetic isolate from the northwest of the 
Netherlands9, which was followed by the cloning of the underlying gene, CRB110. 
In 1959 Schappert-Kimmijser et al described an isolated Dutch population living on 
a former island with a relatively high frequency of LCA11. In 1637 this community 
suffered from the plague, which killed half the population. After the island was 
connected to the mainland in 1941, the 4000 residents could be regarded as 
descendants of at most 150 ancestors. Since then, the population size has 
quadrupled, mostly through endogamous marriages. 
We re-evaluated this population and established a new multigenerational pedigree, 
consisting of ten nuclear families with congenital retinal dystrophy. We undertook 
detailed clinical and molecular studies and identified two RPE65 mutations, one of 
which represents a frequent founder mutation in the genetic isolate.
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Patients and methods
Fourteen patients with congenital retinal dystrophy, 25 of their non-affected siblings, 
and 19 parents were asked to participate in this study. The study protocol adhered 
to the regulations of the Declaration of Helsinki.
Clinical analysis
Parents and patients were questioned about pregnancy, delivery, the age of 
onset of symptoms, night blindness, photophobia and birth defects. Ophthalmic 
examinations were done by one of us (JS, FNB, MMvG). All children were seen 
between 1978 and the present. The mean follow-up period was nine years and 
ranged from two to 15 years. 
Ophthalmic examinations included best corrected visual acuity with age adapted 
functional tests, such as Teller acuity cards in the preverbal period and the Lea 
Hyvärinen test for children who were able to match or name pictures. From the age 
of six years Snellen charts were used. Objective refractive error was measured after 
cycloplegia. Pupillary reactions were tested and nystagmus and photophobia were 
evaluated. Night blindness was tested by observing the patients’ behavior in a dim 
lighted room. The anterior segment was examined using a slit lamp, followed by 
dilated fundoscopy. Kinetic visual fields were measured with Tübinger perimetry (with 
a ten apostilbs background) in13 patients. Electroretinographic recordings were 
made in all patients but one, and were done at two university hospitals. Color vision 
was tested with the Ishihara test for color blindness, Hardy Rand Rittler (H-R-R) 
charts, and Lanthony’s saturated D-15 test. Dark adaptometry was obtained in three 
patients with the Goldmann-Weekers dark adaptometer. Fundus photographs were 
taken with a Topcon retinal camera, model TRC-F.
Molecular analysis
Venous blood was collected and DNA was extracted using a previously described 
protocol12. DNA was analyzed using the highly polymorphic DNA marker D1S2803 
(AFMB361YD5) located 2.5 kilobases (kb) proximal to the RPE65 gene and 
D1S2895 (AFMA099WC1), located approximately 2.7 megabases (Mb) proximal to 
the RPE65 gene according to the human genome project working draft at http://
genome.cse.ucsc.edu (freeze June 2002). 
Amplification reactions were done with 50 ng genomic DNA, 6 pmol of each primer, 
200 µM of dATP, dTTP, dGTP, and dCTP, 2 pmol α[32P]-dCTP. 1 × SuperTaq buffer 
(10 mM Tris-HCl, pH 9.0; 50 mM KCl; 1.5 mM MgCl2; 0.1% (wt/vol) Triton X-100; 
0.01% (wt/vol) gelatine), and 0.1 U Taq DNA polymerase (Invitrogen). Cycling 
parameters consisted of 94°C for 4 min, followed by 30 cycles of 92°C for 1 min, 
55°C for 2 min, 72°C for 1 min, and a final extension of 6 min at 72°C. Polymerase 
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chain reaction (PCR) products were separated on a 6.6% denaturing polyacrylamide 
gel (acrylamide:N,N’-methylene-bisacrylamide 19:1), containing 100 mM Tris-borate, 
2 mM EDTA pH 8.3, and 8.3 M Urea. After electrophoresis and drying of the gels the 
bands were visualized by overnight exposure on an X-Omat AR film. 
After strong evidence of involvement of the RPE65 gene was obtained, we analyzed 
the nucleotide sequence of the 14 exons of the RPE65 gene in genomic DNA of one 
healthy individual and three probands (BII-5, GII-1, and HII-1). We slightly adapted 
the PCR conditions described by Marlhens and coworkers13. The PCR buffer 
contained 3 mM MgCl2 and we employed the following PCR cycling temperatures: 
30 s at 94°C, 30 s at 56°C (exons 4 to 10) or 60°C (exons 1 to 3 and 11 to 14), 
and 1 min at 72°C (30 cycles). Cycle sequencing was done by using the same gene 
specific PCR primers13 to amplify the 14 exons and flanking introns sequences of 
the RPE65 gene. The PCR products were purified by using the Millipore purification 
system and analysed on the ABI3730 or ABI3100 DNA analysers. Automatic 
analysis was done by ABI basecaller.
The presence of the c.1156T>C (p.Y368H) founder mutation was tested in 96 healthy 
controls from the genetic isolate after isolating DNA from buccal swabs. Mucous 
membrane cells were collected by firmly brushing the inside of the cheek, after which 
600 µl 50 mM NaOH were added and the samples were heated for 5 min at 95°C. 
Buccal swabs were removed and 60 µl Tris pH 8.0 was added. After centrifugation at 
13 000 rpm for 10 min, the supernatant was collected and used for PCR of exon 10 
of the RPE65 gene and subsequent restriction fragment analysis using NlaIII. 
Eventually, the same analysis was used to test a panel of 94 healthy controls from 
the Netherlands, 75 Dutch patients with autosomal recessive or isolated retinitis 
pigmentosa, and 86 patients with LCA (15 patients from the Netherlands, 18 from 
Germany, 2 patients from the USA, and 51 from Canada).
Results
Clinical evaluation
The relevant clinical data are summarised in table 4.1. None of the 14 newborns 
followed objects or made eye contact, leading their parents to suspect visual 
impairment within the first three months of life. Most of the children were seen by an 
ophthalmologist within their first year. All experienced night blindness. Nine children 
went to regular schools while the others attended schools for the visually impaired. 
Two of the children (AII-2, HII-5) were considered to have psychomotor retardation 
with an autistic-like contact disorder. One patient (BII-5) underwent surgery because 
of polydactyly. 
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A wide range of visual acuities was observed at the first examination. On follow-up 
visual acuity varied: in nine patients (AII-2, AII-3, BII-5, CII-2, DII-1, EII-1, FII-2, GII-1 
JII-2) it remained relatively stable or seemed to improve, whereas in four (HII-1, HII-
2, HII-5, KII-6) it deteriorated (table 4.1). All but two children showed early-onset 
nystagmus or developed nystagmus within the first six years of life. Eight patients 
showed a mild torticollis. None of the patients had photophobia; on the contrary, 
all children adored bright light. Two patients had moderate hypermetropia, one of 
whom (BII-5) had a father and an older sister who were also hypermetropic but 
did not have a retinal disorder. The other hypermetropic individual (HII-5) had two 
affected siblings who were near emmetropic. Three patients had moderate myopia 
(DII-1, JII-2, KII-6). Six children had strabismus, which led to an amblyopic eye in 
two (table 4.1). Pupillary reactions were normal and symmetrical in all. None of the 
patients had cataract. 
Early fundoscopy was either normal or showed relative hypopigmentation or subtle 
changes in the retinal pigment epithelium. Macular reflexes were still present in all 
patients, while foveal reflexes were present in half the affected individuals. At the 
most recent examination retinal vessels were moderately or severely attenuated 
and the optic discs were pale in all patients. In five patients the periphery appeared 
hypopigmented. All patients had subtle subretinal pigmentary changes. No intra-retinal 
bone-spicules were seen. Macular reflexes were still present later in life, whereas the 
foveal reflexes disappeared in all but one patient (table 4.1 and figure 4.1). 
Seven of the 14 patients were unable to perform color vision tests. In the other 
seven patients color vision was severely disturbed and had an overall tendency to 
the tritan axe (blue-yellow axe). Tübinger visual field assessment was done in 13 
patients. Though visual field defects were slightly progressive over the years, the 
peripheral fields remained relatively stable in ten patients. In only three was there 
marked deterioration. Dark adaptation tests were done in three patients and showed 
monophasic curves with a markedly increased rod and cone segment. ERGs were 
done within the first three years of life in 12 patients. In seven patients no responses 
were detected. In four patients, significantly reduced photopic responses were 
measured, with absent scotopic responses. In only one patient (HII-5) were both 
scotopic and photopic responses recorded (table 4.1).
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Figure 4.1   Fundus photograph of patient HII-1 at the age of eight years with mutations in the 
RPE65 gene
Pale optic disc, moderately attenuated vessels, hypopigmented fundus with a relatively spared maculae. 
Genealogy
Genealogical studies showed that all ten families were related through at least one 
and in most cases several common ancestors (figure 4.2). Some patients were first 
degree cousins (for example, patients from families B and C; patients from families 
D and E); others were only connected through a common ancestor living in the 18th 
century eight generations ago (for example, families F and G). We therefore reasoned 
that the retinal dystrophy in the ten families most probably caused by homozygosity-
by-descent of one or a small number of autosomal recessive mutations. 
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Figure 4.2   Anonymous and simplified pedigree structure of part of the genetic isolate (top) and 
D1S2803 marker alleles in the families with early-onset retinal dystrophy (bottom)
The individuals in the oldest generation were born in the second half of the 18th century. Double bars reflect 
known consanguinity. Numbers in the circles in the youngest generation indicate the number of individuals 
that share the same alleles for marker D1S2803. All affected individuals except GII-1 are homozygous for 
allele b, suggesting the presence of a founder mutation in the affected individuals through homozygosity-
by-descent. Patient GII-1 is heterozygous for marker D1S2803, suggesting the presence of two different 
RPE65 mutations. , unaffected male or female; , male; , female; black figures, affected persons.
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Molecular genetic analysis
The phenotypes described above suggested the involvement of the RPE65 gene, 
as previous studies have implicated this gene in patients with LCA and early-onset 
severe rod-cone dystrophy quite similar to the clinical presentation described in 
patients in this study6,14,15. To test this hypothesis, we undertook linkage analysis 
employing the DNA marker D1S2803 located only 2.5 kb proximal of the RPE65 
gene. Eight of 10 families were partially or fully informative (figure 4.1). All affected 
individuals except patient GII-1 are homozygous for D1S2803 allele b. Given that 
allele b has a frequency of 0.32 (www.gdb.org) the likelihood that it occurs in 19 of 
20 alleles from the probands of the nuclear families is (0.32)19 x 0.68 = 8.6-11. This 
calculation strongly suggests the presence of a homozygous founder mutation in 
these patients. Moreover, analysis of marker D1S2895, situated three cM proximal to 
the RPE65 gene, also revealed homozygosity of one allele in five of eight informative 
families (data not shown).
Subsequently, we analysed the nucleotide sequence of the 14 protein coding exons 
of the RPE65 gene in three probands (BII-5, HII-1, and GII-1) and one control DNA 
sample. We identified a homozygous c.1156T>C nucleotide change (p.Y368H) in 
patients BII-5 and HII-1. Patient GII-1 was found to be compound heterozygous 
for the c.1156T>C nucleotide change and a splice site mutation in intron 1 
(IVS1+5G>A) (data not shown).
We analyzed the segregation of the exon 10 mutation by RFLP analysis as the 
c.1156T>C change introduces a NlaIII restriction site. The normal PCR product of 
exon 10 contains one NlaIII site resulting in restriction fragments of 41 and 205 bp; a 
mutant allele is cut into 41, 85, and 120 bps. As illustrated for family B, patient BII-5 
was indeed homozygous for the mutant restriction pattern (figure 4.3). Five healthy 
siblings were heterozygous for this mutation and two unaffected siblings did not 
carry a mutant allele. NlaIII RFLP analysis of the ten families showed that all patients 
except GII-1 were homozygous for the c.1156T>C nucleotide change and that 
all parents except GI-1, were heterozygous carriers of this mutation. GI-1 instead 
carried the IVS1+5G>A mutation. Among 25 unaffected siblings tested, 17 were 
heterozygous for the p.Y368H mutation and eight did not carry this mutation. No 
other mutations or polymorphisms were found in the three patients and one control 
DNA sample analyzed. 
Using the NlaIII RFLP analysis three of 96 healthy controls from the genetic isolate 
were shown to carry the p.Y368H founder mutation heterozygously. We also 
investigated the frequency of this founder mutation in a panel of 86 patients with 
LCA from different Caucasian populations, 75 patients with autosomal recessive or 
isolated retinitis pigmentosa from the Netherlands, and 94 healthy controls from the 
Netherlands. The p.Y368H mutation was not found in the random control group or 
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in the LCA cohort but was found heterozygously in one Dutch patient with retinitis 
pigmentosa and early-onset visual loss. 
Figure 4.3   Restriction fragment length polymorphism based co-segregation analysis of RPE65 
p.Y368H mutation in family B of the genetic isolate
NlaIII cuts the 246-bp PCR product in fragments of 41 and 205 bp in wildtype alleles and in 41, 80, and 
125 bp in mutant alleles. Five non-affected siblings are heterozygous carriers of the p.Y368H mutation; two 
carry wild-type alleles. Wt, wild-type; mu, mutant, co, constant. Siblings are not depicted in order of age to 
preserve anonymity.
Discussion
We found 14 patients with a congenital retinal dystrophy belonging to ten related 
families from a former genetic isolate in the Netherlands. The age of onset of the 
retinal dystrophy suggests LCA, but several characteristics of the disease – for 
example, visual acuity, visual fields and night blindness - strongly support the 
diagnosis of early-onset retinitis pigmentosa. We therefore classify the phenotype 
of our patients as an early-onset severe retinal dystrophy. Based on a comparison 
of the phenotypes observed in patients of our pedigree with previous genotype-
phenotype studies6,14,15, we hypothesized that the RPE65 gene represented a good 
candidate gene. Linkage analysis of a highly polymorphic marker located very 
near the RPE65 gene revealed homozygosity-by-descent in nine of ten families. 
We found homozygosity for a p.Y368H mutation in nine families, and compound 
heterozygosity of the p.Y368H and IVS1+5G>A mutations in one patient of the other 
family. The p.Y368H mutation has most probably been inherited from a common 
ancestor of all 10 families born in the 18th century or before. The IVS1+5G>A 
mutation is the most frequently encountered LCA associated RPE65 mutation (ref. 5 
and references therein).
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Both RPE65 variants described above have been found previously in patients with 
similar phenotypes and were not found in 50 random control individuals from the 
general population. Moreover, the Y368 residue is conserved among human, bovine, 
canine, rat, chicken, and salamander17. 
Our results clearly show that a homozygous p.Y368H mutation in the RPE65 gene 
can be associated with a large variability in visual acuity. Moreover, over a mean 
nine year follow up period, visual acuity either remained stable, seemed to improve 
slightly, or deteriorated. The observed improvement can be explained by visual and 
mental development that may influence results of visual acuity testing favourably. 
Within families, concordance of progression of the disease was observed. At 
present, six patients are over 20 years of age and have stable visual acuity. Based 
on our findings it is not possible to give patients with a homozygous p.Y368H 
mutation an accurate prediction on their future visual acuity. An explanation for the 
variable clinical outcome cannot be found in the different functional consequences 
of the various mutations. Clearly, other genetic or environmental factors influence 
visual acuity and its progression. No other patients have been described with a 
homozygous RPE65 p.Y368H mutation. Patients who are compound heterozygous 
for this mutation and a p.R91W mutation showed a more severe disease course16,18. 
In a previously identified patient with the same compound heterozygous mutations 
as patient GII-1, the age of onset was five years, with a visual acuity of 20/100 (both 
eyes) and three diopters of hypermetropic correction18, whereas our patient was 
visually impaired since birth, had a visual acuity of 20/200, and was emmetropic by 
the age of three years. Again, knowledge of the mutations seems of no predictive 
value for disease course.
On initial examination patients had normal fundi or mild changes, whereas eventually 
all fundi showed severe and more prominent changes, similar to the development as 
described by Lorenz and co-workers16.
 
Four patients described by Lorenz et al and two described by Felius et al were 
hypermetropic, as were nine of 12 patients with RPE65 mutations described by 
Lotery et al16,18,19. Within our group of 13 patients with a homozygous p.Y368H 
mutation only two were hypermetropic. One hypermetropic patient had two 
unaffected relatives who were hypermetropic, suggesting that other genetic 
factors were involved. The other patient had two affected siblings who were 
near emmetropic. Thus the homozygous p.Y368H mutation, in contrast to other 
combinations of RPE65 mutations, is not associated with hypermetropia.
In a study of the same population 43 years ago, Schappert-Kimmijser and 
coworkers ascertained 13 LCA patients in eight families11. It can be predicted that 
most if not all of these patients carried the p.Y368H founder mutation. Assuming 
that half of the patients seen by Schappert-Kimmijser and co-workers are still alive 
106
and since we have not investigated this population in depth, a conservative estimate 
would be that there are 25 patients with early-onset severe retinal dystrophy in the 
current population (consisting of 16.500 people) carrying the p.Y368H founder 
mutation homozygously. Assuming heterozygosity of this mutation in 1/660 
individuals, we deduced a carrier frequency of ~1 in 13. Analysis of 96 healthy 
individuals from the genetic isolate yielded a p.Y368H carrier frequency of 3.1% 
(95% confidence interval, -0.4% - 6.6%). Based on the observed carrier frequency 
of the p.Y368H founder mutation in this former genetic isolate, patients and 
heterozygous carriers with partners from this population have a risk of ~1 in 56 and 
~1 in 112, respectively, that anyone of their children will develop early-onset severe 
retinal dystrophy.
RPE65 has a crucial, but as yet not fully understood, role in the isomerisation of all-
trans-retinal to 11-cis-retinol in the retinal pigment epithelium20,21. In RPE65 deficient 
mice and dogs, pharmacological and somatic gene therapy based treatments, 
respectively, were successful22,23. It is clear that further assessments of long term 
safety and efficacy are required for various treatment strategies and, as treatment 
may need to be applied very early in life, ethical aspects will have to be considered. 
Nevertheless, patients carrying defects in the RPE65 gene might become eligible for 
future clinical trials, underscoring the importance of their early clinical and molecular 
genetic identification.
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Abstract 
Objectives
To test humans with heterozygous CRB1 mutations for possible clinical or 
functional retinal changes and evaluate whether an LCA patient with CRB1 
mutations, not consistent with previously described CRB1 phenotypes, carried a 
modifier allele in another LCA gene. 
Methods
Seven unrelated heterozygous carriers of    CRB1 mutations, who’s children have 
LCA, underwent phenotyping by full eye examinations (indirect ophthalmoscopy 
and slit lamp biomicroscopy) and functional testing (standard full field 
electroretinography and multifocal ERG). For genotyping of the LCA patients and 
their parents, we performed dHPLC analysis followed by sequence analysis of 
CRB1, followed by sequence analysis of the AIPL1 and CRX genes to identify a 
putative modifier effect in a patient with an atypical CRB1 phenotype. 
Results
We found reduced full-field ERG b-wave amplitudes with scotopic –2dB flash 
(140 ��, p�0.05), normal full field cone ERGs, and significant regional retinal           
dysfunction on mfERG in five out of seven carriers of CRB1 mutations. We 
identified a known AIPL1 mutation (p.R302L) as being a potential modifier allele 
in a LCA patient carrying two CRB1 mutations, with a prominent maculopathy.
Conclusions
In human heterozygotes of CRB1 mutations, we found distinctive regional 
retinal dysfunctions by multifocal ERG measurements consistent with the focal 
histological abnormalities reported for the two CRB1 knockout mice models. 
This phenotypic finding may identify CRB1 carriers and point to the causal gene 
defect in affected LCA offspring, significantly facilitating the molecular diagnostic 
process. We also provide evidence suggestive of a modifier allele in AIPL1 in a 
case of LCA with prominent atrophic macular lesions and homozygous defects in 
CRB1. 
110
Introduction
 
Leber congenital amaurosis (LCA, MIM 204000) is a severe, currently untreatable, 
congenital retinal dystrophy that leads to blindness. Theodor Leber defined LCA 
in 1869 as a congenital form of retinitis pigmentosa (RP) with profound visual loss 
at or near birth, wandering nystagmus, amaurotic pupils, a pigmentary retinopathy 
and autosomal recessive inheritance1. A severely reduced electroretinogram (ERG) 
was later added to this definition as this distinguishes it from a complex set of other 
overlapping congenital retinal disorders2. LCA creates an appreciable burden on the 
affected child, the family and society, as the blindness is lifelong and commences 
at birth. It has a worldwide prevalence of 1 in 100,000 newborns, and it accounts 
for > 5% of all inherited retinopathies and approximately 20% of children attending 
schools for the blind3.
LCA is both genetically and clinically heterogeneous, and since 1996, ten genes/loci 
participating in a wide variety of retinal functional pathways have been implicated    
in the disease process4. LCA associated proteins participate in phototransduction      
(GUCY2D)5, vitamin A metabolism (RPE65, RDH12)6-8, photoreceptor development 
(CRX)9, biosynthesis of cGMP phosphodiesterase (AIPL1)10,11, photoreceptor cell 
development and structure (CRB1)12-14 and disc morphogenesis (RPGRIP1)15-17. The 
discoveries of these genes has led to an increased understanding of the molecular         
determinants of retinal physiology/development by identifying new biochemical and 
cellular pathways. Therefore, LCA serves as a model for all human retinal dystrophies. 
The LCA genes at chromosomal loci 1p36      18, 6q1119 and 14q2420 remain to be 
identified. The seven currently known LCA genes account for ~40% of the cases21, 
while genes underlying the remaining 60% of cases still await discovery. It is now   
evident that different LCA animal models respond to gene replacement therapy22. 
We previously found that obligate heterozygous parents of offspring with LCA 
mutations have unanticipated photoreceptor dysfunctions that appear to be specific 
for the involved gene, which points to the causal gene defect in the child, thereby 
significantly facilitating the molecular diagnostic process, while adding important 
functional information of the heterozygous mutations themselves. We documented 
cone ERG abnormalities in parents carrying GUCY2D defects23, rod dysfunction in 
AIPL1 carriers24, normal rod and cone ERG function in the RPE65 carriers25, cone 
ERG dysfunction in RDH12 carriers26 and cone plus rod dysfunction in the RPGRIP1 
heterozygotes27. We confirmed many of these clinical findings by performing 
mutation-specific in vitro biochemical studies28-30. We also performed detailed clinical 
studies on another 31 obligate heterozygous parents of LCA children with known 
LCA mutations and found that more than 80% of them have mild gene-specific 
functional deficits and/or retinal abnormalities25.
The purpose of the present study was to identify a possible distinctive phenotype 
of Heterozygotes for mutations in the Crumbs homolog-1 gene, CRB1. Recessive 
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mutations in CRB1 are associated with a diversity of retinal phenotypes, including      
autosomal recessive retinitis pigmentosa type 12 (RP12)12, Leber congenital 
amaurosis (LCA)13,14 with or without the well-known retinal findings ”preservation of 
the para-arteriolar retinal pigment epithelium” (PPRPE) and ”Coats-like exudative 
vasculopathy.” A dominant CRB1 mutation has recently been associated with 
pigmented paravenous chorioretinal atrophy31. 
The CRB1 protein is involved in photoreceptor development and photoreceptor 
structure and the two known Crb1 knockout mice both show a distinctive inferior 
focal retinal dystrophy32,33.
We tested the hypothesis that CRB1 heterozygotes have a phenotype distinctive 
for CRB1 defects. We specifically looked for regional retinal changes by multifocal 
ERG testing, which would correlate with the mouse CRB1 phenotype. We observed 
regional areas of cone dysfunction in the carriers of CRB1 mutations. We also 
identified an LCA child with a prominent maculopathy and postulated an AIPL1 
or CRX genotype. We were surprised to find a homozygous CRB1 mutation, but 
further analysis also revealed a pathogenic AIPL1 mutation. We here present clinical 
information on the patient’s and the parent’s phenotype, suggesting that the AIPL1 
defect contributed to the phenotypes as a modifier allele, while the homozygous 
CRB1 mutation is causal. 
Patients and methods
Clinical analyzes 
Molecular diagnostic screening protocol: Our laboratory is involved with the molecular 
diagnostics of >400 LCA patients, and we have set up a protocol in which we 
postulate molecular hypotheses, based on the retinal and disease phenotype of 
the LCA patients. For example; an LCA patient with LP vision and relatively normal 
retinal appearance will be screened for GUCY2D mutations, while an LCA patient 
with measurable or improving vision, night blindness and translucency of the RPE, 
would suggest the RPE65 gene for initial screening. LCA patients with macular 
changes (including macular colobomas) will be screened for CRX and AIPL1 defects, 
while LCA patients with PPRPE are postulated to harbor CRB1 mutations. 
To investigate patterns of regional retinal dysfunction, we measured local 
electrophysiological responses of the retina, and chose the multifocal ERG (mfERG), 
as Vajaranant et al.34 clearly demonstrated by mfERG that in female carriers of 
X-linked mutations, patchy areas of retinal dysfunction exist. The mfERGs were 
performed at two institutions; The Montreal Children’s Hospital at the McGill University 
Health Center (MUHC) and at the Department of Ophthalmology of the University 
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of Illinois at Chicago (UIC) using a VERIS Science 5.1 system (EDI Inc., San Mateo, 
CA, USA). Both eyes were recorded while the pupil was undilated, and the stimulus 
matrix consisted of 61 hexagons scaled with eccentricity and was presented with 
a 7-inch monitor, measuring from 3-300 Hertz. This particular stimulus allowed 
us to record 61 localized cone ERGs from the macular and paramacular regions, 
subtending an area of up to 20° from the central fovea. The stimulus consisted of 
black and white hexagonal stimulus elements arranged concentrically around a 
fixation point. The stimulus was displayed on a digital camera and each element was 
reversed pseudorandomly in binary m- sequence at 75 Hz (frame rate). The stimuli 
were modulated between black (0.45 cd/m2) and white (280 cd/m2). Flash intensity 
was 1.028-log cd/sec/m2, background intensity was 0.727-log cd/sec/m2, while the 
fixation light measured 0.13-log cd/sec/m2. Total recording time was 3 minutes and 
38 seconds. 
A total of seven obligate CRB1 mutation carriers (from four LCA families) were 
ascertained for this study. Six carriers were investigated at the MUHC (Families I-
III), and after we found abnormal focal mfERG measurements in four out of the six 
carriers, we wanted to confirm our results in a second, completely independent 
laboratory, with significant mfERG experience. We therefore recruited one individual 
from a CRB1 pedigree with LCA children at the UIC, and did not share the details of 
our mfERG findings with the investigator. This one additional CRB1 mutation carrier 
was studied in detail at the UIC (Family IV). We also repeated mfERG testing in our 
first subject (Family I:1, figure 5.1) to confirm our results. After each subject was 
counseled, informed consents were signed, approved by the Montreal Children’s 
Hospital and the University of Illinois at Chicago institutional review boards. The study 
adheres to the declaration of Helsinki. Venous blood was drawn for DNA extraction 
and mutation analysis. 
Detailed ocular and visual histories were obtained, pedigrees were drawn, and 
detailed eye examinations were performed on all seven carriers, including best 
corrected visual acuities by projected Snellen charts, cycloplegic refractions, 
slit lamp biomicroscopy, and dilated indirect ophthalmoscopy. Visual fields were 
measured by Goldmann kinetic perimetry, using the V4e and l4e test lights, moving 
the target from non-seeing to seeing retina. Cone and dark adapted mixed rod-cone 
electroretinograms (ERGs) were performed on both eyes and the a- and b-wave 
amplitudes and implicit times (peak times) were averaged in accordance with the 
standards recommended by the International Society for Clinical Electrophysiology 
of Vision (ISCEV).35 We then tested the following two hypotheses: 
Hypothesis 1: Heterozygous carriers of CRB1 mutations have regional retinal 
dysfunction on multifocal ERG (as suggested by the CRB1 mice models) and 
Hypothesis 2: A heterozygous AIPL1 mutation acts as a modifier allele in a LCA 
patient with a severe maculopathy and a homozygous CRB1 mutation. 
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Molecular analyzes
PCR amplification on genomic DNA (of LCA patients and parents) was performed 
with intronic primers designed to flank the splice junctions of each coding amplicon 
of LCA genes CRB1 (12 exons; 27 amplicons), AIPL1 (6 exons; 5 amplicons) and 
CRX (3 exons). Heteroduplex formation of the PCR products for dHPLC analysis 
was induced after heat denaturation and dHPLC analysis were performed with the 
WAVE DNA fragment analysis system (Transgenomics). The values of the buffer 
gradient, start and end points of the gradient and melting temperature prediction 
were determined by the WAVEMAKER software of Transgenomics. Variants in gel 
mobility identified by this technique were then subjected to bidirectional automated 
sequencing (ABI Prism, Applied Biosystems) on a model 3100 automated sequencer. 
Some of the CRB1 mutations in this study were identified by a new LCA genotyping 
microarray, which now contains > 300 known LCA mutations from seven LCA genes 
(see Zernant et al for technical details)21. The LCA disease chip identifies currently 
known LCA mutations, while our conventional mutation screening methods identify 
and add novel changes. After we determined the CRB1 mutations in the LCA 
children, we sequenced the appropriate CRB1 amplicon of the parents DNA to 
assess the parental origin of each mutation. We used the following well-accepted 
set of five criteria to distinguish polymorphisms from pathogenic mutations. 1. The 
predicted effect of the base pair change on the protein product; 2. The relative 
frequency of the variation in LCA patients versus normal ethnically matched controls 
(> 1% in the controls will be assigned as a polymorphism); 3. Co-segregation of the 
mutant allele(s) in the affected families; 4. Homozygosity or compound heterozygosity 
in recessive LCA; and 5. Conservation of the codon across different animal species.
Results
Family I.  In Family I, we identified a child with LCA who exhibited measurable vision 
and the striking PPRPE retinal pattern, which prompted us to screen the CRB1 
gene first and documented a c.2843G>A transition which predicts a p.C948Y 
mutation in CRB1, which we then determined was on the paternal allele (figure 5.1). 
We have not yet identified the maternal mutation, despite sequence analysis of the 
exons and flanking intronic sequences of the CRB1 gene. The 35-year-old father 
complained about difficulties with vision in the right eye, but not the left. He denied 
nyctalopia and photo-aversion. Acuities were 20/20 OU with  – 4.00 +3.00 x 120º 
OD and – 1.75 OS. Retinal examinations were positive for marked narrowing of the 
retinal blood vessels in both eyes. The retina was otherwise normal. Average cone 
b-wave amplitudes were slightly decreased compared to normal at 92 �V with a 30    
ms implicit time, while the averaged mixed rod and cone b-wave amplitudes were 
markedly decreased at 142 �V (normal > 220 �V), with a normal 50 ms implicit time            
(normal is 45 +/- 3 ms). The mfERG of the right eye showed a striking superior, 
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regional pattern of abnormality in the right eye (figure 5.1), which corresponds to 
inferior retinal dysfunction, while the left eye appeared entirely normal (figure 5.1). 
The blue color superiorly indicates decreased retinal sensitivity, which is confirmed 
by the raw data showing the actual waveforms and decreased heights of the waves. 
The central peak corresponding to the foveal input is also lower in the right eye. We 
averaged the superior and inferior mfERG field data and used Student t testing to 
determine statistical differences. We found an average of 13.796 nV/deg2 superiorly 
(5.85 nV SD) and 23.44 nV/deg2 (7.08 SD) inferiorly. The two means are significantly 
different (p<0.001). We repeated the mfERG on this subject two years later and 
confirmed the results (data not shown). The carrier mother was asymptomatic, 
had a completely normal retinal examination, and both the standard ERG (cone 
and rod signals) and the mfERG were normal. There was no superior mfERG field 
abnormality in either eye (figure 5.1). 
Figure 5.1   Pedigree, CRB1 mutation and mfERGs of Family I 
Patient II-1 carries a paternal p.C948Y CRB1 mutation (noted as p.C948Y for ease of illustration). The pa-
ternal mfERG of the OD is shown on the left with the 3D image at the top and the raw data at the bottom, 
both showing the superior defects, corresponding to the inferior retina. The maternal mfERG of the OD is on 
the right and both the 3D and raw data show normal values.
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Family II. In the second LCA family, the affected LCA patient also had the PPRPE 
retinal disease pattern and we again postulated CRB1 involvement. We then 
determined that the child harbored a c.493_501del 9 bp that predicts a deletion of 
three amino acids p.D165_I167del. We also found a c.1360G>A transition, which 
predicts a p.G454R missense mutation in CRB1 (figure 5.2). We then documented 
that both the p.D165_I167del and the p.G454R mutations were on the paternal 
allele. The CRB1 mutation on the maternal allele has not yet been identified, despite 
sequence analysis of the exons and flanking intronic sequences of the CRB1 
gene. The 46-year-old mother was asymptomatic and had a normal retinal exam. 
We measured averaged cone b-wave amplitudes of 100 �V (N>120 �V), which is     
slightly below normal with a 33.5 ms implicit time. Averaged mixed rod-cone b-wave 
amplitudes were normal at 239 �V (N>220 �V) with a normal 39.5 ms implicit time.          
The mfERG of the mother were abnormal for both eyes and showed a regional 
pattern of abnormality with a marked lowering of the central peak (figure 5.2, 
only the right eye is shown). The father was also asymptomatic and had a normal 
retinal exam as well. His cone b-wave amplitudes averaged 98 �V, which is again    
slightly below normal with a 32.3 ms implicit time, and his mixed rod-cone b-wave 
amplitudes averaged 223 �V with 40.5 ms implicit times. MfERGs of both eyes          
showed regional field abnormalities associated with a marked decrease in central 
sensitivity, less obvious than the mother (figure 5.2, only the right eye is shown). 
Figure 5.2   Pedigree, CRB1 mutation and mfERGs of Family II 
Patient II-1 carries the paternal p.D165-I167del and p.G454R CRB1 mutations. The paternal mfERG data 
of the OD is on the left, the maternal mfERG data of the OD is on the right, both showing the superior 
mfERG abnormalities. The abnormalities are especially obvious when comparing the plots to normal plots 
such as displayed on the right side of figure 5.1. 
116
Family III. In the third family (figure 5.3) we diagnosed a child with LCA and a promi-
nent bilateral maculopathy (figure 5.5), and initially postulated sequence variants in 
AIPL1 or CRX, but not CRB1. There was no PPRPE and there were no intraretinal 
white dots. Our genetic analysis revealed a well-known and previously reported 
heterozygous c.905G>T transversion which predicts a p.R302L AIPL1 mutation, 
while no mutations were found in CRX. In our comprehensive screening protocol, we 
were surprised to also find a homozygous c.1345C>T transition, which predicts a 
p.Q449X nonsense mutation in CRB1. We then confirmed that both parents carried 
the p.Q449X CRB1 mutation heterozygously and then determined that the father 
also carried the p.R302L AIPL1 mutation. Both parents were asymptomatic, had 
normal dilated retinal examinations, and both mixed rod-cone and isolated cone 
signals were normal on conventional ERG (mixed rod-cone b-waves > 220 �V; cone  
b-waves > 120 �V). The mother’s mfERG appeared to be normal (        figure 5.3), while 
the father had substantially abnormal recordings on the mfERG, with superior, tem-
poral and inferior field abnormalities, associated with a marked decrease in central 
sensitivities (figure 5.3). 
Because of the potential importance of our previous findings, we wanted to 
confirm our results in a parallel study. We identified a fourth CRB1 family at UIC and 
performed detailed mfERG studies without prior knowledge of the detailed findings.
Figure 5.3   Pedigree, CRB1 and AIPL1 mutations and mfERGs of Family III
Patient II-1 carries the homozygous p.Q449X mutations in CRB1 and the additional paternal p.R302L 
AIPL1 mutation. The paternal mfERG data of the OD is on the left showing striking abnormalities, while the 
maternal mfERG of the OD on the right appears normal.
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Family IV. In the fourth family, we found that three offspring had LCA, with retinal 
pigmentary changes and white intraretinal dots, but without PPRPE. No molecular 
hypothesis could be postulated, and all LCA genes were systematically screened. 
The LCA proband was found to have a c.1463T>C transition which predicts a 
p.F488S and a c.2258T>C transition which would lead to a p.L753P missense 
mutation in CRB1 and a c.1301C>Transition which would lead to a p.A434V 
mutation in RPE65 (figure 5.4). We traced the p.L753P change in CRB1 and the 
p.A434V mutation in RPE65 to the maternal allele and assumed that the p.F488S 
mutation in CRB1 came from the paternal allele, as he was deceased prior to our 
studies. The p.A434V allele is found in 11% of the black population (Dr. EM Stone, 
personal communication), we therefore consider this change a non-disease causing 
polymorphism. The carrier mother was found to be asymptomatic and had a normal 
dilated retinal exam. Her mfERG recordings were, however notably abnormal. The 
right eye was found to have a marked regional mfERG field abnormality, associated 
with a marked decrease in the sensitivity of the fovea, while the left eye was entirely 
normal (figure 5.4). The raw data show a similar pattern. 
Figure 5.4   Pedigree, CRB1 and RPE65 mutations and mfERGs of Family I�
Patient II-1 carries the p.F488S and p.L753P mutations in CRB1 with the additional maternal p.A434V varia-
tion in RPE65. Only the maternal mfERG data is shown, as the father was unavailable for analysis. On the 
left is the left eye (OS) with the 3D image above and raw data below which appear normal, while on the right 
is the right eye (OD) showing abnormal mfERG patterns predominantly in the superior region on both the 3D 
image (above) and raw data (below). 
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Child with LCA and a maculopathy
The child with LCA from Family III was first seen by us at the age of three years, 
and was diagnosed with congenital blindness and nystagmus elsewhere. He was 
a term baby from a consanguineous couple from Lebanon. On our first exam we 
found that the child was able to fix and follow. His cycloplegic refractions were –0.5 
OD and +1.50 OS. He was also found to have rotatory nystagmus, paradoxical and 
amaurotic pupils, a large exotropia, and the oculodigital sign of Franceschetti. He 
much preferred day vision and protested when the lights were turned off. Averaged 
cone b-wave amplitudes were 15 �V (N > 120 �V) with 30 ms implicit times, while the            
mixed rod-cone b-wave was non-detectable. The retinal exam was striking (figure 
5.5a and 5.5b). The optic discs were normal, the retinal vessels were narrow and 
there was an absence of pigmentary degeneration and PPRPE. Both maculae were 
abnormal with multiple, similarly sized, cystic white lesions with surrounding black 
rims (total size, approximately four disk diameters) were observed (figure 5.5a and 
5.5b). At age 5 we found that the cycloplegic refractions had become +2.00 + 1.00 x 
90 OD and + 4.50 OS and the acuities were measurable at 6/200 OU. We postulated 
involvement of the AIPL1 or CRX gene, as these two LCA genes are associated with 
macular colobomas and/or maculopathies. DNA analysis revealed a heterozygous 
p.R302L AIPL1 mutation and an additional homozygous p.Q449X mutation in CRB1.
Figure 5.5a + b.   Fundus pictures of Family III LCA patient II-1
Shown are the posterior poles of the retinas of the right (5a OD) and left eyes (5b OS) of the affected LCA 
child with the homozygous p.Q449X mutation in CRB1 and a heterozygous p.R302L mutation in AIPL1. 
Note the conspicuous maculopathy.
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Discussion
Human photoreceptors are highly specialized and polarized cells which, in the outer 
nuclear layer (ONL), are in close contact with Müller glial cells for structural and 
metabolic support. The adhesion belt named the outer limiting membrane (OLM) 
contains multiple adherence junctions, which are present between photoreceptors 
and Müller cells. These adherence junctions consist of multi-protein complexes and 
are linked to the cytoskeleton of the cell. A core component of these complexes is 
the trans-membrane protein Crumbs homolog-1, CRB132,33.
A natural Crb1 mutant mouse, called retinal degeneration 8 (rd8)32 was found to 
harbor a homozygous single base pair deletion in Crb1 (c.3481delC) causing a 
frameshift and an early stop codon and likely leads to nonsense-mediated decay of 
the encoded RNA. The rd8 mouse develops severe retinal abnormalities, including 
focal photoreceptor degeneration and irregularities of the OLM. Mehalow et al found 
that the rd8 mice developed irregular shaped large white subretinal spots detectable 
at the age of 3 weeks, which were more heavily concentrated in the infero-nasal 
quadrant of the retina. These spots were then found to correspond histologically 
to retinal folds and pseudo-rosettes. They also found OLM fragmentation, outer 
segment shortening, but normal inner segments. By 5 months, the outer segments 
had virtually disappeared, the inner segments were swollen, and the Müller cell 
processes were unusually prominent. The retinal degeneration was unexpectedly 
focal in appearance, with nearly normal retina present at the edge of a region with 
severe degeneration. The reason for this is still unclear. The photoreceptor dysplasia 
and degeneration reported by Mehalow et al in the rd8 mouse with the Crb1 
mutations strongly vary with the genetic background, suggesting modifier effects 
from other retinal genes32.
Van de Pavert et al inactivated both Crb1 alleles to produce a complete null and 
examined the resulting mouse retina33. There were marked differences between the 
Crb1-/- and the rd8 retinal findings. Neither two week nor 2-month-old Crb1-/- mice 
had retinal abnormalities. At 3 months however, the mice developed focal areas of 
retinal degeneration, while the OLM was ruptured, and there was protrusion of single 
or multiple photoreceptors through the OLM into the subretinal space. Also, there 
was ingress of photoreceptors into the inner retina, namely the outer plexiform layer. 
One of the most striking histological findings was a double layer of photoreceptors 
(half rosettes). These rosettes developed normal inner segments and a full OLM, 
very much unlike the rd8 model. This finding suggests that CRB1 is not essential 
for the formation of junctional complexes and OLM, but rather for the maintenance 
of these structures. In six-month-old Crb1-/- mice large ectopic photoreceptor 
layers were identified, which were so large that they resembled a ”funnel” abutting 
the ganglion cell and inner limiting membrane. The authors suggest that the initial 
insult of the Crb1 mutation is the loss of the photoreceptor to Müller glial cell 
adhesion at retinal foci. Light exposure experiments revealed a significant increase 
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in retinal degeneration in the Crb1-/- mouse especially infero-temporally; therefore 
light enhances the retinal degeneration in the Crb1-/- retinas33. These histological 
abnormalities in the two CRB1 mice models prompted us to hypothesize that 
regional retinal abnormalities exist in carriers of CRB1 mutations, and that led to this 
study and the surprizing mfERG abnormalities.
As we have thus far found LCA gene-specific phenotypes in obligate heterozygotes 
with mutations in GUCY2D23 and RDH1226 (cone ERG dysfunction), RPE6525 
(normal ERGs), AIPL124 (rod ERG dysfunction), and RPGRIP127 (rod plus cone ERG 
dysfunction), we wanted to know if CRB1-specific changes occur as well, that 
may be useful in our classification system designed to use simple clinical tests on 
carriers to point to the molecular defect in the blind child or might in the future help 
to identify carrier states in family members of LCA patients. We now report that five 
out of seven CRB1 mutation carriers from four tested families were found to have 
novel and distinctive retinal dysfunction by multifocal ERG testing. We documented 
superior mfERG abnormalities in one carrier (Family I-1 in figure 5.1), supero-
temporal mfERG abnormalities in three carriers (Family II-1 and II-2 in figure 5.2 and 
Family IV-2 in figure 5.4), and supero-temporal-inferior mfERG field abnormalities in 
one carrier (Family II-1 in figure 5.3). We also found that all five patients with regional 
mfERG abnormalities had a co-existent central abnormality, which represents the 
signal from the fovea. 
Abnormalities were detected irrespective of the type or severity of the CRB1 muta-
tion, as we found similar changes in the carriers of a complex mutation consisting of 
a missense mutation (p.G454R) with an in-frame deletion (p.D165_I167del; Family 
II), a nonsense mutation (Family III), and missense mutations (Families I and IV). 
We found however, that not all seven of the CRB1 mutation carriers exhibited a 
regional retinal dysfunction on mfERG testing, as two of the carriers had normal 
recordings. We also found striking asymmetries between eyes of two of the carriers, 
who showed the mfERG abnormalities in one eye, but not in the other. We do not 
yet know the reason for this, but we postulate that other genetic and environmental 
factors may contribute to the CRB1 carrier phenotype. We found that most CRB1 
carriers in this small series had normal or mildly abnormal rod and cone full field 
ERGs except one carrier that exhibited significant rod ERG defects (Family I). This 
is the same carrier who also had obvious narrowing of the retinal blood vessels 
and was the only carrier who was symptomatic. The rest of the carriers were 
asymptomatic and had normal retinal examinations including normal vessel caliber. 
We postulate that the mfERG changes we have documented in the carriers may be 
caused by retinal folds and/or pseudorosettes (as was found in the mice), as a result 
of a disrupted OLM and that light toxicity may play a role in the carrier phenotype, 
as it has been documented in the Crb1 knockout mouse32. It will be very informative 
to perform in vivo high-resolution microscopy (OCT-3) in the CRB1 mutation carriers 
in future studies to test this hypothesis as Jacobson et al documented thickened 
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retinas in affected individuals with LCA and CRB1 mutations36. We also plan to 
perform further psychophysical testing by automated visual field analysis to extend 
our mfERG findings in the CRB1 carriers.
In terms of genetics of the LCA patients and the co-segregation of their CRB1 
mutations, we found that only Family III shows definite autosomal recessive 
inheritance of the CRB1 mutations, with a possible modifier effect from AIPL1. In 
Family IV, only II.1 follows an autosomal recessive pattern of CRB1 variants. The 
other two affecteds in Family IV carry two maternal variants. These patients and 
the patients of Families II and I could be also be digenic. In three of the four families 
reported here, the segregating CRB1 variants therefore do not fully explain LCA 
in the younger generations. In Families I and II, the maternal CRB1 variants could 
not be detected; in family IV, two out of three patients do not carry maternal and 
paternal CRB1 variants. Thus, it is possible that defects in other genes cause, 
or play a major role in, the phenotype of these LCA patients. However, in view of 
the very low incidence of CRB1 variants in the general population (heterozygosity 
frequency between 1/350 and 1/500) (assuming an incidence of LCA between 
1/50.000 and 1/100.000, and a CRB1 share of 10%), the identification of CRB1 
variants in these families (from a total of 250 LCA patients investigated) hardly can 
be coincidental. Thus, we think that the CRB1 variants identified in this study, either 
in combination with as yet unidentified CRB1 defects, or in combination with defects 
in other genes, are causal for LCA in the patients of Families I and II and for two of 
three affected siblings in Family IV. As such, we cannot exclude the possibility that 
mfERG abnormalities in parents of LCA patients are not only due to heterozygous 
CRB1 variants, but, as exemplified by parent I.1 of Family III and parent I.2 of Family 
IV, are due to defects in more than one gene.
In the second part of our study, we identified a homozygous CRB1 mutation 
p.Q449X associated with a retinal LCA phenotype consisting of a prominent and 
unusual maculopathy, which to the best of our knowledge, has not previously been 
described for CRB1 patients24. We wanted to test the hypothesis that CRX or AIPL1 
defects contributed to this phenotype as modifier alleles, as both CRX and AIPL1 
are well known to be associated with maculopathies in LCA24.
In an isolated Dutch population, we previously documented intra-familial phenotypic 
variability (both in severity and progression of disease) in patients with early-onset 
severe retinal dystrophy, and determined that 13 of the 14 affected members share 
a homozygous p.Y368H mutation in RPE6537. Despite sharing an identical genotype, 
we made the surprising observation that the members did not share a common 
phenotype, as we carefully documented three disparate disease types in terms of 
their visual function: some patients deteriorated, some improved, while yet others 
remained stable37. Identical genotypes with disparate disease phenotypes in this 
and other families led us to hypothesize the existence of modifier genes/alleles. We 
tested this idea with a new LCA microarray in a cohort of 200 LCA patients and 
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found that 15% of patients have three sequence variants in two genes, instead 
of the expected two in the same gene21. We found that the phenotype was more 
severe in patients with three sequence variants in five families, which were available 
for meaningful functional comparisons. 
In our LCA patient with homozygous CRB1 mutations and with an unusual 
prominent maculopathy, we also identified a heterozygous p.R302L in AIPL1 and 
postulate that the LCA is caused by the homozygous CRB1 defects and that the 
AIPL1 mutation causes the altered phenotype (maculopathy), and we provide three 
lines of suggestive evidence for this in view of biochemical analysis, which are not 
yet completed. Firstly, a small diffuse maculopathy has only been reported once 
in a patient with CRB1 mutations p.C948Y + T745M, but this macular lesion is 
unlike the maculopathy of our patient38. Second, additional support for an effect of 
the p.R302L mutation in AIPL1 comes from comparing the phenotypes of the two 
carrier parents, the father with the CRB1 p.Q449X and AIPL1 p.R302L and the 
mother with only the CRB1 p.Q449X mutation. The mfERG data strongly suggest, 
that the cone dysfunction in the father is significantly worse than that of the mother 
(or any other carrier in this study). Third is the fact that the p.R302L in AIPL1 has 
been found to have a biochemical abnormality in in vitro studies with NUB1, the 
molecular partner of AIPL139.
The p.R302L mutation in AIPL1 was initially reported by Sohocki et al and lies just 
outside the tetra-tricopeptide region (TPR) 3 domain (3’) of the AIPL1 protein in 
the proposed NUB1 binding area, which spans codons 181-330 of AIPL140. The 
p.R302L mutation was found to inhibit immunoprecipition between the mutant AIPL1 
and endogenous NUB139. The p.R302L mutation however was found not to affect 
the interaction between AIPL1 and farnesylated proteins10. Our data suggests that 
the CRB1 associated phenotype was altered by the p.R302L allele found in AIPL1. 
In summary, we found that the heterozygous phenotype of carrier parents with child-
ren who have LCA caused by CRB1 mutations do not have a normal phenotype as 
suggested by classical Mendelian inheritance models. Instead, we document a novel, 
unique retinal phenotype of the obligate carriers with CRB1 mutations consisting 
of regional retinal dysfunction (found by mfERG testing), which corresponds to 
abnormalities in the opposite mfERG field. This correlates well with both published 
CRB1 knockout animal models. We also present a LCA retinal phenotype with 
homozygous nonsense mutations in CRB1 and with a prominent macular lesion and 
suggest a modifier effect by a heterozygous p.R302L AIPL1 allele. 
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Discussion
The most frequently occurring human eye diseases in the Western world have a 
multifactorial aetiology and as a group they are relatively common. Age-related 
macular degeneration (AMD), for example, is the leading cause of irreversible 
blindness in the Western world, affecting approximately 30% of people over the age 
of 751. Monogenic retinal dystrophies, on the other hand, are far less common with 
an incidence of approximately 1 in 20002. These inherited retinal diseases often have 
an early onset and thereby have a major impact on future prospects concerning 
education and employment of young patients. 
The retinal dystrophies discussed in this thesis are arRP, arCRD, LCA, and STGD1. 
Many causative genes acting in different pathways, have been identified for each of 
these retinopathies, with the exception of STGD1, for which mutations are confined 
to the ABCA4 gene. In the near future, it will become increasingly important to 
determine the molecular causes underlying these diseases, as a molecular diagnosis 
may form the basis for accurate patient counselling including therapeutic advises. 
A molecular diagnosis in every patient with an inherited retinal disease can only be 
achieved by expanding the knowledge on the genes involved, the pathogenicity of 
individual mutations, the genotype-phenotype correlations, and the integration of 
this knowledge. The overall goal is to provide a classification framework for clinicians 
and vision scientists that contains all mutational and detailed phenotypical attributes. 
The main results of the studies presented in this thesis regarding molecular and 
clinical results on inherited retinal diseases, will be discussed below.
The role of ABCA4 in arCRD and arRP
 
ABCA4 plays a key role in the visual cycle and mutations in the ABCA4 gene were 
previously found to underlie STGD1, a significant portion of the arCRD patients, and 
a small percentage of atypical arRP cases3-5. Furthermore, it is a susceptibility locus 
for AMD6. Since these diseases are very different in clinical severity, a genotype-
phenotype model was proposed in which the amount of residual ABCR protein 
activity was inversely correlated to the severity of the retinal dystrophy7. 
In chapter 2.1, a new genotyping technology was used to detect ABCA4 sequence 
variants in a large cohort of CRD and RP patients. Based on these results we 
estimated that a small percentage of the arRP patients carry ABCA4 mutations. 
On the other hand, 33% of the CRD patients in our cohort showed mutations in 
ABCA4. Although this result is consistent with earlier studies (chapter 2.1 and 
references therein), this may well be an underestimate since the APEX genotyping 
array used for mutation screening can only detect previously identified mutations, 
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and subsequent single strand conformation polymorphism (SSCP) testing was 
only conducted when at least one ABCA4 mutation was detected upon microarray 
analysis. Furthermore, based on extensive mutation analysis of STGD1 patients, it is 
estimated that 60% of the ABCA4 mutations are currently known8. 
ABCA4 is the only arCRD gene identified at the moment. Furthermore, arCRD 
loci are mapped at 1q11.2-q14 (CORD8)9 and 8p11 (CORD9)10. ArCRD patients 
with two ABCA4 mutations do not show distinctive phenotypic characteristics in 
comparison to arCRD patients without mutations in ABCA4. Therefore, a clear-cut 
genotype-phenotype correlation for the involvement of ABCA4 in arCRD cannot be 
made and an accurate estimate for ABCA4 involvement in arCRD is complicated. 
Sharon and coworkers11 identified RPGR mutations in 5 of 11 male CRD patients 
who had no female siblings with RP. Among the CRD patients of our cohort without  
ABCA4 variants, 62% are male. Hence, it is possible that several male CRD patients 
actually carry mutations in RPGR or RP2, the two xlRP genes.
It can be concluded that mutation screening of the ABCA4 gene is worthwhile in 
arCRD and isolated CRD cases. A rapid, efficient and affordable first screening 
method would be the ABCR500 APEX microarray8. In this way, approximately 
60% of the alleles are found in patients with STGD1 belonging to the Caucasian 
population. As sequence analysis yields ~80% of alleles12, 75% of the theoretically 
expected alleles can be found this way. 
The Affymetrix arRP Resequencing Array13 identifies all exonic ABCA4 single 
nucleotide substitutions and deletions. In addition, 5 base pairs of flanking intronic 
sequences are analysed. Heterozygous deletions larger than one nucleotide, as 
well as all duplications, are not detected on this screening platform since their 
inclusion would increase the number of oligonucleotide probes on the microarray 
tremendously. Approximately 15% of all ABCA4 variants are abnormalities of this 
kind, which will be missed if present heterozygously (as most variants are in ABCA4). 
Hence, the resequencing microarray can be predicted to identify approximately 65% 
of the theoretically expected alleles. This disadvantage can be partially overcome 
by including oligonucleotide probes on the resequencing array that specifically 
detect the known deletions and insertions. The small extra efficiency of the ABCA4 
resequencing microarray compared to the APEX technology does not outwage the 
much higher (~10-fold) costs involved. Capillary-based heteroduplex analysis or 
direct sequence analysis can be used to identify ABCA4 variants in patients with one 
or no mutation.  
In contrast to arCRD, we showed that mutations in ABCA4 are responsible for just 
a minor fraction of all arRP cases. The arRP phenotype associated with ABCA4 
mutations is relatively specific and is usually characterised by an early-onset 
pan-retinal dystrophy with a severe and highly progressive nature. Patients lose 
both central an peripheral vision before the age of 40 years. We showed a similar 
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phenotype in older arCRD patients (chapter 2.2). The arCRD patients showed pale 
optic discs with severely attenuated vessels and severe atrophy of both the posterior 
pole (maculopathy) and the midperiphery with extensive bone-spicule pigmentations 
throughout the whole retina. An association with nystagmus and atrophic nummular 
areas in the macula was also shown.
In patients with an early-onset, severe and highly progressive arCRD or arRP, 
ABCA4 is a good first candidate gene to screen. However, no systematic analysis 
of arRP patients has yet been performed to validate this assumption. Again the 
ABCR500 APEX microarray8 is a good, relatively cost-effective, first pass screening 
tool for mutation analysis.
The identification of patients with arCRD or arRP carrying ABCA4 mutations might 
become of greater importance since some therapeutic trials look promising. Abcr 
knockout mice were shown to accumulate lipofuscin pigments14-16. The major 
fluorophore of lipofuscin is N-retinylidene-N-retinylethanolamine (A2E)17 of which 
the biosynthesis is dependent on circulating retinol (vitamin A). A2E is cytotxic to 
RPE cells in several different modes. Thus, therapeutic strategies were developed 
to target the biosynthesis of A2E and its accumulation. Furthermore, it was proven 
that the biosynthesis of A2E and its derivates are illumination dependent18. Abcr-/- 
mice raised in total darkness showed complete inhibition of biosynthesis of A2E and 
therefore patients with ABCA4 mutations may possibly benefit from reduced light 
exposure, for instance by wearing sunglasses or dark contact lenses. Pharmaceutical 
interventions are also under investigation. Isotretinoin (a drug used in humans for 
acne treatment) was tested as a competitive inhibitor of the synthesis of 11-cis-
retinal dehydrogenase by lowering the levels of atRAL (primary reactant in A2E 
biosynthesis)14. The retinal degeneration was prevented successfully in an animal 
model19. However, the doses used in these mice were far higher than acceptable 
for humans (systemic toxicity). Alternative therapeutic interventions based on the 
modulation of intracellular retinoid concentrations are currently ongoing, for instance 
with N-(4-hydroxyphenyl)retinamide (HPR)20.  
Leber congenital amaurosis: genotype-phenotype correlations
A cohort of 58 Dutch and Belgian LCA patients was genotyped using a newly 
developed LCA APEX microarray (chapter 3), and mutations were  detected in 33% 
of the cases. In a study performed by Hanein and co-workers, a larger number of 
LCA patients was screened using a more comprehensive but much more labor 
intensive approach (linkage analysis, dHPLC, direct sequencing), which revealed 
mutations in 44% of the cases21. Assuming that 44% is the maximum percentage of 
patients in which variants can be found today, we can conclude that the LCA APEX 
microarray detected 75% of the expected mutations. 
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In our patient cohort, mutations were most frequently identified in the CRB1 gene 
(16%) and all carried either the p.C984Y or the p.K801X mutation. The second most 
frequently involved gene was GUCY2D. The GUCY2D p.R768W mutation appears 
to be a founder mutation in the Northwest of Europe, because of it unusually high 
frequency. In previous studies, mutations in CRB1 were found to underlie 10-13% 
of the LCA cases21-23. Recently, den Hollander and co-workers analysed 24 French-
Canadian LCA patients and found only one mutated allele22. On the other hand, a 
Spanish study revealed CRB1 to be the causative gene in ~2/3 of all LCA patients 
with proven mutations, suggesting that the CRB1 gene is a major LCA causing 
gene in Western Europe (Vallespin E, personal communication, 2005). The latter two 
studies illustrate extensive ethnic and geographical differences in the occurrence of 
CRB1 mutations. 
In chapter 3 specific genotype-phenotype correlations were made for three 
LCA genes. Patients with AIPL1 mutations showed very poor visual acuity and 
hypermetropia with essentially normal appearing fundi on initial examination. After 
the age of eight years, extensive pigmentations became present with a striking 
bulls’ eye maculopathy. All patients with   CRB1 mutations showed some or all signs 
of the RP12 phenotype, being relatively normal appearing optic discs and vessels, 
a distinct maculopathy, a nummular type of pigmentations, yellow-white subretinal 
dots, PPRPE, Coats-like exudative vasculopathy and vascular sheathing. LCA 
patients with GUCY2D mutations showed an extremely severe phenotype of no light 
perception and relatively normal appearing fundi until at least the age of 30 years.  
In a relatively large LCA cohort, Hanein and co-workers suggested that symptoms 
such as night blindness and photophobia may be distinctive symptoms that point 
to the gene involved23. Our study did not confirm this correlation. Night blindness 
or photophobia as gene-specific characteristics may be applicable to a group of 
patients with a certain genotype; however they cannot be used as good predictors 
in the individual patient. Unfortunately, although we presented specific genotype-
phenotype correlations, it may still be very difficult to predict the gene involved in a 
single LCA patient after one clinical examination. Our study, although small in size, 
did indicate that there are trends in the correlation between LCA gene defects and 
the resulting phenotype. This correlation likely becomes more complete in the near 
future, as more detailed structural (optical coherence tomography) and functional 
(autofluorescence) imaging techniques are now available. These results, together 
with a longer follow up of the LCA patients, will add new phenotypic aspects to the 
genotype-phenotype correlations. In the future, more genotype-phenotype studies 
need to be performed in order to establish better indicators for which specific gene 
is involved.
In chapter 4 the gene encoding the retinal pigment epithelium-specific 65-kDa 
protein (RPE65) was studied. RPE65 is the only gene studied in this thesis that 
is expressed exclusively in the RPE. The most detailed phenotypic description of 
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patients suffering from autosomal recessive early-onset retinal dystrophy caused 
by RPE65 mutations consistently showed preserved vision in childhood24-26 with 
a useful visual function beyond the second decade of life27, which later declined. 
Interfamilial variations in the RPE65-associated phenotype were found in these 
studies, which were attributed to the effects of different types of mutations (different 
amount of residual protein function). 
In chapter 4 we  reported on the existence of intrafamilial variations in patients with 
the same homozygous mutation in RPE65. In a large, previously isolated Dutch 
population a p.Y368H RPE65 mutation was detected homozygously in 13 out of 14 
patients from 10 related families. The patients all showed signs of night blindness, 
nystagmus, severe visual impairment with relatively well-preserved visual fields and a 
non-detectable ERG in early childhood. On fundoscopy, the older patients showed 
optic disc pallor, attenuated vessels and a hypopigmented periphery. Surprisingly, a 
wide range of visual acuity (VA) and natural history of visual function was observed. 
Approximately one third of the patients showed mild improvement, one third showed 
deterioration and one third showed a stable VA over a mean 9-year follow-up 
period. Clearly, other genetic and/or environmental factors must be involved in the 
heterogeneous phenotype in this pedigree. 
Further studies of this population revealed the founder mutation heterozygously in 
1/28 of healthy controls rendering a risk of 1 in 56 for the child of a patient with a 
partner from this population to develop the retinal dystrophy due to homozygous 
RPE65 mutations. Likewise, heterozygous carriers with partners from this population 
have a risk of 1 in 112 that any of their children will develop the disease. Recently, 
additional patients from this population with either arRP or early-onset RP were 
ascertained. Sequence analysis of the RPE65 gene revealed new mutations in this 
gene, rendering the relative burden of RPE65 mutations in this population even 
higher (S. Yzer, F.P.M. Cremers, unpublished data). Our studies now enable p.Y368H 
carrier detection in this population, which theoretically could lead to a significant 
decrease of children born with this severe sensory handicap. 
It is estimated that autosomal recessive mutations in RPE65 account for 6-16%24,28,29 
of the LCA cases in the world. The identification of patients with RPE65 defects has 
become very important since gene therapy studies in RPE65 deficient animal models 
proved to restore photoreceptor function both on observational and functional (ERG) 
studies30-32. A human clinical trial for single dose subretinal delivery of recombinant 
adeno-associated virus carrying wild-type RPE65 cDNA, is not far off. 
As illustrated in our studies, LCA is a remarkably heterogeneous disease, both 
clinically and genetically. Genotyping-phenotyping efforts as presented in this 
thesis will ultimately lead to a more detailed knowledge facilitating phenotypical 
differentiation. Together with new technologies these efforts will facilitate and speed 
up the molecular diagnostic process. Unfortunately, the current knowledge on LCA 
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phenotypes does not provide enough information for accurate gene selection in 
individual patients. In order to aid a more profound genotype-phenotype correlation 
in the future, more mutations need to be identified, other LCA genes need to be 
identified and additional genotype-phenotype correlation studies are needed. Until 
then, the most logical and most cost-effective genotyping approach would be to 
have a patients’ DNA tested using the APEX LCA microarray. 
Carriers of LCA mutations show distinctive functional 
abnormalities
Classical genetic definitions (Mendelian inheritance) teach that recessive mutations 
only cause a phenotype in the individual that carries two defective genes. A carrier 
with only one copy of the defective allele is thought to be protected by the wild-type 
allele and therefore show no obvious disease signs. Obligate heterozygous carriers 
of LCA mutations in the AIPL1, GUCY2D, RDH12 and RPGRIP1 genes, however, 
were shown to have distinct ERG abnormalities33,34, without any other signs or 
symptoms. Carriers of AIPL1 mutations showed abnormal rod amplitudes33 whereas 
carriers of heterozygous GUCY2D pathogenic sequence changes showed cone 
abnormalities, as did carriers of RDH12 variants. RPGRIP1 heterozygotes showed 
both rod and cone ERG dysfunction34. In contrast to carriers of AIPL1, GUCY2D, 
RDH12 and RPGRIP1 pathogenic sequence changes, the heterozygous carriers of 
RPE65 mutations show normal ERG function35-37.  Apparently, the presence of only 
one wild-type LCA allele in most families is not enough to suppress a (sub)clinical 
phenotype. Our goal in chapter 5 was to elucidate the possible CRB1 heterozygous 
phenotype.
Two different Crb1 animal models were previously studied. In a natural Crb1 mutant 
mouse, the predicted Crb1 protein is truncated lacking the transmembrane and 
intracellular domain. Histologically, these animals show irregularities at the outer 
limiting membrane and loss of the photoreceptors, eventually resulting in multiple 
intraretinal pseudorosettes localized to the inferior nasal quadrant of the fundus36. 
In the second mouse model both Crb1 alleles were inactivated by deleting a 2.9 kb 
segments of genomic Crb1 sequence containing the upstream promoter region, 
exon 1 (encoding the start of the protein) and part of intron 1. This model shows 
giant half rosettes in the inferior temporal quadrant but no loss of overall retinal 
function on ERG 37. 
In chapter 5 obligatory carriers of CRB1 mutations were tested for gene specific 
electroretinography abnormalities. Since the retinal dystrophies in the mouse models 
were localized we decided to use a specific mfERG (cone) pattern for testing the 
heterozygous CRB1 mutation carriers. Five out of 7 obligatory carriers demonstrated 
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specific infero-nasal mosaic retinal dysfunction. The other two carriers showed no 
abnormalities on mfERG recordings. 
The previously mentioned mouse model studies also provided information on 
Crb1 to be essential in the maintenance of the adherens junctions between 
photoreceptors and Müller glia cells during light exposure. It was therefore proposed 
that Crb1 might play a crucial role in the prevention of retinal disorganization and 
retinal dystrophy. Light may consequently influence the development of retinal 
disease in the presence of CRB1 mutations37. Difference in light exposure may for 
that reason also play a role in the mfERG recording differences in the tested CRB1 
mutation carriers. 
Interestingly, McKay and co-workers recently reported on a family with autosomal 
dominant inherited pigmented paravenous chorioretinal atrophy due to a p.V62M 
mutation in the CRB1 gene38. This is of special interest because the chorioretinal 
atrophy was subtle in the early disease stage and limited to the inferior quadrant. 
Disease expression was variable and males where more likely to exhibit a severe 
phenotype compared to females which remained virtually asymptomatic. 
Although the cohort of heterozygous CRB1 carriers studied is rather small, the 
majority of our tested individuals display an abnormal phenotype. Moreover, this 
phenotype is different from previously described heterozygous carrier phenotypes 
in other tested LCA genes. In the future, mfERG testing of additional heterozygous 
carriers may specify the ocular carrier phenotype and may also provide 
characteristic findings in the parents of LCA offspring and add important information 
on the gene involved in their offspring. MfERG testing in parents of LCA children may 
therefore be an informative tool in differentiating which gene is involved, potentially 
facilitating the molecular diagnostic process.
This thesis has supplied information on the usefulness and efficiency of newly 
developed microarrays that facilitate molecular diagnostics in a portion of autosomal 
recessive retinopathies. Furthermore, important clinical data on ABCA4 associated 
arCRD and arRP as for AIPL1, CRB1 and GUCY2D associated LCA and RPE65 
associated early-onset rod-cone dystrophy were provided. 
In conclusion, molecular and clinical studies of retinal diseases provide crucial 
knowledge for the understanding of normal and abnormal retinal development and 
function. 
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Summary
Inherited retinal dystrophies affect approximately 1 in 2000 persons worldwide, 
which leads to legal blindness in a significant fraction of these patients. Retinal 
dystrophies display unexpected and surprising clinical and genetical heterogeneity. 
To date more than 60 genes involved in retinal disease have been identified and at 
least as many still await discovery. For many years molecular genetic and clinical 
aspects of retinal dystrophies were studied extensively in order to provide insights 
in the understanding of these complex disorders and at the same time provide 
clues for their possible treatment. At least as many questions have been raised as 
answered, but to date, for the first time in history we are expecting the first human 
therapy trials for inherited retinal diseases. Most of these putative future therapies 
are gene specific which emphasizes the importance of knowing the causative 
gene in individual patients. For the near future this means that all genes involved 
in inherited retinal diseases should be identified, that rapid, affordable and reliable 
screening tools become accessible, and that straightforward genotype-phenotype 
correlations are available.
Autosomal recessive RP displays a wide clinical and genetic variability. To date 19 
genes have been cloned and another 5 loci have been mapped. Chapter 2.1 shows 
that only a minority of arRP patients have disease caused by mutations in ABCA4. 
These patients don’t show the typical arRP phenotype associated with mutations 
in ABCA4, being one of an early-onset, severe and highly progressive retinal 
degeneration. This phenotype however was shown in arCRD patients in chapter 
2.2. An association with nystagmus and atrophic nummular maculas in these 
patients was also provided. Furthermore, two fast and reliable screening methods 
were used to detect mutations in this gene, i.e. the ABCR500 APEX technology 
and the arRP Affymetrix Resequencing Array technology. The APEX technique 
is relatively cheap and detects 60% of the theoretically expected mutations. The 
resequencing technique is relatively expensive and detects 65% of the mutations. 
The APEX technique is also of use for mutation analysis in a significant fraction 
of the arCRD patients, as the majority of the CRD cases carry causative ABCA4 
mutations. 
The identification of ABCA4 mutations is of great importance since studies with Abcr 
-/- mice proved that retinal function could be improved by extensive light reduction 
and/or treatment with isotretinoin. In chapter 3 we provide genotype-phenotype 
correlations for a cohort of predominantly Dutch and Belgian LCA patients. As a 
genotyping tool the APEX LCA microarray was used which proved to be an efficient 
first-pass screening tool. Mutations were found in ~1/3 of the patients. Mutations 
were most often found in CRB1, followed by GUCY2D. Surprisingly, all patients 
with CRB1 mutations had either the p.C984Y or the p.K801X mutation. Eight of 
12 GUCY2D alleles carried the p.R768W mutation, which suggests that this is a 
founder mutation in the northwest of Europe. 
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Specific genotype-phenotype correlations were made for three genes (AIPL1, CRB1, 
GUCY2D) that are involved in a substantial fraction of the patients. LCA patients 
with AIPL1 mutations showed hyperopia, light perception and essentially normal 
appearing fundi on early examinations. Fundus abnormalities start to appear in 
early childhood. After the age of eight years these patients showed a consistent 
fundoscopic picture, consisting of bull’s eye maculopathies with peripheral 
intraretinal pigment migration. All LCA patients with CRB1 mutations showed 
a distinct phenotype with some or all fundoscopic characteristics of the RP12 
phenotype. This phenotype consists of relatively normal optic discs and vessels, a 
distinct maculopathy or macular dysplasia, nummular pigmentations, yellow-white 
retinal dots, para-arteriolar preservation of the retinal pigment epithelium, Coats-like 
exudative vasculopathy, vascular sheathing. Most patients showed moderate to high 
hyperopia, nystagmus and some of them had a keratoconus. Patients with LCA 
caused by mutations in GUCY2D show an extremely severe phenotype of no light 
perception at initial examination and virtually no signs of improvement later in life. 
Fundus examinations were relatively normal even later in life.
The RPE65 gene is generally considered a LCA gene, although most patients 
described previously with mutations in this gene do not fit the strict LCA criteria. 
These patients are preferably referred to as suffering from autosomal recessive early-
onset retinal dystrophy. In chapter 4, a large Dutch consanguineous pedigree was 
described. Thirteen out of 14 patients from 10 nuclear families were found to have 
the same homozygous p.Y368H mutation in RPE65. One patient was found to be 
compound heterozygous for this mutation and the most frequently encountered 
RPE65 mutation worldwide, IVS1+5G>A. Clinical analysis showed that all patients 
suffered from night blindness, nystagmus, extensive central visual impairment with 
relatively well preserved peripheral vision and an non-detectable electroretinogram 
(ERG). Remarkably, there was a wide range of visual acuities (VA) in this pedigree 
and a wide variety in clinical course of vision. The VA deteriorated in approximately 
one third of the patients, whereas one third showed a stable VA and another third 
had some improvement of the VA over the years. This clinical variability has been 
observed in other studies but these differences were attributed to the different 
functional consequences of different (combinations of) mutations in the RPE65 
gene. Apparently, other genetic and environmental factors play a role in the disease 
expression pattern of this pedigree. 
Since this large Dutch consanguineous pedigree belongs to a rather isolated 
population, this mutation very likely represents a founder mutation. Mutation analysis 
in healthy controls from this population reveals that patients with a partner from this 
population have a risk of 1 in 56 that any of their children will develop the retinal 
dystrophy.
In previous studies gene-specific ERG abnormalities in obligate heterozygous 
carriers of AIPL1 (rod ERG abnormalities), GUCY2D (cone ERG abnormalities), 
RPE65 (normal ERGs) and RPGRIP (rod and cone ERG dysfunction) mutations, 
have been reported. In chapter 5, parents of patients with proven CRB1 mutations 
underwent clinical ophthalmologic examination including a mfERG to study the 
possibility of the existence of CRB1-specific ERG changes in carriers of CRB1 
sequence changes. Indeed a significant portion of heterozygous carriers of CRB1 
mutations show a specific infero-nasal mosaic retinal dysfunction on mfERG, 
primarily affecting cone photoreceptors. This specific pattern is probably caused by 
inferior retinal folds and/or pseudorosettes, which is in accordance with Crb1 animal 
models. In the future, ERG testing of parents of LCA infants may aid in the prediction 
of the gene involved.
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Samenvatting 
Wereldwijd komen retinale dystrofieën (erfelijke netvliesaandoeningen) voor bij 1 op 
de 2000 mensen. Een deel van de mensen met deze aandoening is maatschappelijk 
blind (maximaal gecorrigeerde visus van minder dan 3/60 of een centraal 
gezichtsveld van 10 graden of minder in het beste oog (International Statistical 
Classification of Diseases)). 
Retinale dystrofieën zijn klinisch en genetisch heterogeen. Momenteel zijn er voor 
deze aandoeningen ongeveer 60 genen bekend en het is te verwachten dat nog 
een groot aantal genen in de toekomst ontdekt zal worden. De laatste jaren zijn 
zowel de moleculair genetische als ook de klinische aspecten van deze dystrofieën 
bestudeerd om een beter inzicht in deze complexe groep aandoeningen te krijgen. 
Door dit type onderzoek is er tevens meer kennis omtrent de normale functie van 
het netvlies vergaard. Daarnaast kunnen deze onderzoeken aanwijzingen opleveren 
voor eventuele behandelingsmogelijkheden. 
 
Een deel van de toekomstige therapeutische mogelijkheden zal genspecifiek zijn, 
en daarom is het van belang om het gendefect in individuele patiënten te kennen. 
Dit betekent dat in de toekomst alle genen betrokken bij erfelijke retinale dystrofieën 
geïdentificeerd moeten zijn, en dus dat er snelle, goedkope en betrouwbare 
methoden voor mutatiedetectie toegankelijk moeten zijn. Daarnaast zullen duidelijke 
genotype-fenotype correlaties een bijdrage leveren aan de identificatie van de 
oorzakelijke genmutaties in individuele patiënten.
Hoofdstuk 2 laat zien dat patiënten met CRD en mutaties in het ABCA4 gen een 
heterogeen klinisch beeld vertonen. Tevens worden nieuwe klinische kenmerken, 
geassocieerd met dit beeld beschreven, namelijk nystagmus en atrofische 
maculopathie. Daarnaast worden in dit hoofdstuk twee snelle en betrouwbare 
ABCA4 mutatie-screening methodes beschreven, de ABCR500 APEX microarray 
technologie en de arRP Affymetrix Resequencing Array (AGRA) technologie. Het 
gebruik van de APEX technologie is relatief goedkoop en detecteert 60% van de 
theoretisch te verwachten mutaties. In vergelijking met de APEX techniek is het 
gebruik van de AGRA technologie relatief duur en detecteert deze 65% van de 
mutaties. 
In hoofdstuk 3 worden de genotype-fenotype correlaties voor een cohort van vooral 
Nederlandse en Belgische LCA patiënten beschreven. Voor de genotypering is de 
APEX LCA microarray gebruikt hetgeen een efficiënte methode blijkt te zijn, omdat 
deze 1/3 van de te verwachten ziekte allelen geïdentificeerd heeft. Mutaties zijn het 
meest frequent in het CRB1 gen gevonden, gevolgd door mutaties in GUCY2D. Alle 
patiënten met mutaties in CRB1 blijken drager te zijn van de p.C984Y of de p.K801X 
mutatie. Acht van de 12 GUCY2D allelen dragen de p.R768W mutatie welke zeer 
waarschijnlijk een founder mutatie in Noordwest Europa is.
In dit hoofdstuk zijn tevens specifieke genotype-fenotype correlaties voor drie 
genen (AIPL1, CRB1, GUCY2D) gemaakt. LCA patiënten met mutaties in AIPL1 zijn 
hypermetroop, hebben enkel lichtperceptie en vertonen als baby een vrijwel normale 
fundus. Vanaf de leeftijd van 6 jaar hebben alle AIPL1 geassocieerde LCA patiënten 
fundusafwijkingen in de vorm van een “bull’s-eye” maculopathie met beenbalk-
achtige intraretinale pigmentveranderingen in de periferie. De LCA patiënten met 
mutaties in CRB1 vertonen allemaal kenmerken van het RP12 fenotype. Het RP12 
fenotype wordt onder andere gekarakteriseerd door een relatief normale papil met 
normale vaten, een uitgesproken maculopathie en ronde pigmentaties. Andere 
klinische kenmerken zijn geelwitte subretinale puntjes, para-arteriolaire sparing van 
het retinale pigmentepitheel, een Coats-achtige vasculopathie, vaatschedevorming 
en keratoconus. De meeste patiënten met CRB1 mutaties uit deze studie zijn daarbij 
(hoog) hypermetroop en hebben een nystagmus. De patiënten met mutaties in het 
GUCY2D gen vertonen het meest ernstige fenotype. Zij hebben geen lichtperceptie 
met een vrijwel normaal fundusbeeld, welke niet verandert gedurende hun leven. 
In hoofdstuk 4 wordt een Nederlandse stamboom beschreven met daarin een groot 
aantal consanguine families met 14 patiënten met een autosomaal recessieve, vroeg 
ontstane retinale dystrofie. Dertien van de 14 patiënten van de 10 kerngezinnen 
hebben een homozygote mutatie (p.Y368H) in het RPE65 gen. Eén patiënt blijkt 
samengesteld heterozygoot te zijn voor deze mutatie en de IVS1+5G>A mutatie, 
welke wereldwijd de meest voorkomende mutatie in het RPE65 gen is. Alle patiënten 
zijn nachtblind en vertonen nystagmus. Verder hebben ze relatief gespaarde perifere 
gezichtsvelden en een niet te meten electroretinogram (ERG). Binnen deze familie 
is er een grote verscheidenheid in de gezichtsscherpte en het beloop daarvan. 
Bij éénderde van de patiënten verslechtert de visus, bij éénderde blijft de visus 
nagenoeg stabiel en bij éénderde verbetert de visus in de loop der jaren. Deze 
klinische variabiliteit is in de literatuur al beschreven en wordt toegeschreven aan de 
verschillende functionele consequenties voor het eiwit door de verschillende RPE65 
mutaties. Het is aannemelijk dat andere genetische- of omgevingsfactoren een rol 
spelen in de ziekte-expressie van patiënten uit deze familie.
Aangezien deze groep patiënten uit een relatief geïsoleerde populatie afkomstig is, 
representeert de p.Y368H mutatie waarschijnlijk een founder mutatie. Aanvullende 
mutatieanalyse van DNA van gezonde personen afkomstig uit deze gemeenschap 
toont dat patiënten met een niet consanguine partner uit deze populatie een risico 
hebben van 1 op 56, dat hun kinderen deze retinale dystrofie zullen ontwikkelen.
In hoofdstuk 5 is beschreven hoe ouders van LCA patiënten met mutaties in 
het CRB1 gen een uitgebreid oogheelkundig onderzoek ondergaan, inclusief 
mfERG, zodat mogelijke CRB1-specifieke veranderingen in dragers van CRB1 
mutaties bekeken kunnen worden. Eerdere studies tonen genspecifieke ERG’s bij 
obligate heterozygote dragers van mutaties in AIPL1 (staafjes afwijkingen op ERG), 
GUCY2D (kegel afwijkingen op ERG), RPE65 (normaal ERG) en RPGRIP1 (staaf en 
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kegel afwijkingen). Het blijkt dat een significant deel van de heterozygote dragers 
van CRB1 mutaties een specifiek patroon, van voornamelijk kegel dysfunctie in 
het inferonasale kwadrant, in het mfERG vertoont. In de toekomst kunnen ERG 
resultaten bij ouders van LCA patiënten, mogelijk bijdragen aan de voorspelling, in 
welk gen mutaties bij hun kinderen de aandoening veroorzaakt. 
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Wat was het geweldig om met zoveel verschillende onderzoekers / coauteurs te 
mogen samenwerken. Ik heb van ieder van jullie veel mogen leren. Het resultaat 
mag er zijn! Bart, voor jou toch speciaal: “many hugs!”.
Lieve vrienden, dat jullie er nog zijn. Thanks! Maj, Jos, Nishy, Lon, Steef, Loes, René, 
Mieke, Ralf en Ilse, jullie moet ik toch even noemen. Jullie hebben zo nu en dan heel 
wat met mij te verduren gehad. Hartelijk dank voor jullie belangstelling, vriendschap 
en de vele gezellige, bijzondere en mooie momenten samen. 
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Dear Alireza, Alexandra, Irma, Norma, Alison and Joanne, you made my stay in 
Montreal so wonderful and unforgettable. The memory of my fantastic time in 
Canada is a sweet memory of you.
Sharola, thank you for making this day even more special!
Mijn paranimfen, Aniek en Anneke. Aniek, we go way back. Net 12 jaar oud en 
samen op de MAVO. Wat deden we daar? Na de HAVO zijn we ieder onze eigen 
weg gegaan en toch zijn we er gelukkig steeds voor elkaar geweest. Anneke, 
jemig, dat wij daar straks samen staan. Jouw hulp in het lab, jouw kennis van de 
moleculaire genetica van LCA / arRP, maar bovenal jouw vriendschap betekenen 
veel voor me. Het is gewoon vanzelfsprekend dat wij dit met zijn drieën doen.
Lieve pa en ma, Esther en Emiel. Jullie hebben je vaak afgevraagd waar ik nou toch 
mee bezig was. Na mijn studie geneeskunde ineens het lab in, en wat deed ik daar? 
In het weekend de kleinste koffer uitzoeken en dan met de trein (later gelukkig de 
auto, ook daarvoor dank), naar patiënten en families om vervolgens met diezelfde 
koffer vol bloedjes terug te komen. Spanning voor praatjes, angst over artikelen 
schrijven / publiceren, naar Canada…………………nou het resultaat van wat ik 
deed ligt nu voor jullie. Hartelijk dank voor jullie geduld, jullie morele steun en het 
voor me klaar staan. Zonder jullie was dit proefschrift er niet geweest.
Al die fijne mensen die zich hebben laten vangen onder het kopje “collega, coauteur 
en vriend / vriendin”, sorry dat jullie niet apart genoemd staan. Weet, dat als je niet 
persoonlijk genoemd wordt, je toch werkelijk niet vergeten bent. 
This is it, for now!
Suzanne
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Color Figures
Figure 2.1.1   Fundus pictures of patients with CRD and RP and mutations in ABCA4 
a. CRD patient 15680 with bull’s eye maculopathy and temporal pallor of the optic disc (with myelinated 
nerve fibers). In the periphery (not visible) there are minor hyperpigmentations but the retinal vessels are 
of normal size. 
b. Chorioretinal atrophy in the posterior pole of CRD patient 16887. Mild granular changes located at mid-
peripheral retina (not visible). This patient was initially diagnosed as STGD1, in view of the yellow flecks, 
which are still faintly visible.  
c. CRD patient 16569, taken at age 12, with an obvious pallor of the temporal optic nerve head and atro-
phic changes in the macula. At that time, the photopic ERG is already nonrecordable and the scotopic 
ERG is severely decreased. 
d. RP patient 17597 shows typical RP features such as bone spiculas in the periphery and attenuated 
retinal vessels. Large choroidal vessels can be seen in the midperiphery indicative of atrophic changes.
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Figure 2.2.2   Fundus photograph of the left eye of patient V:2 with mutations in ABCA4 
(age 46 years)
Note the attenuated vessels, the atrophic lesion in the macula, and bone-spicule pigmentations.  
Figure 2.2.3   Fundus photograph of the right eye of patient V:5 with mutations in ABCA4 
(age 43 years)
Note the pale optic disc, moderate attenuation of the vessels and heavy bone-spicule pigmentation in the
midperiphery with a relatively spared periphery.
Figure 2.2.4   Fundus photograph of the left eye of patient VI:1 with mutations in ABCA4 
(age 52)
Note the  relatively normal optic disc, mild attenuation of the vessels and large atrophic lesion with scattered
pigmentations in the macula. The remaining RPE has a lobular atrophic appearance.
152
color figures  153
Figure 3.1   Fundus photographs of patients with LCA
a.  Patient 2040V1 (AIPL1 p.W278X/p.W278W) at age nine: composite of fundus of the left eye (LE), 
 showing macular dystrophy in a bull’s eye pattern, diffuse RPE alterations with scarce intraretinal pig-
 ment migration with spicular aspect, sub- or deep intraretinal fine white deposits predominantly along 
vascular arcades.
b. Patient 2040V1 (AIPL1 p.W278X/p.W278X) at age nine: autofluorescence image of fundus of the right 
eye (RE), showing fine deposits predominantly along vascular arcades that hyperfluoresce.
c.  Patient 21405 (CRB1 p.C948Y/p.T745M) at age 14: composite of fundus of RE showing an edema-
tous optic disc with perivascular sheating, mild narrowing of the arterioles showing tortuositas with 
 subretinal white dots along arterioles with PPRPE, macular aplasia, atrophic RPE in the periphery with
 PPRPE, and nummular and a few spicular pigmentations. The posterior pole showed edema with a few 
intraretinal hemorrhages.
d. Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): posterior pole of RE at age seven showing an edema-
tous optic disc with preretinal fibrosis, perivascular sheathing, macular dysplasia, and fine, white, deep 
intra- or subretinal deposits.
e.  Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): composite of fundus of RE at age 12 showing an 
edematous optic disc with preretinal fibrosis and perivascular fibrotic sheathing without clear PPRPE apart 
from vessel inferonasal to RE; macular dysplasia remains stable, whereas there is fine nummular intrareti-
nal hyperpigmentation with fine, white, deep intra- or subretinal deposits in the mid- and far periphery.
f.  Patient 21554 (CRB1 p.C948Y/c.2842+5G>A): red free image of the optic disc and inferotemporal  
peripapillary area of LE at age 12 showing a better visualisation of perivascular fibrotic sheathing.
g. Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus picture of LE at age 14; Note that the 
optic disc is fairly normal; the macula is dysplastic; limited vascular attenuation with relative PPRPE; 
nummular hyperpigmentation in the macula and the retinal periphery and multiple white subretinal 
deposits scattered throughout the fundus.
h.  Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus picture of LE at age 30 shows limited 
visibility due to subcapsular cataract, stable dysplasia of the macula but a dramatic increase in the 
number of nummular pigmentations in the posterior pole, vascular attenuation; mixed nummular and 
spicular hyperpigmentation in the retinal periphery and multiple white subretinal deposits scattered 
throughout the fundus.
i.  Patient 21067 (GUCY2D p.R768W/p.A946V): Composite of fundus of RE at age 22 showing arteriolar 
attenuation and mild RPE alterations in the fovea.
j.  Patient 23207 (RPE65 p.R124X/p.F530fs) at age six and a half years: a relatively hypopigmented 
fundus of LE with mild attenuation of arterioles and diffuse RPE alterations.
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Figure 4.1   Fundus photograph of patient HII-1 at the age of eight years  with mutations in the 
RPE65 gene
Pale optic disc, moderately attenuated vessels, hypopigmented fundus with a relatively spared maculae 
Figure 5.5a + b.   Fundus pictures of Family III LCA patient II-1
Shown are the posterior poles of the retinas of the right (5a OD) and left eyes (5b OS) of the affected LCA 
child with the homozygous p.Q449X mutation in CRB1 and a heterozygous p. R302L mutation in AIPL1. 
Note the conspicuous maculopathy.
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